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1
General Introduction and 
Outline of the Thesis
Chapter 1
Intro duct io n
In this thesis, research into the mechanisms of kidney uptake of radiolabeled 
peptides used in peptide receptor radionuclide therapy (PRRT) and methods to 
reduce the resulting nephrotoxicity is described. In PRRT and peptide receptor 
scintigraphy, tumors overexpressing certain receptors are targeted using 
radiolabeled receptor ligands. In peptide receptor scintigraphy these 
radiolabeled peptides are used to image and localize the tumor and /or 
suspected metastases, while the aim of PRRT is to treat tumors and metastases 
through irradiation by therapeutic radionuclides. Currently the most comm on 
and best established form of PRRT is the therapy of neuroendocrine tumors with 
radiolabeled somatostatin analogues. However, the effectiveness and safety of 
somatostatin analogue PRRT is limited by relatively high uptake of the 
radiolabeled peptides in the kidneys, which can lead to renal toxicity. The use of 
several other radiolabeled peptides for imaging and therapy of neuroendocrine 
and other tumors is being studied, but the usability of m any of these peptides is 
also limited by high kidney uptake. Therefore, it is im portant to devise and 
investigate methods tha t reduce the kidney uptake of radiolabeled peptides, 
thereby limiting radiation-induced dam age.
N euroendocr ine  tumors
Neuroendocrine tumors (NETs) are relatively rare benign or m alignant tumors, 
originating from neuroendocrine cells. Neuroendocrine cells secrete specific 
peptide or am ine hormones, and some NETs secrete these hormones as well. 
These so-called functioning NETs can give rise to specific syndromes due to the 
unregulated secretion of hormones. Examples include hypoglycemia caused by 
insulin secretion by insulinomas, or the carcinoid syndrome due to the 
oversecretion of serotonin derivatives by carcinoids. Most NETs arise in the 
gastrointestinal trac t and are referred to as gastroenteropancreatic NETs (GEP- 
NETs), but NETs can also originate in other organs, such as medullary carcinom a 
of the thyroid gland or carcinoid of the lung. The incidence of clinically apparent 
NETs is approxim ately 6 per 100,000 persons per year, but post-mortem studies 
indicate a much higher prevalence of clinically silent (e.g. slow-growing and 
non-functioning) NETs th a t remain undetected '-2. NETs, like the cells from which
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they originate, often express receptors for peptide hormones such as 
somatostatin or gastrin, making them  attractive targets for peptide-receptor 
scintigraphy and PRRT. Somatostatin receptor expressing tumors and metastases 
can be treated successfully by PRRT with somatostatin analogues such as [90Y- 
DOTA0,Tyr3]octreotide and [,77Lu-DOTA°,Tyr3]octreota te  3. Other treatm ent 
options for neuroendocrine tumors include surgery, chem otherapy and 
symptomatic therapies to reduce the hormone secretion of functioning NETs. The 
most im portant symptom-reducing drugs are non-radiolabeled somatostatin 
analogues, such as octreotide and lanreotide. Surgery is an option if no or only 
very limited metastases are present, and chem otherapy is used mostly in 
dedifferentiated tumors. More recently, targeted therapies w ith inhibitors of the 
m am malian target of rapamycin (mTOR), such as everolimus, have shown 
promising results in the treatm ent of advanced neuroendocrine tumors 4. Some 
tumors also take up ,3,I-metaiodobenzylguanidine (MIBG) and can be treated 
with high activity doses of this radiopharm aceutical 2.
K idney protection  in PRRT
As outlined above, the effectiveness of PRRT is limited by high kidney uptake and 
retention of radiolabeled peptides, leading to acute and /o r chronic radiation- 
induced nephritis if high radiation doses are administered 5. To reduce this 
dam age, m any strategies have been studied. The most im portant strategy, 
which is routinely used in patients undergoing somatostatin analogue PRRT, 
consists of the coinfusion of solutions of basic am ino acids such as lysine and 
arginine. These positively charged am ino acids most likely interfere with the 
reuptake of somatostatin analogues in the proximal tubules of the kidney.
In chapter 2, the mechanisms of kidney uptake and retention of radiolabeled 
peptides are explained, and the literature about strategies to reduce the risk of 
nephrotoxicity is reviewed. Several of such strategies are under investigation. 
Some of these interfere with the uptake or retention of radiolabeled peptides, 
while others aim  to prevent the developm ent of radiation-induced dam age. 
Knowledge about the mechanisms of uptake of radiolabeled peptides in the 
kidneys is im portant for designing effective strategies to reduce nephrotoxicity. 
Although much is known about the renal proximal tubular reuptake process, not 
all involved receptors have ye t been identified. In chapter 3, the role of megalin
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in the uptake of five different ^ In-labe led  peptides is described. Megalin is a 
multiligand scavenger receptor tha t is involved in the proximal tubular 
reabsorption of several different peptides and proteins. The kidney uptake of 
^ In-labe led  octreotide, octreota te, exendin, minigastrin and neurotensin in 
megalin-deficient mice and normal (wild type) mice is com pared, using both in 
vivo SPECT and ex vivo measurements. ,n In, in addition to y photons, also emits 
Auger and conversion electrons, which may cause kidney dam age a t high 
doses. Observations of kidney dam age in mice tha t received high doses of ,n In- 
labeled peptides for SPECT imaging are presented in chapter 4. In the 
subsequent chapters, studies on substances tha t m ay com petitively inhibit the 
renal uptake of radiolabeled peptides are described.
Protein-based plasma expanders such as succinylated gelatin were shown to 
cause reversible proteinuria, indicating interference with the proximal tubular 
reuptake of filtered proteins and peptides 6. This prompted us to study the 
potentia l of succinylated gelatin to reduce the renal reuptake of 111In-octreotide. 
The effects of protein-based and carbohydrate-based plasma expanders on the 
biodistribution of ^ In -oc treo tide  in rats and mice are described in chapter 5. In 
chapter 6, the e ffec t of succinylated gelatin on the renal uptake of 111In- 
octreotide in human subjects is eva luated by means of scintigraphy.
Another substance tha t m ay be a promising cand idate for com petitive inhibition 
of the proximal tubular reuptake of radiolabeled peptides is albumin. Albumin is 
an abundant plasma protein and a natural ligand of the megalin receptor. Since 
this large molecule is hardly filtered through the glomerular membrane, we 
studied the effects of injecting fragments of albumin. In chapter 7, studies of the 
e ffec t of albumin fragments on the renal uptake of ^ In-octreo tide , ,n In-exendin 
and ,] , In-minigastrin are described. The uptake is measured in megalin- 
expressing cells and in the kidneys of rats. Albumin fragments consist of a 
relatively undefined mixture of smaller and larger molecules, some of which may 
not inhibit the uptake of radiolabeled peptides, but m ay cause side effects. To 
optimize the inhibitory potency and minimize the chance of side effects, we 
designed specific albumin-derived peptides for reduction of the renal uptake of 
radiolabeled peptides. Since electric charges are thought to play an im portant 
role in the interaction of peptides with renal receptors, the selection of these 
albumin-derived peptides was based on the number and distribution of charges 
in the albumin molecule. In chapter 8, the e ffec t of these peptides is first
12
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evaluated in megalin-expressing cells, and the most promising peptide is 
subsequently studied in rats.
In chapter 9, a summary and discussion of the results of these studies and a 
comparison with related studies from the literature is described.
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A bstract
Peptide-receptor radionuclide therapy (PRRT) w ith radiolabeled somatostatin 
analogs such as octreotide is an e ffective therapy against neuroendocrine 
tumors. Other radiolabeled peptides and antibody fragments are under 
investigation. Most of these compounds are cleared through the kidneys and 
reabsorbed and partially retained in the proximal tubules, causing dose-limiting 
nephrotoxicity.
An overview  of renal handling of radiolabeled peptides and resulting 
nephrotoxicity is presented, and strategies to reduce nephrotoxicity are 
discussed. M odification of size, charge or structure of radiolabeled peptides can 
alter glomerular filtration and tubular reabsorption. Coinfusion of com petitive 
inhibitors of reabsorption also interferes with the interaction of peptides with renal 
endocytic receptors; coinfusion of basic am ino acids is currently used for kidney 
protection in clinical PRRT. Furthermore, nephrotoxicity m ay be reduced by dose 
fractionation, use of radioprotectors or m itigating agents.
Decreasing the risk of nephrotoxicity allows for administration of higher radiation 
doses, increasing effectiveness of PRRT.
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Intro duct io n
The potentia l to irradiate tumors using radiolabeled antibodies tha t target tumor- 
associated epitopes was first reported in the 1950's. A drawback of conventional 
radioim m unotherapy is the very slow extravasation and c learance of in tact 
antibodies from the blood due to their size (~150 kDa). The optim al tumor-to- 
background ratio is reached only after several days, and the radiosensitive bone 
marrow receives a considerable radiation dose. Radiolabeled antibody 
fragments and analogs, such as Fab fragments and affibodies, were developed 
to improve pharmacokinetics and increase tumor-to-normal tissue dose ratios.
An alternative approach to tumor targeting is provided by the overexpression of 
specific cell-surface receptors by certain tumors. For example, somatostatin 
receptors can be targeted by somatostatin analogs such as octreotide. The use 
of radiolabeled somatostatin analogs for imaging and therapy of 
neuroendocrine tumors was first studied in the 1990's ’ . Nowadays, PRRT with 
somatostatin analogs has an established role in the therapy of metastasized 
neuroendocrine tumors 2. M any other radiolabeled peptides have been studied, 
for example gastrin and cholecystokinin (CCK) analogs, targeting the 
CCK2/gastrin receptor and exendin, targeting the glucagon-like peptide 
receptor 34.
Hydrophilic radiolabeled peptides, including small antibody fragments, are 
mainly excreted via the kidneys and are partly reabsorbed in the proximal 
tubular cells. The renal retention of therapeutic radionuclides causes a relatively 
high radiation dose to the kidneys, which can lead to kidney failure '5 . This 
toxicity precludes the use of higher doses, thus limiting the efficacy of therapy. 
Insight in the mechanisms of renal retention and toxicity of radiolabeled peptides 
is necessary for the study, design and use of strategies to reduce nephrotoxicity 
in PRRT and radioimmunotherapy. Several of such strategies have already been 
studied, including structural modification of radiolabeled peptides, com petitive 
inhibition of their renal reabsorption, and use of radioprotectors. Reduction of 
nephrotoxicity m ay enable the administration of higher activ ity doses, thus 
improving the efficacy of therapy.
This article presents an overview  of the mechanisms of renal handling, retention 
and toxicity of radiolabeled peptides and antibody fragments and discusses 
strategies to reduce nephrotoxicity.
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Ph ys io lo g y  of renal h a n d l in g  a n d  retention of rad iolabeled  peptides
In the human kidneys approxim ately 180 liters of plasma are filtered through the 
glomeruli each day, forming the ultrafiltrate tha t enters the lumen of the proximal 
tubules. About 99% of the filtered w ater and a large part of the solutes is actively 
reabsorbed from the ultrafiltrate and mostly transported back into the 
bloodstream, to prevent the excessive loss of w ater and useful nutrients and 
preserve homeostasis. The major part of the filtered load of proteins and peptides 
is reabsorbed in the proximal tubules. O ther solutes are active ly cleared from the 
blood into the ultrafiltrate by tubular secretion 6. Figure 2.1 presents an overview  
of glomerular and proximal tubular handling of peptides and proteins.
Glomerular ultrafiltration
The degree of filtration of solutes is largely dependent on their size, charge and 
protein binding. Molecules with an e ffective radius of < 1.8 nm (or weighing less 
than approxim ately 12 kDa) are freely filtered through the pores in the glomerular 
membrane, whereas molecules larger than 4.2 nm (weighing > 70 kDa) are not 
filtered, or only to a very limited extent. Small molecules tha t are bound to larger 
transport proteins such as albumin will not pass the glomerular filter. Evidence 
indicates tha t cationic and neutral molecules are filtered more efficiently than 
anionic molecules 6, although this concept of charge selectivity has been 
challenged in recent years 7. Most radiolabeled peptides are not bound to 
proteins and weigh < 12 kDa; consequently they are cleared efficiently via 
glomerular filtration.
Proximal tubular reabsorption and processing
In the proximal tubule, approxim ately 50 - 60% of filtered w ate r and solutes is 
reabsorbed by active and passive transport processes. The main driving force for 
these processes is the Na+-K+-ATPase in the basolateral m embrane, which pumps 
Na+ out of the cell and K+ into the cell. The ensuing concentration gradient 
stimulates re-entry of Na+ through various symporters and antiporters, providing 
energy for the co-transport of other molecules am ong which most am ino acids 6.
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Figure 2.1. O verv iew  o f g lom eru la r and  proxim a l tubu la r hand ling o f proteins and  peptides. 
AA = am ino ac id  transporter, PEPT = o ligopep tide transporter, OAT/OCT = organ ic  an ion /  
ca tio n  transporter, SSTR = som atosta tin  receptor.
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Multiple transport mechanisms are involved in the proximal tubular reabsorption 
of proteins and peptides. Some oligopeptides are hydrolyzed a t the brush border 
of proximal tubular cells, after which the resulting am ino acids and di- or 
tripeptides are transported into the cells by am ino acid transporters and the 
oligopeptide transporters (PEPT), respectively 6. Larger peptides and proteins are 
internalized via endocytosis. Most peptides are almost quantita tive ly reabsorbed 
in the proximal tubules.
Receptor-mediated endocytosis
Endocytosis is triggered by the binding of ligands to endocytic receptors, 
providing a positive feedback mechanism which accelerates endocytosis in 
response to an increase in the am ount of filtered proteins. After binding of 
ligands to endocytic receptors, the plasma m em brane invaginates, forming 
clathrin-coated pits and early endosomes. Early endosomes fuse with late 
endosomes, in which the acidic pH causes dissociation of ligands from receptors. 
The receptors concentrate  on one side of the endosomal membrane, which 
buds off and recycles to the cell membrane. The late endosomes fuse with 
lysosomes, in which the ligands are catabolized by proteolytic enzymes. The 
cytoskeleton plays an im portant role in the intracellular trafficking of these 
vesicles 6.
Megalin and cubilin, large endocytic receptors, play an im portant role in the 
proximal tubular reabsorption of various structurally different proteins, peptides, 
drugs and other molecules, including albumin, apolipoproteins, hemoglobin, 
gentam ycin and m any others 8. Megalin and cubilin are expressed exclusively on 
the apical membrane of proximal tubular cells 8. The cubilin receptor does not 
possess an intracellular signaling domain, and evidence suggests tha t expression 
and endocytosis of the cubilin receptor are dependent on interactions with 
megalin and amnionless, another transmembrane protein 9-w. Several ligands 
have been reported to bind both to megalin and cubilin 8. In vitro studies have 
indicated tha t radiolabeled somatostatin analogs are actively reabsorbed in 
proximal tubular cells by receptor-m ediated endocytosis, probably involving 
megalin and /o r cubilin 11. Autoradiography studies of rodent kidneys showed 
tha t various radiolabeled peptides accum ulate mainly in the renal cortex l2. De 
Jong e t al. reported th a t the renal uptake of 111In-octreotide was significantly
20
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decreased in kidney-specific m egalin-deficient mice 13 and our group recently 
found tha t renal uptake of 111In-labeled octreotate, minigastrin, exendin and 
neurotensin was also decreased by 40 - 70% in these m egalin-deficient mice l4, 
implying tha t megalin and /  or m egalin-dependent receptors such as cubilin, are 
indeed involved in the proximal tubular reabsorption of these radiolabeled 
peptides.
Cationic peptides are generally reabsorbed more efficiently by the proximal 
tubules than neutral and anionic peptides. This is thought to be caused by 
preferential binding of cationic groups to anionic binding sites on the brush 
border membrane. However, the highly anionic peptide minigastrin also 
expresses high renal uptake 3 and megalin ligands can be cationic or anionic. 
This indicates tha t other ligand properties, like structure and charge distribution, 
also determ ine reabsorption.
Role of ligand-specific receptors
Particular peptides m ay also be taken up by ligand-specific receptors, such as 
somatostatin receptors ,s. Abundant expression of all somatostatin receptor 
subtypes has been described in the human and murine kidney ,6-'7 and subtypes 
3 and 4 were found in rat kidneys l8. Rolleman e t al. retrospectively studied 111In- 
octreotide scans of patients tha t were scanned before and during treatm ent 
with unlabeled octreotide. A m ean 18% reduction in kidney uptake during 
octreotide treatm ent was found, suggesting some involvem ent of somatostatin 
receptors in the renal uptake of 111In-octreotide l9. However, an excess of 
unlabeled octreotide m ay also interfere with binding of 111In-octreotide to other 
receptors such as megalin. Expression of CCK2 and GLP-1 receptors on proximal 
tubular cells was described 20-2', and m any other ligand-specific receptors may 
be expressed in the kidneys. The im portance of these receptors for the renal 
uptake of radiolabeled peptides remains to be determined.
o the r pathways for reabsorption
Fluid-phase endocytosis (pinocytosis) is likely to play a role in the proximal tubular 
reabsorption of proteins and peptides. However, the capac ity  of this pathw ay is 
reported to be much lower than the capac ity  of receptor-m ediated endocytosis
21
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22. For hydrophobic molecules, passive diffusion across the luminal membrane 
m ay play an additional role.
Part of the transport of w a te r and electrolytes occurs via the intercellular 
pathway, through pores in the tight junctions between cells and through the 
interstitium. It is unknown whether small peptides m ay be reabsorbed through this 
route. Recently, a transcellular pathw ay for reabsorption of albumin has been 
proposed, consisting of large endocytic vesicles tha t are transported rapidly from 
the apical to the basolateral m em brane of proximal tubular cells 7. This route 
m ay also play a role in the reabsorption of radiolabeled peptides, but its 
existence remains controversial 23. In any case, peptides and proteins transported 
via these routes are thought to be returned to the circulation in tact and are not 
retained in the kidneys. Therefore, these pathways are unlikely to contribute to 
nephrotoxicity significantly.
Peritubular absorption and tubular secretion
M any endogenous and exogenous substances, such as hormones and drugs, 
are actively secreted from the blood into the lumen of the proximal tubules by 
the processes of peritubular absorption and tubular secretion. Several 
transporters involved in these energy-requiring processes have been identified, 
such as members of the organic anion transporters (OAT) and organic cation 
transporter (OCT) families, PEPT carriers and the multidrug resistance proteins 
(MRPs) 6. Different transporters are expressed on the basolateral and on the 
apical membranes of the proximal tubular cells, and some are also involved in 
the reabsorption of substances from the tubular lumen. The substrates 
transported by these pathways are relatively small. The tripeptide 99mTc- 
m ercaptoacetyltrig lycine (99mTc-MAG3) is mainly excreted by tubular secretion, 
and Trejtnar e t al. reported tha t three 99mTc-labeled tetrapeptides were secreted 
in the proximal tubules 24. A recent study suggests tha t OATs m ay be involved in 
the tubular uptake of 111In-octreotide, either from the lumen or from the plasma
in tracellu lar catabolism  and retention
Peptides and proteins tha t are endocytosed in the proximal tubules are 
subsequently catabolized into am ino acids in lysosomes. These am ino acids are
22
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transported or diffuse out of the lysosomes into the cytoplasm and return to the 
circulation. Monoiodotyrosine, the primary radiolabeled catabolite  from 
iodinated antibodies, is indeed released quickly from cells 26. Other radiolabeled 
catabolites, such as lysine-chelate conjugates, N-terminal am ino acid chelate 
conjugates 27 and specifically engineered iodinated products 28, cannot cross 
the lysosomal membrane. These products, tha t are trapped in the lysosomes, are 
referred to as residualizing radiolabels. Both for scintigraphy and PRRT, the 
entrapm ent of radiolabels is a desirable e ffect in target cells, enhancing the 
tum or-to-background ratio. However, it also contributes to the relatively high 
retention of radioactivity in the kidneys.
Oligopeptides tha t are taken up by transporters such as OATs or OCTs can leave 
the cell via similar transporters or by diffusion, or can be processed further in the 
cytosol or in lysosomes 6. The contribution of these transporters to the renal 
retention of radiolabeled peptides remains to be investigated.
K idney tox ic ity
The bone m arrow is the dose-limiting organ in most types of radionuclide 
therapy, since its rapidly dividing cells are very sensitive to radiation. Acute 
myelodepression can occur in the first days to weeks after trea tm ent and can be 
m anaged by supportive measures or by bone m arrow transplantation in the 
case of m yeloablative therapy. Up to years a fter therapy, late myelotoxicity such 
as myelodysplastic syndrome and leukemia can develop, which m ay also be 
treated with bone m arrow transplantation 29-31. However, the kidneys are 
sensitive to radiation as well, and given the relatively high renal retention of many 
radiolabeled peptides, the kidneys are often the dose-limiting organs in PRRT
5,32,33.
Nephropathy after external beam  radiation therapy (EBRT)
Radiation nephropathy caused by EBRT has been described extensively 3435. The 
only signs of radiation nephropathy m ay be solitary hypertension or 
asym ptom atic proteinuria. Acute radiation nephropathy is defined as signs of 
kidney failure (proteinuria, hypertension, heart failure, azotem ia and anemia) 
developing within 6 to 12 months after irradiation. Pathologic kidney changes
23
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include atrophy, tubulointerstitial scarring, mesangiolysis and, in severe cases, 
throm botic m icroangiopathy. Acute radiation nephropathy can be reversible or 
progress to chronic nephropathy. Chronic radiation nephropathy can also 
develop up to m any years after irradiation and is characterized by loss of kidney 
mass and function 36. In animal models, early kidney dam age developing in the 
first days to weeks after irradiation has been described, including dam age to 
glomeruli, tubuli and vasculature 3S. The initial radiation-induced dam age is DNA- 
dam age, which is mostly caused indirectly through the form ation of reactive 
oxygen species and can lead to cell death. Subsequent tissue reactions to this 
dam age, m ediated in part by the renin-angiotensin-aldosterone system (RAAS), 
are involved in the developm ent of chronic dam age 36.
Nephropathy after radionuclide therapy
Data about nephrotoxicity resulting from radionuclide therapy are limited. In 
mice, acute radiation nephritis with uremia and pronounced tubular dam age 
developing in the first weeks after administration of 90Y-labeled anti-CEA Fab 
fragments (9-15 MBq) and 225Ac-labeled antibodies (13 kBq) has been described 
37'38. Renal dam age in rats was described 3 to 9 months after injection of 278 - 
555 MBq [177Lu-DOTA0,Tyr3]octreota te  (177Lu-DOTATATE) 3940. In patients, acute 
radiation nephropathy developing 0.5 to 6 months after treatm ent with > 7.4 
GBq/m2 [90Y-DOTA0-Tyr3]octreotide (90Y-DOTATOC) has been described ]'4], as 
well as chronic radiation nephropathy after PRRT with 90Y-labeled somatostatin or 
gastrin analogs 3242.
In EBRT, kidney dose limits of 15-17 Gy in 2 Gy fractions are considered safe 43. 
Doses of 23 Gy cause chronic kidney failure in approximately 5% of patients 
within 5 years 44. However, the reaction of tissue to radiation does not only 
depend on the tota l absorbed dose, but also on dose rate, fractionation, 
(micro)distribution of dose within the organ and radiation type (a-, p>- or y- /  X- 
radiation) and energy 29,33,43. Typically, in PRRT dose rates are much lower than in 
EBRT, distribution within the organ is more inhomogeneous and the radiation has 
a shorter range of penetration. Therefore, maximum tolerable dose limits for PRRT 
m ay differ significantly from those for EBRT. Use of the biological e ffective dose 
(BED), which takes the effects of dose fractionation and sensitivity of the organ to 
radiation into account, m ay be more appropriate for setting dose limits than the
24
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absorbed dose. Barone e t al. described a group of 18 patients treated with 90Y- 
DOTATOC and found tha t a kidney BED of > 45 Gy increased the risk of rapid 
deterioration of renal function a fter PRRT 45. Bodei e t al. studied dosimetry in 28 
patients receiving PRRT with 90Y-DOTATOC or 177Lu-DOTATATE and found tha t a 
BED of < 40 Gy was safe in patients w ithout preexisting risk factors for renal 
disease, such as hypertension, diabetes or old age (n=16), and tha t a lower BED 
threshold of < 28 Gy was safe for patients w ho did have these risk factors (n=12)
M ethods to  reduce nephrotoxic ity
Several d ifferent approaches to reduce the risk of nephrotoxicity in PRRT have 
been studied. Most of these methods aim  a t decreasing the radiation dose to 
the kidneys, for example by reducing the proximal tubular reabsorption of 
peptides. Other methods focus on reducing the harmful effects of the radiation. 
An overv iew  of these methods is presented in Table 2.1.
Reduction of renal uptake
Structural modification o f radio labeled peptides
Various attempts have been m ade to change the elim ination characteristics of 
radiolabeled peptides in order to reduce their renal retention. Structural change 
of a peptide m ay result in reduced glomerular filtration, e.g. by increasing size or 
protein binding, or in reduced tubular reabsorption, e.g. by reducing affinity of 
the peptide for renal transporters. Obviously, affin ity of the radiolabeled peptides 
for their specific receptors, which is im portant for accum ulation in target tissues, 
should remain intact.
Several studies have shown tha t the introduction or substitution of positively or 
negatively charged groups can influence the renal uptake of peptides and 
antibody fragments. Ekblad e t al. studied the renal uptake of 99mTc-labeled HER2 
Affibody molecules (Z h e r2 :342) with different chelators. They reported tha t the 
substitution of a negatively charged glutam ic acid residue by a neutral serine 
residue in the chelator sequence m ercaptoacetyl-G lu-G lu-G lu, significantly 
reduced renal uptake w ithout reducing tumor uptake 46.
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Table 2.1. Processes and factors in the renal handling and retention o f 
rad io labe led  peptides, and strategies to interfere
Site Process M ethod to reduce  
neph ro tox ic ity
Examples
G lomerulus Ultrafiltration Increase b ind ing  to A lbum in b ind ing
a lbum in or o the r proteins sequence
Increase size PEGylation
Proximal D eg rada tion  b y  brush
tubule  bo rde r enzymes
Reabsorption by  
endocytosis or 
transporters
Insert c le a vab le  linker
Decrease a ffin ity  by  
m od ifica tion  o f structure 
and  /  or cha rge  o f the  
pep tid e
Glycyl-lysine linker
Substitution, 
add itio n  or removal 
o f cha rged  groups; 
PEGylation
D eg rada tion  and  
re ten tion in lysosomes
Saturate w ith  com pe titive  
inhibitors
Decrease endocytosis  
(e.g. b y  reduc tion  of 
ene rgy supp ly or 
in te rfe rence w ith  fo rm a tion  
or tra ffick ing of 
endosomes)
Use non-residualizing  
radio labels
Peritubular absorp tion Block transporters
Coinfusion o f lysine 
/  arg in ine /  
succ in y la ted  
ge la tin
M a lea te , co lch ic ine
Conven tiona lly  
io d in a ted  pep tides
P robenecid
Whole k idney  Radia tion d am age  
and  repa ir
Use short-range  
rad ionuclides to limit 
rad ia tion  dose to the  
glomeruli
l77Lu instead o f 90Y
Scaveng ing o f free  
radica ls using 
rad iopro tecto rs
Am ifostine
Increase time to repa ir 
sublethal d am age
Dose frac tio na tion
M itiga te  dam ag ing  
processes
Spirono lactone, L- 
158,809
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M iao e t al. found tha t the renal uptake of 90Y- and ,77Lu-labeled alpha- 
m elanocyte stimulating hormone (MSH) analogs was decreased by adding a 
glutam ic acid residue to the peptide. Although the uptake in m elanom a was 
significantly decreased as well, an improved tumor-to-kidney uptake ratio was 
achieved 47. Removal of the anionic N-terminal pentaglutam ic acid sequence of 
minigastrin analogs, or rep lacem ent by a histidine - histidine - glutam ic acid 
sequence, resulted in a marked decrease in kidney uptake. Again this was 
accom panied by a decrease in tumor uptake, but an increased tumor-to-kidney 
ratio 48. Replacing minigastrin's pentaglutam ic acid sequence by a neutral 
pentaglutam ine sequence reduced uptake in CCK2-receptor positive tumors 
and organs more than it reduced renal uptake 3. 99mTc-labeled bombesin 
analogs were shown to express higher renal uptake when two glutam ic acid 
residues were introduced as com pared to one 49.
Akizawa e t al. studied the renal uptake of ’ ’ ’ In-DTPA-L-Phe’ -octreotide analogs in 
which the neutral phenylalanine residue was substituted by either a neutral 
methionine, a positively charged lysine or a negatively charged aspartic acid 
residue. They observed tha t the renal uptake of ’ ’ ’ In-DTPA-L-Lys’ -octreotide was 
significantly higher than tha t of ’ ’ ’ In-DTPA-L-Phe’ -octreotide, whereas the renal 
uptake of ’ ’ ’ In-DTPA-L-Asp’ -octreotide was lower. However, the e ffec t of these 
substitutions on the uptake in SSTR-positive organs was not reported 50. Dimeric 
cyclic RGD peptides also showed increased renal accum ulation when a lysine 
residue was introduced in the spacer linking both RGD moieties 51.
Apart from the substitution, addition or deletion of am ino acids, other molecules 
can also be coupled to peptides to alter their pharmacokinetics. Examples 
include poly(ethylene glycol) (PEG) groups or albumin binding sequences (ABS). 
Addition of PEG groups (which can range in molecular weight from ~ 2 kDa to > 
200 kDa) is referred to as ‘PEGylation' 5253. PEGylation can alter a molecule's 
pharmacokinetics by increasing its size, increasing hydrophilicity, masking 
charges and decreasing antigenicity. Insertion of 2 - 4 kDa PEG groups was 
reported to reduce the renal uptake and increase the tumor-to-kidney ratio of 
’ 25I- and ’ 8F-labeled RGD-peptides 52-54. Addition of larger PEG groups or ABS can 
reduce glomerular filtration and increase circulatory half life of peptides 5355. 
Coupling of ABS to  radiolabeled Fab-fragments and affibodies resulted in 
increased circulatory half-life, reduced kidney uptake and good tumor targeting
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as compared to the native constructs 55S6. However, an increased circulatory 
half-life also increases the bone m arrow radiation dose.
Use o f different radiolabels, linkers or chelators
As described above, after endocytosis and catabolism  in the proximal tubules, 
iodinated tyrosine can diffuse freely out of the lysosomes and the tubular cells, 
leading to relatively low  renal retention of conventionally radioiodinated 
products. However, m any peptides and antibodies are also internalized in the 
target organs or tumors, from which iodine is also rapidly cleared. This leads to 
low  target-to-background ratios and renders conventionally ,3,I-labeled products 
less useful for labeling of internalizing antibodies or peptides 57. 
Radiom etal-chelated products are retained longer in targeted tissue, but also in 
the kidneys. A strategy to reduce the kidney retention of radiolabeled peptides 
involves the insertion of metabolizable linkers between the rad iom etal-chelator 
complex and the peptide. These linkers must be stable in plasma. Specific linkers 
w ere designed to be c leaved in the kidneys by hydrolases a t the proximal 
tubular brush border membrane, releasing the radiom etal-chelator complex 
from the peptide before it is endocytosed. The radiom etal will then be excreted 
in the urine. Uehara e t al. used a glycyl-lysine bond which can be cleaved by 
renal brush border enzymes. A radiolabeled construct of Fab-fragments with 
these linkers, [,88Re]tricarbonyl-(cyclopentadienyl)-glycyl-lysine-Fab, expressed 
significantly lower kidney uptake than the native construct. Tumor uptake was 
not a ffec ted  58.
Other linkers tha t have been studied are cleaved by lysosomal enzymes, 
releasing the radiom etal-chelator complex from the cells a fter endocytosis. 
Tibben e t al. found tha t a c leavable ester bond between a chelator and a Fab'- 
fragm ent reduced the kidney uptake of Fab'-fragments w ithout affecting tumor 
uptake 59. Smith-Jones e t al. studied the biodistribution of ’ ’ ’ In-DTPA-labeled 
somatostatin analogs with several ester and diester linkers. None of the 
metabolizable linkers led to higher tumor-to-kidney ratios, because tumor uptake 
decreased more than kidney uptake 60.
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Competitive inhibition o f proximal tubular reabsorption
The interaction of peptides with receptors or transporters on the apical 
m em brane of the proximal tubular cells m ay be disturbed by other ligands of 
these transporters. An excess of ligands in the ultrafiltrate during the elimination 
phase of the radiolabeled peptides causes com petitive inhibition of the renal 
transport mechanisms, leading to a reduction in the uptake of the radiolabeled 
peptides. Again, the used substances should not interfere with the specific 
binding of the peptides to their native receptors, because this would also 
decrease uptake in target lesions.
The inhibition of tubular reabsorption of proteins by positively charged (basic) 
am ino acids was first described in the 1970s. Several years later, coadministration 
of the basic am ino acids lysine and arginine was found to reduce the renal 
uptake of radiolabeled antibody fragments and somatostatin analogs 6'-62. Behr 
e t al. reported tha t poly-L-lysine was more potent than L-lysine or D-lysine in 
reducing the renal retention of radiolabeled Fab'-fragments in rats, but poly-L- 
lysine was also more toxic. No difference between L-lysine and D-lysine was 
found 63. Rolleman e t al. reported a significant decrease in parameters of kidney 
dam age after coinfusion of lysine in rats receiving 177Lu-DOTATATE therapy 40. The 
same group studied the effects and side effects of coinfusion of either an am ino 
acid mixture, L-lysine or a com bination of L-lysine and L-arginine during PRRT with 
[111In-DTPA0]octreotide in patients. The com bination of 25 g of lysine and 25 g of 
arginine was more effective than 50 g of lysine and caused relatively fe w  side 
effects. The highest dose of 75 g of lysine was most e ffective in reducing renal 
uptake but frequently caused side effects, such as vomiting 64. Therefore, further 
increasing the lysine dose to improve kidney protection is not recom m ended. For 
somatostatin analogs, a maximum reduction of the kidney radiation dose of 
approxim ately 50% has been achieved 6465. Coinfusion of basic am ino acids is 
currently the standard renoprotective regimen in clinical PRRT.
The renal uptake of minigastrin, a peptide tha t lacks positively charged am ino 
acid residues, is not reduced by coinfusion of lysine 4-66. Behe e t al. found tha t 
negatively charged polyglutamic acid chains of a t least 5 g lutam ic acid residues 
did reduce renal uptake of minigastrin significantly 66.
Our group found tha t the plasma expander succinylated gelatin (Gelofusine®, 
Braun) efficiently reduced the renal reabsorption of 111In-octreotide in humans 67 
and of 111In-labeled octreotide, minigastrin and exendin in rats 68-69. Succinylated
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gelatin consists of peptides with an average molecular weight of 30 kDa and a 
net negative charge. The group of Baum e t al. used succinylated gelatin 
combined with the abovem entioned lysine /  arginine mixture for kidney 
protection in 902 courses of PRRT with 90Y-DOTATOC (mean activity 14 ± 4.8 GBq 
in 4 cycles) or 177Lu-DOTATATE (mean activity 28 ± 6 GBq in 4 cycles). Since this 
regimen has been in use, no serious kidney toxicity has occurred. Mild to 
m oderate allergic side effects (common toxicity criteria grade ’  or 2) of the 
renoprotective regimen were recorded in 1.4% of courses, and grade 3 reactions 
occurred in 0.6% (Richard P. Baum, written com m unication, November 2009). 
Extensive experience with the administration of succinylated gelatin to patients in 
acute care or during surgical procedures exists, and serious side effects are very 
rare. Severe anaphylacto id reactions are described in approxim ately 0.04% 70.
We recently described tha t coadministration of fractionated albumin or an 
albumin-derived peptide efficiently reduced renal uptake of radiolabeled 
peptides in rats. Five mg of the albumin-derived peptide was equally e ffective as 
20 mg succinylated gelatin in reducing the renal uptake of ’ ’ ’ In-octreotide, 111 In­
minigastrin and ’ ’ ’ In-exendin 71. This peptide consists of the 36 C-terminal am ino 
acid residues of albumin and contains 3 positively and 6 negatively charged 
residues.
The w ide variety of substances able to reduce the renal reabsorption of 
radiolabeled peptides m ay very well reflect the non-selective nature of renal 
transport systems such as the megalin receptor. The selectivity of certain 
com petitive inhibitors, like lysine for octreotide and polyglutamic acid for 
minigastrin, m ay reflect their binding to different binding sites on megalin, or the 
involvem ent of other receptors or transporters.
Alternative ways to interfere with proximal tubular reabsorption 
Apart from  com petitive inhibition, the process of endocytosis m ay be disturbed 
a t various other stages. Albumin endocytosis was reported to be decreased by 
extracellular hypertonicity, which interferes with the form ation of clathrin lattice, 
thus inhibiting the form ation of clathrin coated pits 72. Gekle e t al. also reported 
tha t alkalinisation of endosomes by addition of NH4Cl or bafilomycin A ’ to 
opossum kidney cells in vitro reduced the receptor m ediated endocytosis of 
albumin, but did not a ffe c t fluid phase endocytosis of dextran 73. The same group 
described reduced endocytosis of albumin by cytochalasin D, which disrupts the
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actin cytoskeleton, and by nocodazole, which interferes with m icrotubule 
formation 72. However, toxicity of these agents m ay preclude their clinical use. 
Disruption of microtubule form ation by pretreatm ent of rats with colchicine also 
significantly reduced the renal uptake of 111In-octreotide 74.
Since the process of endocytosis requires energy, disrupting energy supply also 
reduces endocytosis. De Jong e t al. showed tha t m aleate, an inhibitor of the 
citric acid cycle, reduced the renal uptake of 111In-octreotide in rats significantly. 
However, because of reported renal toxicity of m aleate, its use in PRRT was not 
studied further. Acidification of urine by administration of NH4Q  significantly 
reduced the renal uptake of 111In-octreotide as well, possibly through 
neutralization of negatively charged membrane binding sites 65.
Stahl e t al. recently described tha t probenecid, an inhibitor of OATs and MRPs, 
reduced the renal uptake of 111In-octreotide in rats by 30%. Octreotide is an 
organic cation, but OATs have been described to transport neutral and w eak 
cations as well as anions 25.
The influence of increasing urinary flow  on the excretion of radiolabeled peptides 
has been studied in rats as well, either by increasing fluid intake or by 
administration of furosemide. However, increasing fluid intake had no e ffec t on 
renal uptake of 111In-octreotide 65, and furosemide even caused a 44% increase 
in uptake 25.
Reduction of nephrotoxicity a t a given radiation dose
Other approaches to preventing nephrotoxicity aim  a t reduction of the dam age 
induced by a given absorbed radiation dose. These strategies are decribed 
below.
Use o f radioprotectors
Radioprotectors reduce oxidative stress by scavenging free radicals. Since the 
form ation of free radicals depends on the presence of oxygen, healthy, well- 
oxygenated tissues are protected to a larger extent than tumors, which are 
usually hypoxic. Furthermore, amifostine, the prototype radioprotector, is 
converted to its active m etabolite by alkaline phophatase. In healthy tissue, 
including the renal brush border membrane, this enzyme is expressed a t much 
higher levels than in tumor capillaries, leading to 1 0  -  1 0 0  fold higher
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concentrations of the active m etabolite in healthy tissue than in tumor cells 7S. 
Amifostine is approved for use in EBRT and has been studied in PRRT. Rolleman e t 
al. coadministered this radioprotector to rats during administration of 177Lu- 
DOTATATE and for 7 days following PRRT. They found tha t amifostine was equally 
e ffective as lysine in preventing nephrotoxicity 76.
Use o f m itigating agents
Mitigating agents aim  a t reducing the risk of nephrotoxicity by inhibiting 
counterproductive tissue reactions to radiation-induced dam age 77. From 
research in EBRT it is known tha t inhibition of the renin-angiotensin-aldosterone 
system (RAAS) after irradiation of the kidneys can prevent nephropathy 78. 
Activation of the RAAS can be inhibited by angiotensin converting enzyme (ACE) 
inhibitors, angiotensin II (AT-II) receptor blockers or aldosterone receptor blockers. 
Jaggi e t al. studied the effects of RAAS inhibition in mice tha t were injected with 
a-em itting 225Ac-labeled untargeted antibodies. Starting 10 days after injection, 
the mice were treated for 39 weeks with either spironolactone (an aldosterone 
receptor antagonist), captopril (an ACE inhibitor), L-158,809 (an AT-II receptor-1 
blocker) or placebo. Animals receiving p lacebo developed significant kidney 
dam age (tubulolysis, thickening of basement membranes and e levated blood 
urea nitrogen), which was efficiently reduced by administration of 
spironolactone and to a lesser extent by L-158,809, but not by captopril 77.
Dose fractionation
Dose fractionation is used in EBRT to utilize the potential of normal tissue to repair 
sublethal dam age between irradiation cycles. In radionuclide therapy, dose 
fractionation is difficult because of the relatively low  dose rates, long residence 
times and long half-lives of the radionuclides. In PRRT, comparisons between 
different dose fractionation schemes are scarce. Barone e t al. analyzed 18 
patients tha t were treated with 90Y-DOTATOC and found tha t patients receiving 
large radiation doses with little fractionation had the highest risk of developing 
nephrotoxicity 45. Rolleman e t al. studied fractionation of 177Lu-DOTATATE therapy 
in rats. Dividing the tota l dose over two fractions significantly reduced kidney 
dam age, and three fractions caused significantly less kidney dam age when
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given a t weekly or monthly intervals than when given a t daily intervals. No 
significant differences in tumor response were found between these regimens 40.
Influence o f radionuclide characteristics
Renal toxicity appears to occur less frequently a fter therapy with 177Lu-DOTATATE 
than after therapy with 90Y-DOTATOC 42. Of 504 patients receiving up to 30 GBq 
of 177Lu-DOTATATE (predicted kidney dose < 23 Gy), only 2 (0.4%) developed 
nephrotoxicity which was probably unrelated to PRRT 31. In another series of 60 
patients receiving up to 15 GBq of 90Y-DOTATOC (again a predicted kidney dose 
< 23 Gy), 7 (12%) developed kidney toxicity 5. The difference m ay be due to the 
lower ^-energy and the consequently lower range of the ^-emission of 177Lu, 
which results in a relatively lower radiation dose to the radiosensitive glomeruli.
Combination strategies
Several groups have studied combinations of renoprotective strategies for PRRT 
in rats. Combining lysine and succinylated gelatin showed additive reduction of 
the kidney uptake of 111In-DTPA-octreotide and 111In-DOTA-octreotate, while 
tumour uptake was not a ffec ted  4-79. Kidney uptake of 111In-exendin was reduced 
most potently by a com bination of polyglutamic acid and succinylated gelatin 4. 
Combining lysine with colchicine also additively reduced the renal uptake of 
111In-DTPA-octreotide 80. All abovem entioned strategies used combinations of 
agents tha t interfere with proximal tubular endocytosis. Combinations of these 
with other strategies, such as radiation protection or mitigation, are likely to 
further reduce the risk of nephropathy.
C o n c lu s io n  a n d  future directions
High kidney uptake of radiolabeled peptides can cause dose-limiting 
nephrotoxicity after PRRT. Reduction of this uptake can enable the administration 
of higher activities, which improves therapy effectiveness. Although this also 
increases the risk of bone m arrow toxicity, the high radiation dose to the kidneys 
remains a problem in current somatostatin analog PRRT with renoprotective 
regimens, especially when 90Y-labeled analogs are used. For other peptides such 
as minigastrin and exendin, which express significantly higher kidney uptake than
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somatostatin analogs, e ffic ient reduction of kidney uptake will be even more 
im portant to enable safe PRRT. Evidence indicates tha t the most im portant 
pathw ay for the renal uptake of most radiolabeled peptides (including antibody 
fragments) consists of glomerular filtration followed by receptor-m ediated 
endocytosis and retention in the proximal tubular cells. M any strategies have 
been designed to improve the target-to-kidney ratio of radiolabeled peptides, 
several of which show promising results. Subtle changes in the am ino acid 
sequence of a peptide, thereby changing its structure and /  or charge 
distribution, can a ffec t renal uptake considerably. Several peptide analogs have 
been designed tha t exhibit lower renal retention with unaltered target uptake. 
Another approach focuses on enhancing the c learance of radiolabeled 
products from the kidneys. Linkers tha t are selectively cleaved in the kidneys may 
prevent the accum ulation of radiolabels in the kidneys w ithout loss of retention in 
targeted tissues. In clinical PRRT, an established m ethod to reduce the absorbed 
kidney dose is the coinfusion of com petitive inhibitors of proximal tubular 
reabsorption. These have been shown to significantly reduce the renal uptake of 
various peptides. However, a baseline renal uptake of radiolabeled somatostatin 
analogs seems to persist, possibly reflecting non-saturable fluid phase 
endocytosis. Different methods to interfere with endocytosis, such as disruption of 
m icrotubule form ation, m ay also reduce fluid-phase endocytosis. To prevent 
nephrotoxicity a t a given radiation dose, dose fractionation and trea tm ent with 
radioprotectors or mitigating agents have shown promising results.
Since most of these strategies interfere with different mechanisms of kidney 
uptake and dam age, the combination of two or more strategies is likely to 
reduce kidney dam age progressively. Combining two agents tha t both reduce 
endocytosis has a lready been shown to further reduce the kidney uptake of 
various radiolabeled peptides.
Most strategies for the reduction of kidney dam age in PRRT and RIT have, as yet, 
not been tested in patients, and more research is needed to study their potential 
for clinical application. If w e can further reduce the risk of renal dam age caused 
by radiolabeled peptides, higher activity doses can be administered safely, and 
highly e ffective targeted tumor therapy comes within reach.
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A bstract
Purpose: Radiolabeled peptides used for peptide-receptor radionuclide therapy 
are excreted mainly via the kidneys and are partly reabsorbed and retained in 
the proximal tubular cells. The resulting high renal radiation dose can cause 
nephrotoxicity, limiting the maximum activ ity dose and the effectiveness of 
peptide receptor radionuclide therapy. The mechanisms of kidney reabsorption 
of these peptides are incom pletely understood, but the scavenger receptor 
megalin has been shown to play a role in the reabsorption of ’ ’ ’ In-octreotide. In 
this study the role of megalin in the renal reabsorption of various relevant 
radiolabeled peptides is investigated.
Methods: Groups of kidney-specific m egalin-deficient mice and wild type mice 
w ere injected with ’ ’ ’ In-labeled somatostatin, exendin, neurotensin or minigastrin 
analogs. Single photon emission com puted tom ographic (SPECT) images of the 
kidneys were acquired and analyzed quantitatively, or animals were euthanised
3 h post injection and the activity concentration in the kidneys was measured. 
Results: M egalin-deficient mice showed significantly lower uptake of all studied 
radiolabeled peptides in the kidneys, ranging from 22% (’ ’ ’ In-octreotide) to 65% 
(’ ’ ’ In-exendin) of uptake in wild type kidneys. Quantitative analysis of renal 
uptake by SPECT and ex vivo measurements showed very good correlation. 
Conclusions: Megalin is involved in the renal reabsorption of radiolabeled 
octreotide, octreotate, exendin, neurotensin and minigastrin. This knowledge can 
help in the design of strategies to reduce this reabsorption and the resulting 
nephrotoxicity in peptide-receptor radionuclide therapy, enabling more 
effective therapy. Small animal SPECT is an accurate  tool, allowing in vivo 
quantification of renal uptake and serial measurements in individual mice.
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Intro duct io n
In peptide-receptor radionuclide therapy (PRRT), radiolabeled peptide analogs 
are used to target tumors expressing particular receptors, such as the 
somatostatin receptor. Most radiolabeled peptides are predominantly cleared 
from the body via the kidneys. Rapid c learance of the radiolabeled peptides 
from the blood and low  retention in the kidneys minimise the radiation dose to 
normal tissues. However, part of the filtered load of these small proteins and 
peptides is reabsorbed from the ultrafiltrate in the proximal tubules. Evidence 
suggests that, after glomerular filtration, proteins and peptides in the ultrafiltrate 
bind to endocytic receptors a t the luminal surface of proximal tubular cells and 
are internalised. Subsequently, the compounds are transferred to the lysosomes, 
where they are proteolytically degraded into am ino acids '. These are 
transported back into the bloodstream. However, residualizing radiolabels (e.g. 
N-terminal am ino acid chelate conjugates or lysine chelate  conjugates) are 
trapped in the tubular cell lysosomes and can deliver high radiation doses to the 
kidney tubules and glomeruli 2. Nephrotoxicity is dose limiting in PRRT with 
somatostatin analogs such as 90Y-DOTA-Tyr3-octreotide 34.
The receptors involved in the tubular reabsorption of peptides have not ye t been 
com pletely characterised, but for various non-radiolabeled peptides 
involvem ent of megalin has been shown 5. Megalin is a multiligand receptor 
belonging to the LDL receptor family. The receptor contains four large cysteine 
rich ligand binding domains and is a high-capacity pathw ay for the reabsorption 
of different structurally non-related peptides and proteins such as albumin, 
vitam in D binding protein, 2^-microglobulin and aprotinin 56. De Jong e t al. 
recently described tha t the renal uptake of ’ ’ ’ In-octreotide was significantly 
lower in kidney-specific m egalin-deficient mice than in their wild type 
counterparts, implicating involvem ent of megalin in the renal reabsorption of 
radiolabeled somatostatin analogs 7. M any other radiolabeled peptides tha t are 
being studied for their potential in tumor imaging and PRRT display a renal 
retention severalfold higher than octreotide. Examples include exendin and 
minigastrin, targeting glucagon-like peptide-1 and cholecystokinin2 receptors, 
respectively 89. It is unknown whether megalin is also involved in the renal uptake 
of these peptides.
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In clinical PRRT with somatostatin analogs, the standard renoprotective regimen 
nowadays consists of coinfusion of basic am ino acids, which are thought to 
interfere with the binding of somatostatin analogs to megalin or other endocytic 
receptors on the proximal tubular cells w-n . However, G otthard t e t al. showed 
tha t the renal uptake of ’ ’ ’ In-minigastrin was not reduced significantly by 
coinfusion of basic am ino acids 9, suggesting tha t the reabsorption of this 
peptide is mediated by other receptors. Knowledge about the molecular 
mechanisms of proximal tubular reabsorption of different radiolabeled peptides 
is im portant to devise new  methods to reduce their renal retention, for example 
by selecting or designing more effic ient inhibitors of their renal reabsorption, or by 
structurally modifying the peptides to reduce their binding to renal receptors.
In this study the role of megalin in the renal retention of [’ ’ ’ In-DTPA-D-Phe’ ]- 
octreotide (’ ’ ’ In-octreotide), [’ ’ ’ In-DTPA0-D-Phe’ ,Tyr3]-octreota te (’ ’ ’ In- 
octreotate), [Lys40(’ ’ ’ In-DTPA)]-exendin-3 (’ ’ ’ In-exendin), [’ ’ ’ In-DOTA-Glu’ ]- 
minigastrin (’ ’ ’ In-minigastrin) and [’ ’ ’ In-DTPA0]-neurotensin[&-’3l (’ ’ ’ In-neurotensin) 
was studied in mice. The renal uptake of the peptides was measured by single 
photon emission com puted tom ography (SPECT) imaging and by ex vivo 
measurements of kidney-specific m egalin-deficient mice and wild type mice. 
Since the level of renal uptake of radiopeptides m ay differ between fem ale and 
male mice 12, both genders were im aged by SPECT.
M ethods 
Animals
Megalinlox/lox; apoECre (kidney-specific megalin-deficient) mice 13 w ere used. The 
principles of creating tissue-specific gene knockout models are described in 
detail elsewhere ,4-'5. In short, in megalinlox/lox; apoECre mice, expression of the 
enzyme Cre recombinase is controlled by the apolipoprotein E (apoE) promotor. 
Therefore, Cre recombinase is only produced in tissues where the apoE gene is 
transcribed. In these tissues, Cre recombinase excises sequences from the 
genom e tha t are flanked by two loxP sequences, in this case the megalin gene 
l4. Animals were bred locally using males heterozygous in the apoECre gene. 
Offspring expressing the apoECre gene were identified by means of polymerase 
chain reaction (PCR) analysis as described below. Animals not expressing the
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apoECre gene (megalinlox/lox mice) were used as wild types in the biodistribution 
studies. In the SPECT studies, C57Bl/6 mice were used as wild types.
PCR analysis
For PCR the primers CCCAAGAAGAGGAAGGTG (forward) and 
GCTGGCCCAAATGTTGCTG (reverse) were used. The reaction mixture consisted 
of approxim ately 50 ng mouse DNA in a tota l of 25 |jl_ colorless PCR-buffer (Go 
Taq Flexi Reaction buffer, Promega) with 5 mM MgCh (Promega), 0.5 mM 
deoxyribonucleotide triphosphate mix (dNTP, Promega), 12.5 pmol forward 
primer, 12.5 pmol reverse primer and 2.5 IU Taq polymerase (Promega). This 
mixture was heated for 4 minutes a t 95 °C, followed by 32 cycles of 30 s a t 95 °C, 
30 s a t 56 °C and 30 s a t 72 °C. After these cycles, the tem perature was 
m aintained a t 72 °C for 10 min and subsequently lowered to 10 °C. The formed 
DNA was analyzed by agarose gel electrophoresis.
Radiolabeled compounds
The following peptide derivatives were studied: [DTPA-D-Phe1]-octreotide 
(Covidien) l6, [DTPA0-D-Phe1,Tyr3]-octreotate (Biosynthema) l7, [DTPA0]- 
neurotensin[6-13] (Biosynthema) l8, [Lys40-DTPA]-exendin-3 (Peptide Specialty 
Laboratories) l9, [DOTA-Glu1]-minigastrin (Peptide Specialty Laboratories) 20. 
Relevant properties of the peptides are summarized in Table 3.1.
Table 3.1. Characteristics o f studied peptide  analogs *
Peptide ana log Target recep to r M o lecu la r
we igh t
(kDa)
Num ber o f AA residues 
(pos itive /negative )
Charge  
a t pH 7
’ ’ ’In -oc treotide Somatostatin R2 1.5 8 (1+ /  0-) + 1
’ ’ ’In -oc treo ta te Somatostatin R2 1.5 8 (1+ /  0-) + 1
’ ’ ’In-exendin G lucagon-like  
pep tid e  R-1
4.8 39 (4+ /  6-) -2
’ ’ ’In-minigastrin Cholecystokin in R2 
and  Gastrin R
2.1 13 (0+ /  7-) -7
’ ’ ’In-neurotensin Neurotensin R 1.3 8 (1+ /  0-) + 1
* R = receptor, AA = am ino acid.
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Peptides were labeled with 111InCl3 (20 MBq/nmol for SPECT studies, 10-80 
MBq/nmol for ex vivo biodistribution studies) as described previously 2’ . Labeling 
efficiency and radiochemical purity of the labeled peptides were determined by 
silica gel instant thin layer chromatography (SG-ITLC) and reverse phase high 
performance liquid chromatography (RP-HPLC). Radiochemical purity was >95% 
for all compounds.
SPECT studies
Megalin-deficient and wild type mice (male and female, n = 4-6 per group) 
received an intravenous (i.v.) injection of 40 MBq (0.2 mL, 2 nmol) 111 In­
octreotide. The exact injected activity was determined by measuring the syringe 
in a dose calibrator before and after injection. Three hours and 24 hours after 
injection, a 24 min SPECT scan of the kidney region was acquired with the four­
headed helical NanoSPECT/CT system (Bioscan) using Nucline software (v2.01, 
Mediso). Multi pinhole mouse collimators with 9 pinholes (1.4 mm diameter) per 
head were used, with a matrix of 256x256 and 24 projections (2 min per 
projection). During the scan the animals were isoflurane/O2 anesthesized and 
body temperature was maintained. This procedure was repeated in the same 
mice with 111In-octreotate, 111In-exendin, 111In-neurotensin and 111In-minigastrin 
consecutively, after intervals of a t least three weeks. Some of the animals 
developed signs of kidney dam age a t the end of this series of experiments, 
probably caused by the relatively high renal uptake of 111In-exendin, resulting in 
a high radiation dose to the kidneys 22. Therefore, the 111In-exendin, 111In- 
neurotensin and 111In-minigastrin data were discarded and an extra experiment 
with these peptides was carried out in a new set of animals. To reduce the risk of 
kidney damage, the injected activity of 111In-minigastrin and 111In-exendin was 
reduced to 10 MBq, while the peptide dose was kept constant at 2 nmol. In this 
second series, SPECT scans were acquired only at 3 h post-injection (p.i.).
SPECT scans were reconstructed iteratively, using InVivoScope software (v1.32, 
Bioscan) with medium noise reduction, a voxel size of 0.3 mm3 and standard 
reconstruction settings. The amount of radioactivity in a volume of interest drawn 
around the kidneys was quantified and expressed as % of injected dose /  gram 
tissue (%ID/g). To achieve accurate quantification, the camera was calibrated
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by scanning a 20 mL polypropylene tube mouse phantom filled with a known 
amount of 111In activity.
After the final SPECT scan, the animals were euthanized and biodistribution of
111 In-minigastrin and 111In-exendin was studied as described in the next section, to 
confirm the accuracy of the SPECT measurements.
Ex vivo biodistribution studies
Animals (n = 4-6 per group) received an i.v. injection of 0.4 MBq (0.2 mL, 5-40 
pmol) 111In-octreotide, 111In-exendin, 111In-neurotensin or 111In-minigastrin. For ^ In -  
octreotide the experiment was performed with male and female mice, for the 
other peptides only female mice were used. Three hours after injection, the 
animals were euthanized and organs were dissected. Biodistribution of the 111In- 
labeled peptides was assessed by weighing the organs and measuring 
radioactivity in a gamma counter. Measured activity was expressed as %ID/g. 
The right kidney of each animal was cut in half. One half was snap-frozen in liquid 
nitrogen and processed for cryosectioning, the other half was processed for 
paraffin sectioning. Frozen 10-jm sections were mounted on glass slides to 
perform autoradiography. A phosphor imaging screen was exposed to the 
sections for two days and scanned using a BAS 1800-II phosphor imager (Fujifilm).
Immunohistochemistry
Frozen 5 jm  kidney sections were fixed in 4% formalin for 10 min. After rinsing with
0.05% polysorbate 80 in PBS, the sections were incubated with goat anti-rat 
megalin polyclonal antibody (SC-16478, Santa Cruz) 10 jg /m L in PBS, 5% BSA for 1 
h at room temperature, followed by incubation with horseradish peroxidase- 
conjugated donkey anti-goat IgG, F(ab')2 (SC-3851, Santa Cruz) 1/100 for 30 min 
at room temperature. Peroxidase activity was visualized with diaminobenzidine 
(Powervision) and nuclei were counterstained using hematoxylin. Slides were 
dehydrated with ethanol and xylene and embedded in slide mounting fluid 
(Permount), after which they were studied microscopically. Megalin expression 
was scored visually by an independent, blinded observer on an arbitrary scale of 
0 (negative) to 4 (all tubules positive).
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Statistical analysis
Data are presented as mean values ± standard deviation. Comparison of renal 
uptake values was performed using Student's t-test. For the SPECT studies of 111In- 
minigastrin and 111In-exendin, after which the mice were sacrificed, the 
correlation between renal uptake measured on the SPECT images and uptake in 
the same mice measured ex vivo was determined. Spearman's rank correlation 
coefficient was calculated with SPSS 16.0 (SPSS Inc).
Results
Immunohistochemistry
Immunostaining revealed lower expression of megalin in the kidney cortex of the 
megalin-deficient mice as compared to the wild type mice. The expression of 
megalin in the megalin-deficient kidneys varied considerably, ranging from 
almost absent (score 0) to moderate expression (score 2). Examples are shown in 
Figure 3.1.
SPECT measurem ent of renal peptide uptake
As shown in Figure 3.2, the kidneys were visualized very well on the SPECT scans 
acquired a t 3 h p.i. The images indicated that the radioactivity mainly 
accumulated in the renal cortex.
The measured renal uptake values of the 111In-labeled peptides as derived from 
the SPECT images a t 3 h p.i. and the ratios of uptake between megalin-deficient 
mice and wild type mice are presented in Table 3.2A. The data are summarized 
together with the ex vivo biodistribution data in Figure 3.3. 111In-exendin 
expressed the highest renal uptake: 371 ± 35 %ID/g in female wild type mice. The 
peptide with the lowest renal uptake (15 ± 2.7 %ID/g in female wild type mice) 
was 111In-neurotensin. In the SPECT studies, the renal retention of all 111 In-labeled 
peptides was significantly lower in megalin-deficient mice than in wild type mice, 
both in males and females. The effect was most prominent for 111In-neurotensin, 
for which the renal uptake in female megalin-deficient mice was only 23% of the 
uptake in wild type mice (p<0.0001). The least effect was observed with 111In- 
exendin, for which the uptake in female megalin-deficient mice was 62% of the 
uptake in wild type mice (p=0.003).
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Figure 3.1. Anti-m egalin im munostaining o f kidney cortex from a wild type mouse (A) and  
two m ega lin -defic ien t mice, exhibiting relatively high (B) and  relatively low (C) residual 
expression o f megalin
Figure 3.2. SPECT images o f the kidneys o f w ild type (A) and  m egalin -defic ien t (B) m ice, 3 h 
p.i. o f ’ ’ ’In-minigastrin. Left: maxim um  intensity projections; right: co rona l slices.
The data measured 24 h p.i. are presented in Table 3.2B. The renal uptake of the 
studied radiolabeled peptides remained significantly lower in the megalin- 
deficient mice, both in females and in males.
49
Chapter 3
The uptake of 111In-octreotide and 111In-octreotate was significantly lower in male 
mice than in female mice after 24 h. The retention of 111In-octreotide in males 
was too low to delineate the kidneys and the uptake of 111In-octreotate was 
more than threefold lower in males than in females. For 111In-exendin, no 
difference between the genders was observed.
Table 3.2. Renal uptake of radiolabeled peptides in mice on SPECT
A. Uptake 3 h p.i. *
Wild type  
(% ID /g ± SD)
M egalin- 
de fic ien t 
(% ID /g ± SD)
Ratio m egalin- 
de fic ien t /  w ild type  
(%)
"'In -oc treo tide fem ale 17 i  2.4 8.Ó i  2.6 49% (p^CEH)
m ale 22 i  Ó.6 Ó.7 i  2Æ 26% (p=0.0003)
'''In -oc treo ta te fem ale 16 i  4.6 7.6 i  2.4 46% (p=0.007)
m ale 16 i  2.8 Ó.9 i  1.9 36% (p=0.Q001)
'''In -exend in fem ale 371 i  30 23Q i  08 62% (p=0.003)
m ale 328 i  01 171 i  34 ó2% ( p ^ jx n )
'''In-m inigastrin fem ale 89 i  1Q 33 i  8.9 37% (p<0.0001)
m ale 1Q4 i  13 02 i  14 49% (p=0.0003)
'''In-neurotensin fem ale 10 i  2.7 3.6 i  1.18 23% (p<0.0001)
m ale 18 i  9.Q 4.6 i  1.1 2ó% (p=Q.Q2)
B. Uptake 24 h p.i. *
Wild type  
(% ID /g ± SD)
M egalin- 
defic ien t 
(% ID /g ± SD)
Ratio m egalin- 
de fic ien t /  w ild type  
(%)
’ ’ ’In-octreotide fem ale 2.2 i  Q.2Ó 1.4 i  Q.47 64% (p=0.0001)
m ale N.m. N.m. -
’ ’ ’In-octreotate fem ale Ó.3 i  Q.97 2.Ó i  Q.71 47% (p ^JX H )
m ale 1.6 i  Q.37 Q.44 i  Q.2Q 28% (p=0.0003)
’ ’ ’In-exendin fem ale 148 i  11 82 i  24 00% (p=0.0005)
m ale 142 i  1Q 69 i  19 49% (p ^ J ^ X !!)
* % ID/g = % in jected dose /  gram  tissue; SD = standard devia tion; N.m. = no t measurable.
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Ex vivo measurem ent of renal uptake
The ex vivo measured renal uptake of the ’ ’ ’ In-labeled peptides in megalin- 
deficient and wild type mice is presented in Table 3.3 and summarized in Figure 
3.3. The renal uptake of ’ ’ ’ In-octreotide, ’ ’ ’ In-octreotate, ’ ’ ’ In-minigastrin and 
’ ’ ’ In-neurotensin was significantly lower in the megalin-deficient mice than in the 
wild type mice. The effect was most prominent for ’ ’ ’ In-octreotide, for which the 
renal uptake in female megalin-deficient mice was only 2 2% of the uptake in wild 
type mice (p=0.0007). For ’ ’ ’ In-exendin, no significant difference in renal uptake 
between both groups was observed when a peptide dose of 5 pmol was used. 
However, when a higher peptide dose of 2 nmol was administered for SPECT 
imaging, a significant difference was measured, both on SPECT and ex vivo (see 
Table 3.3).
Table 3.3. Renal uptake of radiolabeled peptides measured ex vivo, 3 h p.i. *
Wild type  
% ID /g ± sd
M egalin- 
de fic ien t 
% ID /g ± sd
Ratio m egalin- 
de fic ien t /  w ild type  
(%)
"'In -oc treo tide fem ale 38 ± 9.8 8.4 ± 3.5 22% (p=0.0007)
m ale 25 ± 12 7.9 ± 2.7 32% (p=0.03)
1 ' 'In-exendin 2 nm ol** fem ale 331 ± 33 215 ± 34 65% (p=0.00’ )
'''In -exend in 5 pm ol** fem ale 225 ± 35 183 ± 39 8 ’ % (ns)
'''In-m inigastrin fem ale 66 ± 5.9 ’ 7 ± 9 .’ 26% (p<0.000’ )
'''In-neurotensin fem ale 5.1 ± 0.94 ’ .7 ± 0 .’ 8 34% (p<0.000!)
* Renal uptake o f rad io labe led peptides In w ild type an d  m egalln-deflc lent m ice. P.I. = post 
Injection, % ID/g = % in jected dose /  gram  tissue; sd = standard devia tion; ns = not 
significant. ** ' ' 'In-exendin was m easured ex vivo in two experiments: a fte r the final SPECT 
scan using 2 nm ol peptide , an d  in a  separate biodistribution experim ent using 5 pm o l 
peptide .
Autoradiography of the kidneys revealed a patchy distribution of the ’ ’ ’ In­
labeled peptides, mainly in the renal cortex (Fig. 3.4) and confirmed lower 
uptake in the kidneys of the megalin-deficient mice.
Biodistribution of ’ ’ ’ In-labeled octreotide, octreotate, neurotensin and minigastrin 
in organs other than the kidneys did not differ significantly between the wild type 
and megalin-deficient mice (data not shown). For the high dose of ’ ’ ’ In-exendin 
(2 nmol), lung uptake in the wild type animals was significantly higher than in the
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megalin-deficient mice (1.2 i  0.18 %iD/g vs. 0.23 i  0.037 %iD/g in females and
0.98 i  0.039 %iD/g vs. 0.26 i  0.034 %iD/g in males, both p<0.0001). However, in the 
animals that received the low dose of 5 pmol ’ ’ ’ in-exendin, no difference in lung 
uptake was observed: both in wild-type and in megalin-deficient mice, the lung 
uptake was 11 %iD/g, much higher than in the animals that received 2 nmol of 
peptide.
Figure S.4. A uto rad iog raphy o f kidneys o f w ild type (left) an d  m egalin -defic ien t m ice (right) 
tha t rece ived ’ ’ ’In-exendin (A), ’ ’ ’In-minigastrin (B) or ’ ’ ’In-neurotensin (C)
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Correlation betw een biodistribution and SPECT
The correlation between renal uptake values measured with biodistribution and 
SPECT was very good, as depicted in Figure 3.5. Spearman's rank correlation 
coefficient was 0.924 (r2 = 0.85, p<0.0005).
Figure 3.5. Correlation be tw een renal uptake measured ex vivo and  uptake m easured with 
SPECT. D a ta  from individual m ice tha t were studied ex vivo a fte r the final SPECT-scan (’ ’ ’In­
minigastrin and  ’ ’ ’In-exendin). Solid lines: linear fitted trend line with 95% con fidence  interval
D is c u s s io n
In the present study we show that the multi-ligand receptor megalin is involved in 
the proximal tubular reabsorption of ’ ’ ’ In-octreotate, ’ ’ ’ In-minigastrin, ’ ’ ’ In­
neurotensin and probably of ’ ’ ’ In-exendin, and we confirm megalin's role in the 
reabsorption of ’ ’ ’ In-octreotide: the renal uptake of these peptides in megalin- 
deficient mice was reduced to 23% - 65% of the uptake in wild type mice.
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The remaining renal uptake of the radiolabeled peptides in the megalin-deficient 
mice may be due to residual megalin expression. The knock-out of megalin 
expression in the kidneys of these megalinlox/lox; apoECre mice occurs in a mosaic 
pattern, with a considerable percentage of tubular cells expressing normal levels 
of megalin, presumably caused by insufficient expression of Cre recombinase. 
Leheste et al. initially reported that approximately 10% of the proximal tubular 
cells of these mice express normal levels of megalin l3, and Motoyoshi reported 
residual megalin expression in 35%-50% of the proximal tubular cells 23. 
Immunohistochemical staining of kidney sections in the present study confirmed 
residual megalin expression and considerable variation between individual mice. 
In addition to residual expression of megalin, part of the residual uptake may also 
be explained by the involvement of other uptake mechanisms in the 
reabsorption of these peptides, such as fluid phase endocytosis 24 or other 
receptors. Proximal tubular expression of ligand-specific receptors for 
somatostatin, glucagon-like peptide -1 and cholecystokinin2 has been described 
25-27. Cubilin, another multiligand receptor, is dependent on other 
transmembrane proteins such as megalin and amnionless for its internalization 
28'29. In megalin-deficient mice, the internalization of cubilin may therefore also 
be reduced.
The data obtained in the current study with 111In-exendin were paradoxical: 
significantly reduced renal uptake in megalin-deficient mice was measured 
when the animals received an imaging dose of 2  nmol, but no significant 
difference between the two groups was found at a biodistribution dose of 5 pmol 
111In-exendin. This paradox may very well be caused by the residual megalin 
expression in the megalin-deficient mice. The residual megalin receptors may still 
be able to internalize much of the 5 pmol dose, while they are saturated by the 2 
nmol dose. Even though proximal tubular endocytosis is regarded as a low 
specificity, high capacity  pathway, it can be blocked competitively by excesses 
of ligands 303'. The difference between 111In-exendin and the other peptides in 
this respect might be explained by a relatively high affinity of 111In-exendin for 
megalin and/or associated receptors such as cubilin. This may also account for 
the very high baseline renal uptake of this peptide (225 -  371 %ID/g) and 
suggests that megalin is indeed involved in the renal reabsorption of 111In- 
exendin.
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The renal uptake of the radiolabeled peptides at 3 h p.i. was similar in male and 
female mice. However, a t 24 h p.i. the uptake of ’ ’ ’ In-octreotide and ’ ’ ’ In- 
octreotate was significantly lower in male mice, which has been described 
previously l2. This suggests that the proximal tubular processing and retention of 
’ ’ ’ In-labeled somatostatin analogs differ between male and female mice, 
leading to more rapid wash-out of radioactivity in males. However, the ratios of 
uptake between megalin-deficient and wild type mice were comparable in 
both genders at both timepoints, which suggests that the role of megalin in the 
reabsorption of radiopeptides is independent of gender influences.
Reduced proximal tubular reabsorption of radiolabeled peptides is expected to 
cause increased excretion of the radiolabeled peptides in the urine without 
affecting plasma clearance, since glomerular filtration is not affected and 
reabsorbed radiolabeled peptides are not returned to the bloodstream. This is 
confirmed by our observation that the radioactivity concentrations of these 
radiolabeled peptides in the blood and in most organs other than the kidneys 
did not differ between megalin-deficient and wild type mice. The one exception, 
lower uptake of ’ ’ ’ In-exendin in the lungs of megalin-deficient mice, was only 
observed at the high peptide dose of 2 nmol. At the lower dose of 5 pmol, no 
difference between megalin-deficient and wild type animals was observed, and 
lung uptake was approximately 5-fold to 20-fold higher than in the 2 nmol groups. 
The lower uptake a t higher peptide dose is most likely due to saturation of 
specific lung uptake, which was also described recently by Brom et al. I9. The 
lower lung uptake in the megalin-deficient mice in this group may indicate 
involvement of megalin in the pulmonary uptake of this peptide. Megalin is 
expressed in the lungs 32, and this high-capacity receptor may contribute 
significantly to peptide uptake a t higher concentrations, when specific 
glucagon-like peptide-’ receptor mediated uptake (high affinity but lower 
capacity) is saturated. Although the megalinlox/lox; apoECre mice are described to 
be kidney-specific megalin-deficient mice l3, apoE is also expressed in the lungs
33, which may cause reduced expression of megalin in the lungs of these animals. 
Possible lower expression of megalin in the lungs is unlikely to have affected the 
renal uptake of the studied peptides, as their concentrations in blood and other 
organs did not differ significantly between the megalin-deficient and wild type 
mice.
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In this study the renal uptake measured ex vivo and on SPECT images correlated 
very well, which confirms the previously reported accuracy of the small animal 
SPECT system 34. SPECT enables serial measurements in vivo and possibly reuse of 
animals in multiple experiments. However, SPECT remains much less sensitive than 
ex vivo organ measurement, which means that only organs with a considerable 
uptake can reliably be imaged and relatively high radiation doses have to be 
administered. This can lead to complications: in the present study, mice that 
received a relatively high kidney radiation dose from ’ ’ ’ In-exendin developed 
long-term kidney dam age - which is described and analyzed in detail elsewhere
22. In addition, high activity doses require administration of a relatively high 
peptide dose, which can influence a peptide's pharmacokinetics and 
biodistribution ’935.
Our results indicate that megalin plays an important role in the renal reabsorption 
of these diverse ’ ’ ’ In-labeled peptides. The variety of radiolabeled peptides and 
other ligands that are taken up via megalin suggests that it may also be involved 
in the renal reabsorption of other radiolabeled peptides. The knowledge that 
megalin is involved in the renal uptake of these radiolabeled peptides can help 
to develop new strategies for the reduction of PRRT-induced nephrotoxicity. For 
example, the reduction of renal uptake of radiolabeled peptides by 
coadministration of compounds such as succinylated gelatin and albumin 
fragments 2’■36-38, is probably due to their competitive binding to megalin. Lysine, 
a positively charged amino acid, is used to reduce nephrotoxicity of clinical 
somatostatin analog PRRT 10. However, Gotthardt et al. showed that lysine did 
not reduce the renal uptake of negatively charged minigastrin analogs, whereas 
negatively charged polyglutamic acids did reduce uptake of ’ ’ ’ In-minigastrin, 
but not of the positively charged ’ ’ ’ In-octreotide 9. These observations suggest 
that different mechanisms are involved in the uptake of these radiolabeled 
peptides and seems to contradict our present findings that megalin is involved in 
the renal uptake of both peptides. However, megalin contains four large binding 
domains 6, and lysine and polyglutamic acid may bind selectively to distinct 
regions of these domains, thereby only interfering with the binding of specific 
radiolabeled peptides. The peptide mixtures in succinylated gelatin and albumin 
fragments are more likely to block several of megalin's binding regions, thereby 
interfering with the binding and uptake of several different radiolabeled 
peptides.
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C o n c l u s io n
The multiligand receptor megalin plays an important role in the renal 
reabsorption of ’ ’ ’ In-labeled octreotide, octreotate, minigastrin, exendin and 
neurotensin. This knowledge can be used to develop new methods to reduce 
the renal retention of these peptides, thus reducing the risk of nephrotoxicity and 
improving the possibilities for safe and effective PRRT.
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A bstract
Purpose: We determined the renal radiation dose of a series of 1,1 In-labeled 
peptides using animal SPECT. Because the animals' health deteriorated, renal 
toxicity was assessed.
Methods: Wild type and megalin-deficient mice were imaged repeatedly a t 3- to
6-week intervals to quantify renal retention after injection of 40-50 MBq 111In- 
DTPA-labeled peptides (octreotide, exendin, octreotate, neurotensin, and 
minigastrin analogs) and the absorbed kidney radiation doses were estimated. 
Body weight, renal function parameters, and renal histology were determined 
16-20 weeks after the first scan and compared with those in naive animals.
Results: Because of high renal retention, 111In-DTPA-exendin-4 scans resulted in a 
70 Gy kidney radiation dose in wild type mice. Megalin-deficient kidneys 
received 20-40 Gy. The other peptides resulted in much lower renal doses. Kidney 
function monitoring indicated renal dam age in imaged animals.
Conclusion: Micro-SPECT imaging enables longitudinal studies in one animal. 
However, long-term nephrotoxic effects may be induced after high renal 
radiation doses, even with 111In-labeled radiotracers.
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In t r o d u c t io n
Malignant cells often express a high density of membrane receptors for 
regulatory peptides such as somatostatin, gastrin and exendin '. Radiolabeled 
peptide analogs specifically targeting these receptors are used as either 
diagnostic or therapeutic tools in tumor imaging and radionuclide therapy. 
Peptide receptor radionuclide therapy (PRRT) using 90Y- or ,77Lu-labeled 
somatostatin analogs (Tyr3-octreotide or Tyr3-octreotate) have led to significant 
therapeutic results in terms of tumor response, survival, and quality of life 2. 90Y 
and ,77Lu both are p-particle emitting radionuclides, whereas ’ ’ ’ In emits mainly y- 
rays and additionally Auger and conversion electrons (CEs). The mean range in 
tissue is 3900 |jm (p,-) and 200 pm (P-) for 90Y and ’ 77Lu, respectively, and 0.02-10 
pm (Auger) and 200-500 jm  (CE) for ’ ’ ’ In. When ’ ’ ’ In-labeled analogs were 
applied during PRRT less therapeutic benefit was generated 3-4, probably 
because of the short range of the Auger electrons, which have a high linear 
energy transfer and little crossfire effect. In line with these observations, ’ ’ ’ In- 
octreotate was more efficacious for the treatment of smaller, than larger tumors 
in CA20948 tumor-bearing rats 5.
A potential side effect of PRRT with somatostatin analogs is late renal damage 
due to partial renal retention of radioactivity in the proximal tubules. Nephrotoxic 
effects in patients have been described after administration of 90Y-PRRT 6, but 
rarely after ’ 77Lu-PRRT 7, and not after ’ ’ ’ In-PRRT 3.
The scavenging receptor megalin, facilitating the renal reabsorption of many 
proteins and peptides in the proximal tubules, has proven to be essential for renal 
reabsorption of radiolabeled octreotide in mice. The uptake of ’ ’ ’ In-octreotide 
was significantly less in kidney-specific megalin-deficient mice than in wild type 
(WT) mice in biodistribution studies 8, similar to the reducing effect of co­
administration of lysine in WT animals 9. We examined the role of megalin in the 
renal retention of ’ ’ ’ In-labeled somatostatin analogs and other peptides by 
imaging WT and megalin-deficient mice using a dedicated animal micro- 
SPECT/CT camera. In consecutive experiments, five different ’ ’ ’ In-labeled 
peptide analogs were administered to the same animals a t intervals of at least 
three weeks l0. Relatively high activity doses of ’ ’ ’ In (40-50 MBq per mouse) were 
injected, permitting accurate quantification of renal radioactivity. The renal
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uptake of all tested peptides in megalin-deficient mice was only 23% - 62% of the 
uptake in WT mice l0.
The purpose of the current study was to assess the effects of high dose SPECT 
imaging using ’ ’ ’ In-labeled peptide analogs with regard to risk of nephrotoxicity. 
The total absorbed radiation dose to the kidneys of WT and megalin-deficient 
mice was calculated. These results were correlated with renal histology and 
kidney function parameters, which were determined approximately 20 weeks 
after the start of the experiment.
Figure 4.1. K idney histology in naive m ice and  m ice tha t rece ived 11 'In (histology 
determ ined '6-19 weeks a fte r adm inistration o f ' ' 'In-DTPA-exendin-4.) A: Renal dam age  
score o f w ild-type (WT) an d  m egalin de fic ien t (meg def) m ice. Scores are based on 
histological exam ination o f pe riod ic  acid-Schiff-stained sections acco rd ing  to a  grading  
scale from 0-4 ''. n = 2-5 pe r group. Values are presented as m ean  ± standard devia tion  
(SD). B: Examples o f PAS stained 4 jm  paraffin  k idney sections, m agnifica tion  250x. Observe 
both glomerulosclerosis ( ^ ) an d  tubular basal lam ina thickening a n d /o r necrosis o f tubular 
epithe lia l cells (*).
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M aterials  a n d  M eth o d s  
A nimals
Animal studies were conducted in accordance with the guidelines of the Animal 
Welfare Committee of both medical centres. Kidney-specific megalin-deficient 
mice (Megalinlox/lox; apoECre), generated as described previously '2, were kindly 
provided by Thomas E. Willnow (Berlin, Germany). Animals were bred locally and 
animals expressing the apoECre gene were identified by polymerase chain 
reaction analysis. Megalin-deficient animals were compared with WT C57Bl/6 
mice (Harlan, Horst, the Netherlands); five animals of each strain and sex were 
imaged. Urine, serum, and kidneys from naive animals were tested for reference 
values.
Radionuclides and peptides
’ ’ ’ InCb was purchased from Covidien (Petten, the Netherlands). 
Diethylenetriaminepentaacetic acid (DTPA)-peptides, as listed in Table 4.’ , were 
radiolabeled as described previously '3,'4. Specific activity was 20 MBq/nmol 
peptide with a radiochemical yield exceeding 95%, as confirmed by thin-layer 
chromatography '3.
Table 4.1. Structure of investigated peptide analogs, their molecular weight (MW) 
and manufacturers
Peptide Structure MW Com pany
O ctreotide DTPA-Tyr3-octreotide 1000 Covidien, Petten, The Netherlands
O ctreo ta te DTPA-Tyr3-octreotate 1000 Mallinckrodt, St Louis, MO, USA
Exendin DTPA-Lys40-exendin-4 4200 Peptide Specia lty Laboratories 
GmbH Heidelberg, G erm any
Neurotensin DTPA-
G(Pip)6,G(Pam)8,tBuG’ 2-
neurotensin6-’ 3
815 BioSynthema, St Louis Mo, USA
Minigastrin 0 DTPA-D-Glu-(Glu)5-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2)
1832 Kindly p rovided by  Dr. M. Behe, 
M arburg, G erm any
M olecular imaging
Mice were imaged using a four-headed multi-pinhole SPECT/CT camera 
(NanoSPECT/CT, Bioscan Inc., Washington D.C., USA). Scans were obtained a t 3
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and 24 h post injection (p.i.) of 40-50 MBq ’ ’ ’ In-DTPA-peptide (2 nmol) while the 
animals were anesthetized with isoflurane/O2 and body temperature was 
maintained using a heated bed. The imaging procedure was repeated in these 
animals after a t least three weeks decay of ’ ’ ’ In. The order and intervals of the 
experiments are listed in Table 4.2. After the final scan the animals were 
euthanized; relevant tissues were dissected, weighed and their activity was 
determined in a gamma counter.
Nine-pinhole collimators with a pinhole diameter of ’ .4 mm were used on each 
head of the camera; the field of view was ’ 6 mm. On the basis of the CT 
topogram, a body range of 30 mm covering the renal region was scanned in 24 
min with ’ 20 s per projection. Settings of the ’ ’ ’ In energy peaks were ’ 7’ and 245 
keV. The amount of radioactivity in a volume of interest of the kidneys was 
quantified using InVivoScope software (Bioscan, Inc.) Detected counts were 
converted to MBq using a correction factor obtained by scanning a phantom, 
filled with a known amount of ’ ’ ’ In activity, with the same volume as the mouse 
body to correct for attenuation.
Dosimetry
The mathematic dosimetry model for mice as developed by Hindorf et al. was 
used ,s. The residence time of ’ ’ ’ In was assumed to follow a single exponential 
clearance pattern. Furthermore, only the kidney self-radiation dose was 
assumed. The renal uptake of ’ ’ ’ In-labeled octreotide in male mice and ’ ’ ’ In­
labeled neurotensin in both sexes was too low to quantify a t 24 h p.i.; therefore, 
the clearance rate was assumed to be similar to that of ’ ’ ’ In-labeled octreotide 
in female mice.
Analytical procedures
Urinary protein was measured using a commercially available colorimetric assay 
purchased from BioRad (Veenendaal, The Netherlands). Urine was collected for 
24 h in metabolic cages, ’ 2 weeks (male mice) or ’ 6 weeks (female mice) after 
’ ’ ’ In-DTPA-exendin-4 imaging. At euthanasia, four or three weeks later 
respectively, serum was collected to determine urea and creatinine levels using 
standard clinical chemistry procedures.
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Histology
One of the dissected kidneys was fixed in 10% buffered formalin and em bedded 
in paraffin. Sections (4 pm) were cut, stained with hematoxylin-eosin or periodic 
acid-Schiff reagent and evaluated microscopically to score renal damage 
according to a scale from grade 0 (no damage) to grade 4 (severe damage) as 
described previously 11.
Results
The absolute amount of retained radioactivity in WT female controls 3 h p.i. 
ranged from 5% (neurotensin), 10-15% (somatostatin analogs), 65% (minigastrin) 
to 225% (exendin) injected activity per gram of kidney. All peptides tested 
showed less renal uptake in megalin-deficient mice than in WT controls, 
reductions ranging from ~40% (exendin), ~55% (minigastrin), ~60% (somatostatin) 
to ~75% (neurotensin) l0. The measured uptake values and kidney mass, and 
published S-values 15 were used to calculate the absorbed kidney dose after 
each scan (Table 4.2). As an example, the data used for calculation of the 
kidney aborbed radiation doses after administration of 111In-DTPA-exendin-4 are 
shown in Table 4.3. Calculated absorbed doses ranged from 20-40 Gy in 
megalin-deficient to over 70 Gy in WT mice.
Table 4.2: 
peptides
Absorbed kidney radiation doses after injection of
■o0 
"ÌS■Q01c
Female mice Male eUË
Time 
(wk)
M ean absorbed dose ± SD 
(Gy)
Time
(wk)
M ean absorbed dose ± SD 
(Gy!
WT M eg def WT M eg def
octreo tide 0 2.1 ± 0.5 1.0 ± 0.2 0 1.9 ± 0.5* 0.4 ± 0.2 *
exendin 4 73 ± 9 38 ± 11 4 72 ± 6 21 ± 4
octreo ta te 13 3.3 ± 1.0 1.1 ± 0.3 9 2.9 ± 0.6 0.5 ± 0.1
neurotensin 20 0.8 ± 0.2 * 0.16 ± 0.04 * 13 0.7 ± 0.2 * 0.16 ± 0.04 *
minigastrin 23 28 ± 4 5 ± 3 20 30 ± 2 7 ± 1
* C learance assumed to be equ iva len t to octreo tide  In females
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Table 4.3: Example of calculation of the absorbed kidney dose after ,u In-DTPA- 
exendin-4 administration*
Mouse
group
In jected
activ ity
(MBq)
3 h p.i.
K idney
ac tiv ity
(MBq)
% IA
24 h p.i.
K idney % IA 
activ ity  
(MBq)
K idney
mass
(mg)
m G y/
MBq
Absor­
bed
dose
(Gy)
Female
Wild type 42.4 27.2 64.0 15.5 44.4 140 1.66 73
M eg de f 42.6 16.1 37.8 8.5 24.6 156 0.86 38
Male
Wild type 39.2 33.2 69.3 16.3 42.7 189 1.46 72
M eg de f 35.5 17.5 42.0 7.0 20.7 225 0.50 21
* Values are presented as means
Surveillance of the animals revealed that female WT mice showed some 
subdued, but still responsive behavior, approximately 16 weeks after this dose. 
Body weight loss was observed as well (data not shown). Grading of histological 
renal dam age revealed that the most pronounced effects were found in 
scanned female WT mice, showing thickening and necrosis of tubular basal 
lamina and glomerulosclerosis. In megalin-deficient mice similar histological 
dam age was detected, but less frequently (Fig. 4.1). Some increase in urinary 
protein levels was observed, although the difference with naive animals was not 
significant (Fig. 4.2). Some weeks later, serum urea and creatinine levels were 
found to be significantly elevated in scanned animals - creatinine both in WT and 
megalin-deficient mice, urea only in WT animals (Fig. 4.2).
D is c u s s io n
Recent improvements in resolution and sensitivity of small animal SPECT cameras 
opened new possibilities in preclinical research, including serial imaging of the 
same animal leading to reduction of animal numbers l6. In this study in mice we 
quantified renal uptake of several 111In-labeled peptides, enabling dosimetric 
calculations. Although the sensitivity of multi-pinhole micro-SPECT cameras is 
relatively high, we aimed for 1 MBq in the targeted organ to allow accurate 
quantification. In this comparative study, we administered 40-50 MBq of each
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111In-labeled peptide to achieve reliable quantification of renal retention even in 
megalin-deficient mice with an expected renal uptake lower than that in WT 
mice.
Figure 4.2. Urinary prote in (A), serum urea (B) an d  serum creatinine (C) o f w ild type and  
m egalin-defic ient m ice tha t either had  no t rece ived rad ioactiv ity  (naive) or ha d  rece ived  
rad ioactiv ity  12-20 weeks earlier (’ 1 ’In). n = 2-8 p e r group. Values are presented as m ean  ± 
SD.
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However, renal dam age developed a t approximately 16 weeks after an 
unexpectedly high (38-70 Gy) kidney radiation dose. On the basis of these 
findings, we had to repeat imaging of some peptides in naive animals to exclude 
the possibility that results were affected by impaired renal function.
Patients treated with 111In-DTPA-octreotide PRRT did not encounter long-term 
nephrotoxic effects after a cumulative kidney dose of 45 Gy 3, whereas a safe 
kidney dose limit of 23 Gy was adapted from external-beam radiation 17. These 
patients acquired the total 111In-dose fractionated in a minimum of eight cycles 
with a t least two week intervals, whereas the mice in the current study received 
the 40-70 Gy kidney dose after a single administration. Kidney protection by dose 
fractionation also was observed after 177Lu-octreotate PRRT in rats " .
Dose calculations were based on published S-values for 111In in mouse kidneys 15; 
other authors have described different, but comparable, S-values ,8' ' 9. All dose 
calculation models are voxel-based, using either geometrical shapes 
representing organs 15, or more realistic shapes ,8-'9, assuming homogenous 
distribution of the radioactivity. This may lead to underestimation of the effective 
dose, because renal radioactivity is primarily localized in the cortex, resulting in 
higher radiation doses to the tubules (and glomeruli) 20. Another reason for dose 
underestimation might be the assumption of exponential clearance based on 
only two time points. Acquiring images a t more, especially later, time points will 
provide better insight into the clearance and residence time of radiolabeled 
peptides and lead to more accurate dosimetry. In addition, biodistribution 
studies should be performed when relatively low renal uptake has to be 
quantified '3. In humans, the total kidney dose delivered by 111In is partially due to 
Y-irradiation; in mice, this is less important because of their much smaller kidneys. 
Taken together, these issues hamper comparison between mice and men 
concerning effects of absorbed kidney doses.
Body weight loss was the first indication of nephrotoxicity in these mice. Renal 
dysfunction was confirmed by elevated urinary protein and elevated serum urea 
and creatinine levels. Microscopic evaluation of kidney sections revealed 
histological damage in both tubuli and glomeruli. So, after megalin-mediated 
reabsorption of 111In-labeled peptides into proximal tubular cells, the glomeruli 
were also affected. The maximal range of Auger electrons (0.02-10 pm), and 
especially the longer range of CEs (200-500 pm), is sufficient to reach adjacent 
glomeruli. In the future -  in addition to the chemical and histological studies that
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have been performed 16 - we will perform renographic studies using 99mTc-DMSA 
(dimercaptosuccinic acid), 99mTc-MAG3 (mercaptoacetyltriglycine) and 111In- 
DTPA to gain insight into both tubular and glomerular function after high 
absorbed kidney doses.
In retrospect, 111In-DTPA-exendin-4 imaging should have been performed last in 
the series, and the injected activity dose could have been reduced to 10 MBq 
instead of 40-50 MBq.
C o n c l u s io n
An absorbed kidney dose of more than 40 Gy due to renal accumulation of 111In- 
labeled peptides resulted in long-term nephrotoxicity in mice. The short-range, 
low-energy Auger electrons and conversion electrons emitted by 111In caused 
both tubular and glomerular damage. Micro-SPECT offers the opportunity to 
perform follow-up studies in one animal by consecutive scanning. However, the 
risk of side effects due to high radiation doses must be considered.
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A bstract
Purpose: " ’ In-DTPA-octreotide is generally used for scintigraphic imaging of 
neuroendocrine and other somatostatin receptor-positive tumors. Based on the 
successful targeting of octreotide, radiolabeled somatostatin analogs such as 
90Y-DOTATOC and ,77Lu-DOTATATE were developed for peptide-receptor 
radionuclide therapy (PRRT). However, the maximum tolerated dose of these 
analogs is limited due to high and persistent renal uptake that leads to relatively 
high radiation doses to the kidneys. Renal uptake can be reduced by co-infusion 
of basic amino acids or polypeptides. However, high doses of basic amino acids 
can induce severe side effects. It has been described that infusion of gelatin- 
based plasma expanders resulted in increased low-molecular-weight proteinuria, 
suggesting that these plasma expanders interfere with the tubular reabsorption 
of peptides and proteins. In this study we analyzed the effect of several plasma 
expanders on the renal uptake of ’ ’ ’ In-octreotide in rats and mice.
Methods: Wistar rats and BALB/c mice were injected with 0.5 mL or 0.1 mL plasma 
expander, respectively. Thereafter, the animals received ’ ’ ’ In-octreotide i.v. 
Animals were killed at 20 h after the injection of the radiopharmaceutical. 
Organs were dissected and the amount of radioactivity in the organs and tissues 
was measured.
Results: Administration of 20 mg Gelofusine in rats or 4 mg in mice, was as 
effective in reducing the renal uptake of ’ ’ ’ In-octreotide as 80 mg or 20 mg lysine 
in rats or mice, respectively, without reducing ’ ’ ’ In-octreotide uptake in receptor- 
positive organs. Plasma expanders based on starch or dextran showed no effect 
on renal uptake of ’ ’ ’ In-octreotide.
Conclusion: The gelatin-based plasma expander Gelofusine significantly 
reduced the kidney uptake of " ’ In-octreotide as effectively as lysine. Since 
Gelofusine is a well-known and generally used blood volume substitute that can 
be applied safely without induction of toxicity, evaluation of this compound for its 
potential to reduce kidney uptake of radiolabeled peptides in patients is 
warranted.
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In t r o d u c t io n
Elimination of hydrophilic peptide-based radiopharmaceuticals from the body 
occurs preferably via the kidneys. For scintigraphic imaging and also for 
therapeutic applications, rapid renal excretion of these radiopharmaceuticals 
leads to images with low background activity and relatively low radiation doses 
as compared to gastrointestinal elimination '. On the other hand, when the 
radiopharmaceutical is retained in the kidneys, this may hamper the clinical use 
of the compound. For imaging applications, renal uptake of radiolabeled 
peptides reduces the sensitivity for detection in the vicinity of the kidneys 2. This 
often applies to radiolabeled peptides used for specific receptor targeting of 
tumors, like ’ ’ ’ In-labeled octreotide 3. In therapeutic applications, renal 
accumulation of radiolabeled peptides limits the maximum tolerated activity 
dose that can be administered without inducing radiation nephrotoxicity. In most 
cases of peptide receptor radionuclide therapy (PRRT) the kidney is the dose- 
limiting organ 2. Renal uptake and retention of (radiolabeled) low-molecular- 
weight-proteins and peptides is a complex mechanism that occurs via 
glomerular filtration and tubular reabsorption 45. It is thought that after filtration 
these peptides are reabsorbed by the proximal tubular cells and transferred to 
the lysosomes for proteolytic digestion 24. Subsequently, metabolized amino 
acids reappear in the blood stream. In contrast, radiometal-chelated amino 
acids are trapped in the lysosomes, leading to high radiation absorbed doses to 
the tubular cells of the kidneys 2. Several studies aimed to develop a strategy to 
reduce the renal retention of radiolabeled peptides and antibody fragments 67. 
These studies indicated that co-administration of basic compounds, especially 
amino acids like lysine and arginine, significantly reduced the radioactivity 
concentration in the kidneys, in some cases up to 60% 2-8. The maximal tolerated 
dose of these amino acids is however limited, because these compounds may 
cause side-effects a t high doses (arrhythmias, nausea, hyperkalemia) and 
induce nephrotoxicity themselves 3-6.
Recently, it was found that infusions of low doses polygelines (e.g. Gelofusine) 
caused low-molecular weight proteinuria. It was hypothesized that specific 
components in these plasma expanders might attenuate the tubular 
reabsorption process 9,°. In this study we evaluated whether blood volume 
substitutes reduced the uptake of ’ ’ ’ In-octreotide in the kidneys of rats and mice.
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M aterials  a n d  m e t h o d s
Radiolabeling of Octreotide
DTPA-D-Phe-’ -octreotide (Octreoscan) was obtaind from Tyco Healthcare 
(Petten, The Netherlands). The labeling was performed as described by the 
manufacturer: 37 MBq "MnCb was quickly added to the octreotide reaction vial 
(’ 0 |jg). After an incubation period of 30 minutes a t room temperature, quality 
control was performed. Radiochemical purity was checked by RP-HPLC on a C ’ 8 
column (Zorbax Rx-C’ 8 4.6 mm x 25 cm). A gradient was applied on the column 
from 40-80% 0.05 M ammonium acetate pH 5.5 to methanol over 20 minutes (’ 
ml/min). The unbound ’ "In  eluted with a retention time of 2.7 minutes, whereas 
" ’ In-octreotide showed a retention time of ’ 4 minutes.
Plasma Expanders
Plasma expanders were obtained commercially. Gelofusine (Braun, Oss, The 
Netherlands) is a succinylated gelatin solution (40 g/L). Voluven (Fresenius Kabi 
AG, Bad Homburg, Germany) is a plasma expander based on poly-hydroxyl 
starch molecules (60 g/L). Rheomacrodex solution (NPBI INT. BV, Emmer 
Compascuum, the Netherlands) contains dextran 40 (’ 00 g/L). Haemaccel 
(Aventis Pharma BV, Hoevelaken, The Netherlands), is a plasma expander based 
on degraded gelatin, cross-linked via urea (35 g/L).
Lysine solutions
A solution of ’ 60 mg/mL (rats) or 200 mg/mL (mice) lysine was prepared in 
phosphate buffered saline (PBS).
Animal Studies
For all experiments, groups of 5 female BALB/c mice (weight ’ 8-24 gram) or 4 
male Wistar rats (weight 200-220 gram) were used. Animals were i.v. injected with 
plasma expander (0J mL in mice or 0.5 mL in rats) via the tail vein. At 2-5 minutes 
after injection of the plasma expander or PBS, " ’ In-octreotide was injected 
intravenously (0.4 MBq/mouse, 2 MBq/rat). Animals were killed 20 hours later, a 
blood sample was drawn and organs were dissected. Tissues were weighed and
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the amount of radioactivity was measured in a shielded well-type gamma 
counter (Wizard, Pharmacia-LKB, Uppsala, Sweden), together with the injection 
standards. Radioactivity concentration was expressed as percentage of the 
injected dose per gram tissue (%ID/g).
In a first experiment, the effect of Gelofusine and lysine on the renal uptake of 
’ ’ ’ In-octreotide was analyzed in rats. In a second experiment, kidney uptake of 
” ’ In-octreotide in rats and mice after injection of PBS, lysine or Gelofusine was 
studied. A third experiment was performed to analyze the effects of several 
plasma expanders on ’ ’ ’ In-octreotide biodistribution in rats. In this experiment, 
animals were injected with 0.5 mL of PBS, lysine (80 mg), Gelofusine (20 mg), 
Voluven (20 mg) or Rheomacrodex (30 mg) 2-5 minutes prior to the injection of 
’ ’ ’ In-octreotide. In a last experiment in rats, Gelofusine was injected 3, ’ 5, or 60 
minutes before injection of ’ ’ ’ In-octreotide, to determine the optimal time 
interval between administration of the plasma expander and the tracer.
Statistical Analysis
Values are presented as mean ± standard deviation. Analysis was performed 
using one-way ANOVA. Results were corrected for multiple data sets with the 
Bonferroni multiple comparison test. The significance level was set at 0.05.
Results
The biodistribution of ’ ’ ’ In-octreotide in rats, injected 2-5 minutes after injection of 
PBS, lysine or Gelofusine, is presented in Figure 5.’ . Whereas the uptake of ’ ’ ’ In­
octreotide was very low in most organs and tissues (liver, spleen, lung, intestine, 
muscle, blood), high uptake was observed in the adrenals, pancreas and 
kidneys of the rats. Injection of PBS, lysine and Gelofusine resulted in similar ’ ’ ’ In­
octreotide concentrations in all tissues and organs except for the kidneys. In the 
control animals (pre-injected with PBS) the amount of radioactivity in the kidneys 
was significantly higher (’ .36±0.’ 4 %ID/g) than in the rats that received lysine or 
Gelofusine (0.88±0.08 %ID/g and 0.73±0.’ 5 %ID/g, respectively, P < 0.00’ ). No 
significant difference in kidney uptake was found between the animals injected 
with lysine or Gelofusine.
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Figure 5.1. Biodistribution d a ta  ob ta in ed  20 hours a fte r i.v. in jection o f ’ ’ ’ in -octreo tide in rats. 
Groups o f 4 rats rece ived 0.5 mL PBS, 0.5 mL lysine (80 mg) or 0.5 mL Gelofusine (20 mg) 
intravenously, 2-4 minutes prior to the in jection o f ’ ’ ’in -octreotide. Results are presented as 
m ean %iD/g, error bars ind ica te  s tandard deviation. P-values: ** indicates < 0.0 ’ , * <0.05.
Because Gelofusine reduced the kidney uptake of "'In-octreotide in rats as 
effectively as lysine, we determined if this agent had similar effects in mice. Table 
5.1 shows '''In-octreotide concentrations measured in the organs and tissues of 
rats and mice, that were pre-treated with either PBS, lysine (80 mg) or Gelofusine 
(20 mg). The effects of lysine and Gelofusine on the renal uptake of '' 'In ­
octreotide in mice and rats were similar. Compared to PBS, intravenous 
administration of lysine and Gelofusine reduced the kidney uptake in rats by 35% 
and 46%, respectively. In mice, administration of Gelofusine also demonstrated 
the most prominent reduction of kidney uptake ( ' 6% for 20 mg lysine and 6 '% for
4 mg Gelofusine). In mice, relatively higher radioactivity concentrations were 
present in the lungs, while the concentration in the adrenals and the pancreas 
was considerably lower as compared to that in rats. Although administration of 
lysine and Gelofusine in mice had a similar effect on the renal uptake of '' 'In ­
octreotide, further experiments were performed in the rats because of the higher 
uptake in receptor-positive tissues (adrenals, pancreas), thereby allowing to
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monitor possible effects of plasma expanders on receptor-mediated 111 In­
octreotide uptake.
Table 5.1. 111In-octreoflde blodlstrlbuiion, 20 h after injection (%ID/g); PBS, lysine 
or Gelofusine was injected 2-5 minutes before the injection of octreotide
Rats M ice
PBS Lysine Gelofusine PBS Lysine Gelofusine
Blood 0.01 ±0.00 0.00 ±0.00 0.00 ±0.00 0.02 ±0.01 0.02 ±0.00 0.03 ±0.00
Muscle
0.005
±0.00
0.01 ±0.00 0.01 ±0.00 0.01 ±0.00 0.01 ±0.00 0.01 ±0.00
Lung 0.01 ±0.00 0.01 ±0.00 0.01 ±0.00 0.59 ±0.12 0.79 ±0.25 0.69 ±0.10
Spleen 0.04 ±0.00 0.03 ±0.00 0.05 ±0.01 0.10 ±0.01 0.08 ±0.06 0.11 ±0.01
Kidney 1.36 ±0.14 0.88 ±0.08t 0.73 ±0.15t 1.47 ±0.38
1.23
±0.19*
0.58 ±0.23t
Adrena l 0.72 ±0.20 0.69 ±0.27 0.97 ±0.30 0.13 ±0.01 0.12 ±0.03 0.18 ±0.04
Pancreas 0.39 ±0.05 0.27 ±0.05* 0.40 ±0.05 0.08 ±0.01 0.08 ±0.01 0.08 ±0.02
Liver 0.04 ±0.01 0.03 ±0.01 0.04 ±0.00 0.10 ±0.01 0.10 ±0.02 0.11 ±0.02
Intestine 0.06 ±0.03 0.08 ±0.05 0.06 ±0.04 0.09 ±0.02 0.10 ±0.02 0.11 ±0.02
Results are presented as m ean %ID/g ± SD. * P < 0.05, f P < 0.01.
Subsequently, we determined the effect of various plasma expanders on the 
kidney uptake of ’ ’ ’ In-octreotide. Figure 5.2 shows the results of the biodistribution 
of ’ ’ ’ In-octreotide in rats pre-injected with different blood volume substitutes. 
While, lysine, Gelofusine and Haemaccel reduced the kidney uptake significantly 
(P < 0.00’ ) no significant reduction in kidney uptake was seen after injection of 
Voluven or Rheomacrodex. None of the plasma expanders affected the uptake 
of ’ ’ ’ In-octreotide in the receptor-positive tissues significantly. Uptake in the other 
organs, except for the kidneys was comparable.
Finally, we determined the optimal time interval between Gelofusine 
administration and the injection of radiolabeled octreotide. The results of the 
’ ’ ’ In-octreotide biodistribution are summarized in Figure 5.3. Only the uptake in 
the kidneys is presented, since uptake in other organs was similar as observed in 
the previous experiments.
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Kidneys Adrenals Pancreas
Figure 5.2. Biodistribution d a ta  a fte r i.v. in jection o f 1 " in -oc treo tide  in rats (20 h p.i.). Rats 
rece ived PBS, lysine (80 mg), Gelofusine (20 mg), Voluven (20 mg), Rheom acrodex (30 mg) 
or H eam acce l (17.5 mg) (0.5 mL i.v.), 2-5 minutes prior to the in jection o f 111in -octreo tide . 
Results are presented as m ean %iD/g, error bars ind ica te  SD. * P < 0.05, ** P < 0.01.
PBS 3 15 60
Time between Gelofusine and 111 In-octreotide (min)
Figure 5.3. l l l in -octreo tide  uptake in kidneys o f rats (20 h p.i.). Rats rece ived PBS or 
Gelofusine (20 mg), (i.v., 0.5 mL), 3, 15 or 60 minutes prior to the in jection o f 111in-octreotide. 
Results are presented as m ean %iD/g, error bars ind ica te  SD. * P < 0.05, ** P < 0.01.
No significant differences were measured in the radioactivity concentration in 
the adrenals and the pancreas. When Gelofusine was administered 3 and 15 
minutes prior to the injection of 111In-octreotide, the radioactivity concentration in
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the kidneys was significantly lower as compared to PBS administration (P < 0.01 
and P < 0.05 respectively). However, when Gelofusine was injected 60 min before 
111In-octreotide, no significant difference with the control rats was observed. 
Gelofusine administration apparently did not reduce kidney uptake of 111In- 
octreotide when the time between both injections was too long.
D is c u s s io n
PRRT is a relatively new and promising therapeutic modality for the treatment of 
cancer. In general, applicability of PRRT is limited due to renal uptake of 
radiolabeled peptides, which can cause renal toxicity. In the last decade several 
studies have been performed to develop a strategy to reduce the renal 
retention of radiolabeled peptides to enhance the therapeutic w indow of PRRT 
'-2. Based on the observation that individuals infused with polygeline-based 
plasma expanders developed low-molecular weight proteinuria, we studied the 
effects of blood volume substitutes on renal uptake of 111In-octreotide. We 
demonstrated that the administration of Gelofusine efficiently reduced the 
kidney uptake of 111In-octreotide in rats. A bolus injection of 0.5 mL Gelofusine (20 
mg) prior to injection of the tracer, reduced the radioactivity concentration by 
46%. The reduction in the kidney uptake was comparable with that of 80 mg 
lysine. Since various animal models are used in preclinical PRRT experiments, we 
compared the effect of Gelofusine administration in rats and mice 2. In both 
species initial kidney uptake of the radiolabeled peptide was high and 
administration of Gelofusine effectively reduced the renal uptake of 111In- 
octreotide. Both in rats and in mice, Gelofusine was a t least as effective in 
reducing renal uptake of the radiopharmaceutical as lysine.
Due to the fac t that the radioactivity concentration of 111In-octreotide in kidneys 
and receptor-positive organs of rats was high, while in other organs the 
concentration was very low, we performed additional experiments in rats. 
Comparison of several different blood volume substitutes indicated that only 
blood volume substitutes based on modified gelatin (Gelofusine and 
Haemaccel) reduced renal uptake of 111In-octreotide, while others based on 
poly(O-hydroxyethyl)starch (Voluven) or poly-dextrose (Rheomacrodex) did not. 
Thus, the effect of Gelofusine and Haemaccel on renal concentration of 111In- 
octreotide is not primarily caused by the colloid osmotic pressure of the solution,
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as all blood volume substitutes induce similar hemodynamic effects. Since neither 
Rheomacrodex nor Voluven induced a reduction of the radioactivity 
concentration in the kidneys, apparently, specific component(s) in Gelofusine 
and Haemaccel are responsible for the reduction of ’ ’ ’ In-octreotide uptake. 
Kidney uptake of ’ ’ ’ In-labeled octreotide and the mechanism of renal handling 
of this radiolabeled peptide have been studied intensively '- '3. Evidence 
indicates that ’ ’ ’ In-octreotide is taken up by the proximal tubular cells, partly via 
fluid-phase endocytosis and partly via receptor-mediated endocytosis, in which 
the megalin and cubilin receptors are thought to play a major role l3. Melis et al. 
demonstrated that [’ ’ ’ In-DTPA]octreotide was retained in the proximal tubules 
and co-localized with megalin staining, which confirms the possible role for 
megalin in this process l4. Megalin (gp330) is a very large (660 kDa) multiligand 
transmembrane receptor that facilitates endocytosis of a broad series of 
compounds 5. The receptor consists of several binding domains, binds a broad 
spectrum of proteins and peptides and plays a significant role in reabsorption of 
many filtered peptides and proteins l5. Several studies demonstrated that 
megalin binds proteins rich in positively charged amino acids as well as cationic 
drugs ,6-'7. This supports the concept that lysine and arginine interfere with ’ ’ ’ In­
octreotide uptake via binding to megalin. The reduction in kidney uptake by 
lysine and arginine is believed to interfere with the process of renal reabsorption
7-]4-]a. These cationic amino acids are expected to interact with negatively 
charged (receptor) sites, thereby blocking the receptor-mediated endocytosis of 
radiolabeled peptides.
The results we found with Gelofusine, however, only partially fit with this theory. 
Gelofusine consists of succinylated gelatin and mainly contains negatively 
charged molecules. In addition, degraded gelatin, the main component of 
Gelofusine, consists of peptide helices mainly composed of glycine, proline and 
hydroxyproline, which are neutrally rather than positively charged amino acids. 
Of course, other (cationic) amino acids or groups could be present in gelatine l9. 
On the other hand, polygelines might interact with megalin via other domains 
than cationic amino acids. To understand the mechanism by which polygeline- 
based blood volume substitutes reduce kidney uptake of ’ ’ ’ In-octreotide, the 
identification of the responsible component(s) in these plasma expanders is 
required. Results of the study by Veldman et al. suggested that Gelofusine 
induces competitive inhibition of tubular reabsorption, which is in agreement with
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our findings. Furthermore, their results also imply that megalin plays a role in this 
process because Gelofusine infusion induced urinary excretion of P2- 
microglobulin, a well-known ligand for megalin. Under physiological conditions 
P2-microglobulin is efficiently reabsorbed by the proximal tubular cells 9,’8-20. 
Besides the composition of the blood volume substitute, the time interval 
between the Gelofusine and 111In-octreotide injections appeared to be relevant. 
The short interval needed for Gelofusine to be effective suggests that a specific 
compound in Gelofusine interferes with the renal reabsorption process. We 
expect that when Gelofusine is applied to reduce kidney uptake of radiolabeled 
peptides in patients, the radiolabel should be injected almost immediately after 
injection of the Gelofusine. In patients, the effect of Gelofusine will probably last 
for more than 15 minutes, since its elimination is slower in humans than in small 
animals.
The administration of Gelofusine is safe. Even relatively large amounts of 
Gelofusine do not provoke significant side effects 2'-22. Although very rare, 
Gelofusine may elicit hypersensitivity reactions 23,24. This is in sharp contrast to the 
more severe side effects reported after administration of lysine and/or arginine 
3,2s,26. Gelofusine appears to be a potent and safe agent for the reduction of 
uptake of radiolabeled peptides in the kidneys. This effect was seen both in mice 
and rats and continued in rats until 15 minutes after the injection of Gelofusine.
C o n c l u s io n
The present study demonstrates that gelatin-based blood volume substitutes 
significantly reduce the kidney uptake of 111In-octreotide in mice and rats at least 
as effectively as lysine. Gelofusine is a well-known, widely used plasma expander 
that can be administered safely. Evaluation of this compound to reduce the 
renal uptake of radiolabeled peptides in patients is warranted.
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A bstract
Purpose: Peptide-receptor radionuclide therapy (PRRT) of neuroendocrine and 
other somatostatin-receptor-positive tumors using radiolabeled somatostatin 
analogs has been applied in several experimental and clinical settings. The 
kidneys are the organs responsible for dose-limiting toxicity due to retention of 
radiolabeled octreotide in the renal cortex, leading to a relatively high radiation 
dose which may result in irreversible loss of kidney function. Administration of 
basic amino acids reduces renal uptake, but does have significant side effects. 
We observed that gelatin-based plasma expanders induced tubular low 
molecular weight proteinuria in healthy volunteers and suggested that 
components in these solutions can interfere with tubular reabsorption of proteins 
and peptides. Here, we studied the effects of infusion of low doses of the plasma 
expander succinylated gelatin (Gelofusine) on renal uptake of ’ ’ ’ In-labeled 
octreotide (OCT).
Methods: Five healthy volunteers were given ’ ’ ’ In-octreotide, first in combination 
with normal saline and two weeks later in combination with Gelofusine. 
Scintigraphic images of the kidneys as well as blood and urine samples were 
analysed. To exclude a nonspecific hemodynamic effect of the plasma 
expander, the procedure was repeated in five other volunteers who received 
the carbohydrate-based plasma expander hydroxyethyl starch (HES).
Results: Low doses of Gelofusine were able to effectively reduce kidney retention 
of ’ ’ ’ In-octreotide. The renal radiation dose was significantly reduced by 45 % + 
’ 0 % (p=0.006), whereas HES showed no significant effect (0 % + ’ 2 %). Infusion of 
Gelofusine did not cause any side effects.
Conclusion: Gelofusine effectively reduces renal uptake of ’ ’ ’ In-octreotide. In 
contrast to currently used mixtures of amino acids, infusion of Gelofusine does not 
cause any side effect.
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In t r o d u c t io n
Radiolabeled somatostatin derivatives, such as 90Y-DOTA0-Tyr3-octreotide (90Y- 
DOTATOC) and ,77l_u-DOTA°-Tyr3-octreotate (,77Lu-DOTATATE) are used for 
peptide-receptor radionuclide therapy (PRRT) in patients with somatostatin 
receptor-positive tumors '. These hydrophilic radiolabeled peptides are 
predominantly cleared from the body via the kidneys. As most peptides 
demonstrate a relatively high retention in the renal cortex, the kidneys receive a 
relatively high radiation dose and chronic renal dam age can occur. In some 
cases bone marrow toxicity is observed, but in most cases radiation nephritis is 
responsible for dose limiting toxicity in PRRT 2-4.
In the kidneys, radiolabeled octreotide is filtered through the glomeruli and partly 
reabsorbed in proximal tubular cells 5. The reabsorption has recently been shown 
to be mediated by megalin receptors 67. To enhance the therapeutic window, 
solutions of lysine and/or arginine are coinfused, which block reabsorption of 
octreotide 89. The positive charges on these basic amino acids interfere with the 
interaction of peptides with the receptor on the proximal tubular cells and thus 
block receptor-mediated endocytosis. However, large amounts of these amino 
acids in hyperosmolar solutions are needed to effectively lower the renal uptake, 
resulting in side effects such as hyperkalemia, vomiting, volume overload and 
local irritation a t the injection site l0. Furthermore, lysine itself can cause renal 
tubular toxicity 2.
We recently have demonstrated that infusion of a low dose of the polypeptide 
plasma expanders Gelofusine (succinylated gelatin) or Haemaccel (degraded 
gelatin) increased the urinary excretion of the small peptide 62-microglobulin. The 
data indicated that the effect was caused by competitive inhibition of the 
tubular reabsorption of low molecular weight proteins l3. In the present study we 
assessed whether coinfusion of succinylated gelatin also influences renal uptake 
of ’ ’ ’ In-octreotide in healthy volunteers.
M aterials  a n d  m e t h o d s  
Subjects
Ten healthy volunteers were recruited for this study. Inclusion criteria were age 18 
years or over and a normal renal function (creatinine clearance > 90 ml/min
89
Chapter 6
according to the formula of Cockroft and Gault l4.) Exclusion criteria were 
hypertension, the use of any medication affecting renal function, known 
hypersensitivity to one of the substances used, pregnancy and lactation. The 
study was approved by the instutional review board of the Radboud University 
Nijmegen Medical Centre. Written informed consent was obtained from all 
volunteers.
Succinylated gelatin (Gelofusine) group
To assess the effect of succinylated gelatin (Gelofusine®, Braun, Oss, The 
Netherlands) on the renal uptake of [’ ’ ’ In-diethylenetriamine pentaacetic acid- 
D-Phe1]-octreotide (’ ’ ’ In-octreotide, Octreoscan, Tyco Mallinckrodt, Petten, The 
Netherlands), two series of measurements were performed on 5 subjects (2 male, 
3 female; mean age 48 + 5 years; creatinine clearance ’ 00 + 3 ml/min). Baseline 
renal uptake and blood and urine ’ ’ ’ In-octreotide concentrations were 
measured during and after infusion with normal saline (0.9 % NaCl). Two weeks 
later the procedure was repeated with Gelofusine.
Subjects were pre-treated with a bolus infusion of either saline or Gelofusine (’ 
ml/kg body mass during ’ 0 minutes.) After this, ’ ’ ’ In-octreotide (50 MBq, 5 |ig 
peptide) was administered. Infusion of normal saline or Gelofusine was continued 
a t a rate of 0.02 ml/kg/min during 3 hours. Blood pressure and heart rate were 
monitored during infusion. In the 48 hours following the injection of ’ ’ ’ In­
octreotide, posterior planar images of the kidney region were recorded in a 
’ 28x’ 28 matrix using a gamma camera (ECAM, Siemens, Hoffman Estates, Illinois, 
USA) equipped with medium-energy collimators, using both ’ ’ ’ In photon peaks 
(’ 72 and 245 keV) with 20% symmetrical energy windows. Images were recorded 
immediately, 4, 24 and 48 hours post-injection (’ 5 minutes per image.) An aliquot 
containing a known fraction of the injected dose was placed in the field of view 
for reference purposes.
Blood samples were drawn from an intravenous cannula in the contralateral arm 
at 2, ’ 0, 20, 40, 60 and 90 minutes and 2, 4 and 24 hours after injection.
Urine was collected for 24 hours following injection in two 3-hour intervals, 
followed by a 6-h and a ’ 2-h interval. Radioactivity in blood and urine samples 
was measured using an automatic gamma counter (Wizard ’ 480, Wallac, Turku, 
Finland.)
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Hydroxyethyl starch (HES) group
As Gelofusine is a pharmaceutical agent registered for plasma expansion in 
cases of hypovolemia and may thus induce changes in hemodynamics, a non 
gelatin-based plasma expander (hydroxyethyl starch, HES, Voluven®, Fresenius, 
Den Bosch, The Netherlands) was studied in a group of 5 other healthy volunteers 
(5 female; mean age 3 ’ + ’ 5 years; creatinine clearance ’ 04 + 9 ml/min). The 
same procedure as described above was used in the HES-group, in which two 
weeks after the baseline measurements, HES was infused instead of Gelofusine.
Im age analysis
Regions of interest (ROI) were drawn around the kidneys and the reference 
aliquot. The kidney ROI were copied and placed adjacent to the kidneys to 
determine background activity. Percentage of the injected dose (%ID) in both 
kidneys was calculated as previously described ,s: %IDkidneys = (countsleft kidney -
0.66 * countsleft background + countsright kidney — 0.66 * countsright background) /
(countsreference /  %IDreference). A graph of %IDkidneys against time was plotted and 
the areas under the curve were calculated.
Statistical analysis
Data were analysed with paired and unpaired t-tests using the Prism 4 software 
package (GraphPad Software, San Diego, USA.) The level of significance was set 
at 0.05.
Results
Less than 420 ml of normal saline, Gelofusine, or HES was infused in each subject. 
Gelofusine contains 40 g of succinylated gelatin per liter; the total amount 
administered averaged ’ 2.9 g (SD 2.3). Neither normal saline, Gelofusine, nor HES 
induced any significant changes in blood pressure, heart rate or caused any 
other clinical side effect.
As shown in Figures 6 .’ and 6.2, infusion of Gelofusine significantly reduced renal 
uptake of ’ ’ ’ In-octreotide as compared to normal saline infusion. The area under 
the curve decreased by 45% (SD ’ 0%) (p=0.006).
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Figure 6.1. Percentage o f in jected dose o f ' ' ' In-octreotide in the kidneys (%ID + SD] a fter 
infusion o f norm al saline com p are d  to Gelofusine (A] or HES (B]. Significantly less " 'In ­
octreo tide  was re ta ined in the kidneys a fte r Gelofusine infusion than a fte r norm al saline 
infusion (p=0.006]. A fte r infusion o f HES, no d ifference was observed.
Figure 6.2. Posterior images o f the k idney region, 24 hours a fte r in jection o f " 'In -oc treo tide  
in sub ject from Gelofusine group (A) an d  from HES group (B). Gelofusine lowered renal 
uptake com p are d  to norm al saline, b u t HES d id  not.
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Baseline renal uptake of ’ ’ ’ In-octreotide (after normal saline infusion) in the 
Gelofusine group was similar to that in the HES group (p=0.36). However, in sharp 
contrast to the observations in the Gelofusine group, HES did not alter renal 
uptake of ’ ’ ’ In-octreotide: no difference in area under the curve was observed 
between infusion of either normal saline or HES (mean 0%; SD ’ 2 %; p=0.85). 
’ ’ ’ In-octreotide was rapidly cleared from the blood. After 4 hours approximately
5 %, and after 24 hours approximately 0.6 % of the initial radioactivity was still 
present in the circulation. As shown in Figure 6.3, administration of Gelofusine or 
HES did not a ffect the blood clearance of ’ ’ ’ In-octreotide compared to normal 
saline infusion.
Figure 6.3. Blood c learance  o f 11 'In -ocfreo flde over time. No statistically significant 
differences were observed be tw een groups.
The excretion of ” ’ In-octreotide in urine ranged from 40 to 50 %ID (SD 8 to 10 %ID) 
in the first 3 hours after injection and from 76 to 87 %ID (SD 7 to 15 %ID) in the first 
24 hours. No statistically significant differences in urine excretion due to infusion of 
Gelofusine or HES were observed.
D is c u s s io n
In this study, infusion of relatively small amounts of Gelofusine (less than 420 ml) 
effectively reduced renal retention of ’ ’ ’ In-octreotide by 45 %. Since infusion of 
similar amounts of the carbohydrate based plasma expander hydroxyethyl
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starch (HES) did not a ffect renal retention of ’ ’ ’ In-octreotide, the reduction 
cannot be attributed to nonspecific renal or vascular effects due to plasma 
expansion. The absence of a hemodynamic effect is further supported by the 
absence of changes in blood pressure.
Neither Gelofusine nor HES altered blood clearance or 24-hour renal excretion of 
’ ’ ’ In-octreotide significantly. Since renal retention is reduced after infusion of 
Gelofusine, one would have expected an increase in urinary excretion. The 
absence of a significant effect is probably due to the relatively small fraction of 
the injected dose that is retained in the kidneys (approximately 5 %ID) as 
compared to the large fraction of total excreted activity (approximately 85 + ’ ’ 
%ID in the first 24 hours), and its relatively large standard deviation. The latter may 
be caused by volunteers who failed to collect all urine over 24 hours.
The mechanism of retention of radiolabeled peptides in the kidneys following i.v. 
administration is relatively well understood. In general, peptides with a molecular 
weight less than 20 kDa are readily filtered in the glomeruli and subsequently 
effectively reabsorbed in the cells of the proximal renal tubules. Peptides are 
reabsorbed by the tubular cells via receptor mediated endocytosis and 
pinocytosis. After internalization, the labeled peptides are degraded in the 
lysosomes and the metabolites are mainly transferred back into the bloodstream. 
However, the radioactive metabolites of peptides labeled with radiometals - 
radiolabeled DTPA or DOTA-conjugated aminoacids - cannot leave the 
lysosomes and remain trapped in the proximal tubular cells. De Jong et al 
recently showed that ’ ’ ’ In-octreotide reuptake in kidney proximal tubular cells is 
mediated by the megalin receptor l6. This receptor is involved in the reuptake of 
several low-molecular weight proteins, including 62-microglobulin.
Preclinical studies have shown that infusion of lysine and/or arginine can block 
tubular reabsorption of radiolabeled peptides, thereby reducing kidney retention 
of these peptides ,7-'9. Studies in patients have confirmed that this approach is 
also clinically feasible and it has become part of standard PRRT protocols for 
patients 20~23. However, most of these protocols have significant side effects. 
Infusion of large amounts of cationic amino acids may induce vomiting as well as 
metabolic changes leading to hyperkalemia, which can cause serious cardiac 
problems. To prevent administration of solutions of potentially dangerous high 
osmolarity, large volumes need to be infused. The resulting high volume load 
may cause cardiac problems, especially in cardially compromised patients 24'25.
94
Inhibition of renal octreotide uptake in humans
Current studies focus on reducing these side effects and selecting a protocol 
that is clinically acceptable.
Although a decrease of ’ ’ ’ In-octreotide activity in the kidneys is of minor 
importance to diagnostic procedures, the current findings are of importance for 
therapeutic doses of somatostatin derivatives and other peptides labeled with 
metallic radionuclides. Earlier studies have shown that octreotide and octreotate 
labeled with different radioactive metal ions have similar biodistribution 
characterisics 26. In most studies, ’ ’ ’ In-labeled analogs (e.g. ’ ’ ’ In-DOTATOC or 
’ ’ ’ In-DTPA-octreotide) are used as a surrogate to predict the biodistribution of the 
90Y- or ’ 77Lu-labeled compounds, despite the fac t that the nature of the 
conjugate might a ffect the affinity of octreotide for its receptor and 
consequently its in vivo biodistribution 2728. PET imaging using 86Y-labeled 
DOTATOC has been applied to estimate the radiation dose of 90Y-DOTATOC to 
the kidneys 2930. However, the mean residence times for ’ ’ ’ In-DOTATOC and 90Y- 
DOTATOC in the kidneys are similar.
It has been shown that the renal uptake of e.g. 90Y-DOTATOC or ’ 77Lu-DOTATATE 
can be decreased by co-infusion of amino acid mixtures. Kidney dose reductions 
in the range of 20-50 % have been reported 3N33. Nevertheless, the currently 
optimal amino acid mixture of 25 g of lysine and 25 g of arginine still causes 
hyperkalemia 34. Our study shows that co-infusion of Gelofusine results in a 
reduction in renal uptake of ’ ’ ’ In-octreotide of 45 %, similar to the maximum 
effect reached with amino acid infusions, without any side effects. It appears 
that the gelatin derived peptides more effectively attenuate the reabsorption of 
octreotide than the basic amino acids. Gelofusine is a plasma expander which is 
widely used clinically at high doses with few  or no side effects. In particular, 
infusion of Gelofusine is not associated with hyperkalemia. To achieve a 
reduction of renal uptake of ’ ’ ’ In-octreotide, only a limited amount of gelatin, on 
average ’ 2 .9  g, was needed.
The exact composition of succinylated gelatin is unknown. Gelatin, which mainly 
consists of type I collagen, is rich in the amino acids proline and glycine, but also 
contains lysine residues. We expect that co-infusion of Gelofusine will also 
decrease the renal uptake of therapeutic doses of 90Y-DOTATOC or ’ 77Lu- 
DOTATATE, similar to the effect observed on ’ ’ ’ In-octreotide uptake.
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CONCLUSION
This study shows that infusion of a relatively small amount of succinylated gelatin 
effectively reduces renal uptake of ’ ’ ’ In-octreotide and may thus limit 
nephrotoxicity of PRRT, without any of the side effects associated with amino 
acids infusion. Further in vitro and in vivo studies are in progress to characterize 
the active substances and their exact mechanism of action.
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Chapter 7
A bstract
Purpose: In most types of peptide-receptor radionuclide therapy (PRRT) the 
maximum activity dose that can be administered is limited by high and persistent 
renal retention of the radiolabeled peptides, which is, a t least partly, mediated 
by the megalin receptor. Several agents that interfere with the renal reabsorption 
of radiolabeled peptides have been identified (e.g. lysine, arginine, Gelofusine), 
but none of these inhibit renal reabsorption completely. Albumin, a naturally 
abundant megalin ligand, might be a safe and potent alternative. In this study 
we analyzed the effects of albumin and fragments of albumin (FRALB) on the 
renal reabsorption of ’ ’ ’ In-octreotide, ” ’ In-exendin and ” ’ In-minigastrin.
Methods: The effects of albumin and FRALB on megalin-associated binding of 
’ ’ ’ In-octreotide, ’ ’ ’ In-exendin and ’ ’ ’ In-minigastrin were assessed in vitro using rat 
yolk sac epithelial (BN’ 6 ) cells. In vivo, uptake and localization of ’ ’ ’ In-albumin 
and ’ ’ ’ In-FRALB in the kidneys of Wistar rats were determined, as well as the 
effect of lysine, Gelofusine, albumin and FRALB on kidney uptake of ’ ’ ’ In­
octreotide, ’ ’ ’ In-exendin and ’ ’ ’ In-minigastrin.
Results: FRALB significantly reduced binding and uptake of ’ ’ ’ In-octreotide, ’ ’ ’ In- 
exendin and ’ ’ ’ In-minigastrin by BN’ 6 cells. In rats, renal uptake of ’ ’ ’ In-labeled 
FRALB was significantly higher than that of ’ ’ ’ In-labeled intact albumin (P<0.001). 
FRALB administration effectively reduced renal uptake of ’ ’ ’ In-octreotide, ’ ’ ’ In- 
exendin and ’ ’ ’ In-minigastrin. Administration of ’ -2 mg of FRALB reduced renal 
uptake of ’ ’ ’ In-octreotide as efficiently as 80 mg of lysine.
Conclusion: Renal uptake of ’ ’ ’ In-octreotide and other radiolabeled peptides in 
rats can be effectively reduced by administration of albumin fragments. 
Additional studies to identify the albumin fragments responsible for inhibition of 
renal peptide uptake are warranted.
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In t r o d u c t io n
Elimination of radiolabeled hydrophilic peptides from the body occurs preferably 
via the kidneys. For scintigraphic imaging, rapid excretion of these compounds is 
preferable in order to obtain high quality images with low background activity '. 
In peptide-receptor radionuclide therapy (PRRT), rapid clearance of the 
radiolabeled peptides from the blood and low retention in the kidneys are 
important to minimize the radiation dose to normal tissues, especially the kidneys. 
However, many of these small proteins and peptides are partly retained in the 
kidneys due to tubular reabsorption. Renal reabsorption of (radiolabeled) 
peptides and proteins is a multi-step process 2-3. It is thought that, after glomerular 
filtration, proteins and peptides in the ultrafiltrate bind to endocytic receptors at 
the luminal surface of proximal tubular cells and are internalized. Subsequently, 
the compounds are transferred to the lysosomes and degraded into amino acids 
2 3  These amino acids are transported back into the bloodstream. However, 
radiometal-chelated amino acids are trapped in the tubular cell lysosomes, 
thereby delivering high radiation doses to the kidneys '-4.
The exact mechanism of tubular reabsorption of peptides is not completely 
understood, but several studies have shown a role for megalin 56. Megalin is a 
multiligand receptor belonging to the LDL receptor family. The receptor binds 
various structurally different proteins (albumin, vitamin D binding protein, p>2- 
microglobulin, aprotinin and many others) 5. It has been shown that some ligands 
bind to megalin via their cationic sites, and that co-administration of other basic 
(cationic) compounds can inhibit the renal reabsorption of these ligands bJ. 
Indeed, it has been shown in patients undergoing PRRT with radiolabeled 
octreotide as well as in various animal models, that renal uptake of different 
radiolabeled peptides and antibody fragments can effectively be reduced by 
co-administration of basic amino acids such as lysine and arginine '-4-8-9. 
However, these compounds can cause side effects a t high doses, such as 
nausea, hyperkalemia, arrhythmias, and even nephrotoxicity 7-9-w.
Since megalin seems to play an important role in tubular reabsorption of 
radiolabeled peptides, we hypothesized that the megalin substrate albumin 
could also reduce renal uptake of radiolabeled peptides " - '2. Albumin is a 
protein with a molecular weight of 67 kDa 7. Only a very small fraction of total 
albumin passes the glomerular membrane and is reabsorbed by the renal tubular
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cells 6,13,w s . Because only a small fraction of total intact albumin passes the 
glomerular membrane, we further hypothesized that fragments of albumin might 
be more suitable for inhibiting tubular reabsorption of peptides.
In this study the effect of fragments of albumin on the renal uptake of [111 In-DTPA- 
d-Phe1]-octreotide (111In-octreotide), [Lys40(aminohexanoic acid-DTPA-111In)NH2]- 
exendin-4 (111In-exendin) and [111In-DOTA-Glu1]-minigastrin (111In-minigastrin) was 
analyzed, both in vitro and in rats.
M aterials  a n d  m e t h o d s  
A lbumin fragments
Intact albumin was fragmented by trypsin digestion. Trypsinization was performed 
in 50 mM ammonium carbonate buffer, pH 7.8, by adding 500 mg of trypsin 
(Sigma, St Louis, USA) to 4.5 g bovine serum albumin (Sigma, St Louis, USA) in 15 
mL of buffer. The mixture was incubated at 37 °C for 24 h. The trypsinized albumin 
(FRALB) was analyzed by fast protein liquid chromatography (FPLC) using a 
Superdex 75 size exclusion column (Pharmacia, Uppsala, Sweden). The solution of 
FRALB was purified using 15 mL Centriprep® centrifugal filter units (Millipore, 
Amsterdam, The Netherlands), as outlined in Figure 7.1.
Filter
cut-off 3 kD
Filtrate v Residue 
FRALB<3 * --------- ---------► FRALB-3-50
<3 kD 3-50 kD
Figure 7.1. Production schem e o f FRALB. Albumin was trypsinized and  the resulting FRALB 
solution was purified via centriprep filtration tubes, to ob ta in  solutions con ta in ing fragments 
with a m olecu lar w e igh t <50kD (FRALB<50), 3-50 kDa (FRALB-3-50) and  <3 kDa (FRALB<3).
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After filtration of FRALB with a Centriprep YM-50 (50 kDa cut-off), the residue was 
discarded. The filtrate, containing albumin fragments with molecular weights <50 
kDa (FRALB<50), was further fractionated using a Centriprep YM-3 filter (3.0 kDa 
cut-off), producing two additional solutions: the filtrate containing fragments with 
a molecular weight <3kD (FRALB<3), and the residue containing fragments with 
molecular weights ranging from 3 to 50 kDa (FRALB-3-50). The protein 
concentration in each fraction was estimated based on light absorbance at 280 
nm, as determined spectrophotometrically. The fractions were analyzed by FPLC 
as described above.
DTPA conjugation of albumin and albumin fragments
Albumin and FRALB-3-50 were conjugated with DTPA (diethylenetriamine 
pentaacetic acid) by incubation with a 10 fold molar excess of cDTPA (Sigma, St 
Louis, USA) in 0.1 M carbonate buffer, pH 9.0, as described by Hnatowich et al. 16.
Radiolabeling
[DTPA-d-Phe1]-octreotide (Octreoscan, Tyco, Petten, The Netherlands) was 
labeled with 111In by adding 37 MBq of 111InCl3 to 1 |jg of Octreoscan and 
incubating for 30 minutes a t room temperature.
[Lys40(aminohexanoic acid-DTPA)NH2]-exendin-4 (exendin) was synthesized at 
Peptide Specialty Laboratories GmbH (Heidelberg, Germany) using standard F- 
moc chemistry. The peptide was labeled with 111InCl3 in a 0.25 M ammonium 
acetate buffer, pH 5.5. A mixture of 3.7 MBq of 111In and 1 jg  of exendin was 
incubated for 30 minutes at room temperature. Subsequently, EDTA was added 
(12 jL, 0.05 M) and incubated for 10 minutes, after which Tween80 (60 jL, 0.1%, 
Sigma, St Louis, USA) was added.
[DOTA-Glu1]-minigastrin (minigastrin) was synthesized a t Peptide Specialty 
Laboratories GmbH (Heidelberg, Germany) using standard F-moc chemistry. This 
was labeled with 111InCl3 in a 0.25 M ammonium acetate buffer, pH 5.5, 
containing 0.6 g/l gentisic acid. 5.5 MBq of 111In was added to 0.5 jg  (5 jL) of 
minigastrin. The mixture was incubated a t 95 oC for 25 minutes.
Albumin-DTPA and FRALB-3-50-DTPA were labeled with 111InCl3 in a 0.25 M 
ammonium acetate buffer, pH 5.5. In a total volume of 500 jL, 10 MBq of 111InCl3
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was added to 200 jg  albumin-DTPA or FRALB-3-50-DTPA and incubated for 30 
minutes a t room temperature.
Radiochemical purity and labeling efficiency of all compounds were determined 
by SG-ITLC (silica gel instant thin layer chromatography) and RP-HPLC (reverse 
phase high performance liquid chromatography). Radiochemical purity of all 
compounds was equal to or higher than 95%.
Compounds used to reduce renal reabsorption
Gelofusine (Braun, Oss, The Netherlands) is a succinylated gelatin solution (40 g/L) 
,7-'8. Lysine solution (lysine) was prepared as a 160 g/L solution in phosphate 
buffered saline (PBS). Albumin and fragmented albumin (FRALB<50, FRALB-3-50 
and FRALB<3) were prepared as described above. Molar mass of Gelofusine 
averages 3-104 g/mol (manufacturer's data). Molar mass of FRALB<50 was 
estimated to average 1 -10 4 g/mol.
In vitro studies
Rat yolk sac epithelial (BN16) cells, expressing megalin 19 were kindly provided by 
professor Pierre J. Verroust. Cells were cultured a t 37 °C in BN16-medium, 
consisting of Dulbecco's modified Eagle's medium plus 10 mM glucose (DMEM- 
HG, Invitrogen, Paisley, UK) with 10% fetal calf serum, 100 U/mL penicillin and 100 
|jg/m l streptomycin (Invitrogen, Paisley, UK).
The potency of FRALB to inhibit the interaction of the radiolabeled peptides with 
BN16 cells was compared to the potency of Gelofusine and lysine. The cells were 
seeded into 6-well plates at 3-105 cells/well and cultured until confluent. The cells 
were washed with PBS and incubated for 1 hour with serum free BN16 medium, 
after which they were washed twice with PBS, and 2 mL of Ringer's solution (pH 
7.4) was added. Then the inhibitor was added, either lysine, Gelofusine or 
FRALB<50 a t a 100,000 fold molar excess over the radiolabeled peptide. The 
concentrations of the inhibitors in the medium were 7-10-4 g/L lysine, 1 -10-1 g/L 
Gelofusine and 3-10-2 g/L FRALB<50. Directly after addition of the inhibitor, 1 kBq 
of 111In-octreotide, 111In-exendin or 111In-minigastrin was added. After 1 hour of 
incubation a t 37 °C, cells were rinsed once with Ringer's solution and harvested 
using cotton swabs. Radioactivity was measured in a shielded well-type gamma 
counter (Wizard, Wallac, Turku, Finland).
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Animal studies
Groups of 4 male Wistar rats (200-220 g) were used in all experiments. To 
investigate whether FRALB reached the proximal tubule of the kidney more 
efficiently than albumin, 111In-albumin and 111In-FRALB were administered 
intravenously (i.v.) to rats.
To compare the potency of FRALB to inhibit renal reabsorption of radiolabeled 
peptides to the potency of known inhibitors, animals were injected i.v. with 0.5 
mL of the inhibitor (either PBS, lysine (80 mg), Gelofusine (20 mg) or FRALB<50 (5 
mg)) via the tail vein. Two to five minutes later, 111In-octreotide, 111In-exendin or 
111In-minigastrin was injected i.v. (2 MBq/rat). For 111In-octreotide, a dose- 
response study of FRALB<50 was done, and the potencies of the filtered FRALB 
preparations (FRALB<50, FRALB-3-50 and FRALB<3) were compared.
Animals were killed 20 hours after injection, a blood sample was drawn and 
organs were dissected. Tissues were weighed and counted in a shielded well- 
type gamma counter (Wizard, Wallac, Turku, Finland) together with the injection 
standards. Radioactivity concentration was expressed as percentage of the 
injected dose per gram tissue (% ID/g). For autoradiography, a central 5 -jm  
section was cut from each kidney and mounted on poly-L-lysine coated slides. 
Kidney sections were exposed to a phosphor screen overnight, which was 
subsequently scanned in an imaging system (Molecular Imager GS363, BioRad 
Laboratories, Hercules, CA) at a pixel size of 100 x 100 jm .
Statistical analysis
Data are presented as mean values ± standard deviation. Analysis of cell binding 
and kidney uptake was performed using Student's t-test. Biodistribution data in 
other organs was analyzed by one-way ANOVA with a correction for multiple 
data sets using Bonferroni's multiple comparison test. The significance level was 
set a t 0.05.
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Results 
Analysis of albumin fractions
The FPLC elution profiles of albumin and of the three FRALB preparations are 
shown in Figure 7.2. Approximately 50% of intact albumin was still present in the 
unpurified FRALB preparation (Fig. 7.2B). After ultrafiltration, FPLC analysis 
demonstrated that FRALB<50 contained less than 30% intact albumin (Fig. 7.2C). 
In FRALB<3 no detectable intact albumin was present (Fig. 7.2D).
Figure 7.2. FPLC elution profile o f album in and  trypsinized albumin (FRALB). Analysis o f 100 
j g  album in (A), unpurified FRALB (B), FRALB<50 (C) an d  FRALB<3 (D). AU = Arbitrary Units.
In vitro studies
The BN16 assay showed that FRALB<50 decreased 111In-octreotide binding by 48 
± 5.7% (p<0.001), as illustrated in Figure 7.3A. Gelofusine decreased uptake by 46 
± 3.0% (p<0.001). Lysine did not significantly reduce binding of octreotide in this 
assay (p=0.14).
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A  Octreotide B Exendin C M inigastrin
0 .7-1 7-1 2 -
Figure 7.3. Inhibition of binding / uptake of "'In-octreotide (A), '''In-exendin (B) and "'In ­
minigastrin (C) in BN '6 cells by lysine, Gelofusine, or FRALB<50. Results are presented as 
mean %  bound activity, error bars indicate standard error of the mean. ** p < 0.005.
Binding of ’’’In-exendin to BN 16 cells was decreased by Gelofusine and 
FRALB<50 by 81 ± 1.9% (p<0.001) and 91 ± 1.3% (p<0.001) respectively (Fig. 7.3B). 
Lysine did not significantly reduce n 1In-exendin binding (p=0.10).
Binding of 111In-minigastrin was reduced by 96 ± 0.5% by FRALB (p<0.005), by 92 ± 
2.7% by Gelofusine (p<0.005) and was not decreased significantly by lysine (Fig. 
7.3C). Higher concentrations of lysine, up to 2 mg (106 fold molar excess), did not 
reduce binding significantly either (data not shown).
Biodistribution of albumin and FRALB
Measurement of tissue radioactivity concentration in rats 20 hours after injection 
of ^In-labeled albumin or FRALB-3-50, demonstrated that kidney retention of 
^In-albumin was significantly lower than retention of 1n In-FRALB (2.47 ± 0.28% 
ID/g vs. 15.2 ± 1.2% ID/g respectively, p<0.0001). Furthermore, the radioactivity 
concentration of 111In-albumin in the blood was significantly higher (0.069 ±
0.004% ID/g vs. 0.011 ± 0.002% ID/g, p<0.0001), indicating faster blood clearance 
of the low molecular weight albumin fragments. Autoradiography of kidney 
sections confirmed that the renal radioactivity concentration of 111In-FRALB was 
much higher than that of 111In-albumin and demonstrated that radioactivity was 
mainly present in the renal cortex, as shown in Figure 7.4.
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A
Figure 7.4. Autoradiography of renal sections o f '' 'In-albumin (A) or '' 'In-FRALB-3-50 (B) 
dissected from rats, 20 h post injection. Radiolabeled compounds were mainly present in 
the renal cortex.
Renal uptake of radiolabeled peptides
The effect of FRALB on the renal uptake of 111In-octreotide in rats is shown in 
Figure 7.5. A dose of 5 mg FRALB<50 reduced the renal uptake of 111In-octreotide 
by 30 ± 2.7% (p<0.0001), which is similar to the effect of 20 mg Gelofusine (32 ± 
7.0%, p<0.0001) and 80 mg lysine (30 ± 9.1%, p<0.0001).
Figure 7.5. Kidney radioactivity concentrations 20 h after i.v. injection of '''In-octreotide. 
Two to four min prior to the injection o f ' ''In-octreotide, rats received 0.5 mL of either PBS, 
lysine, Gelofusine, different concentrations of FRALB<50, or other filtered preparations of 
FRALB. Error bars indicate standard error of the mean. * p<0.05, ** p<0.005.
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Doses of 1 mg and 0.5 mg FRALB<50 reduced uptake by respectively 10 ± 4.6% 
(p<0.005) and 8.1 ± 5.5% (p<0.05). The two other purified FRALB preparations 
(FRALB-3-50, 1 mg; FRALB<3, 4 mg) both significantly reduced renal uptake of 
111In-octreotide (p<0.0001) and were as potent as 80 mg lysine.
Renal uptake of 111In-exendin (Fig. 7.6A) was reduced by FRALB<50 by 52 ± 4.7% 
(p<0.0001), more potently than by either Gelofusine (25 ± 13%, p<0.0005) or lysine 
(15 ± 18%, p<0.05). Figure 7.6B shows that renal uptake of 111In-minigastrin was 
almost completely blocked by FRALB<50 (93 ± 0.62% reduction, p<0.0001). 
Reduction in uptake by Gelofusine was 82 ± 2.5% (p=0.0001). Lysine did not 
reduce uptake of minigastrin significantly.
A Exendin B Minigastrin
Figure 7.6. Kidney radioactivity concentrations 20 h after i.v. injection of ’’’In-exendin (A) or 
’’ ’In-minigastrin (B). Two to four minutes prior to the injection of the radiolabeled peptide, 
rats received 0.5 mL of either PBS, lysine, Gelofusine or FRALB<50. Results are presented as 
mean %  ID/g, error bars indicate standard error of the mean. * p<0.05, ** p<0.005.
In all experiments the albumin fragments did not significantly affect uptake of 
111In-octreotide in tissues and organs other than the kidneys (blood, spleen, 
adrenals, pancreas), as determined by ANOVA with subsequent Bonferroni 
testing (data not shown).
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D isc u ss io n
In this study we tested the hypothesis that fragments of albumin, a natural ligand 
of megalin, might be potent inhibitors of renal reabsorption of radiolabeled 
peptides. We hypothesized that fragments of albumin (FRALB) may pass the 
glomerular membrane efficiently ’8■20 and may subsequently competitively inhibit 
the megalin-mediated reabsorption of these peptides.
The in vitro experiments with 111In-octreotide, 111In-exendin and 111In-minigastrin 
demonstrated specific binding of exendin and minigastrin to megalin-expressing 
cells, supporting the involvement of megalin in the uptake of these peptides. 
However, a contribution of other mechanisms of uptake cannot be excluded. 
Relatively small amounts of FRALB inhibited binding of 111In-octreotide, 111In- 
exendin and 111In-minigastrin to the BN16 cells at least as efficiently as Gelofusine. 
Remarkably, lysine did not reduce binding in vitro significantly.
The biodistribution studies of 111In-DTPA-albumin and 111In-DTPA-FRALB in rats 
support the hypothesis that albumin fragments pass the glomerular membrane 
more efficiently than intact albumin. The renal activity concentration of FRALB 
was more than 5-fold higher than the concentration of intact albumin, and it was 
mainly retained in the renal cortex; the same anatomical location where 
previous studies showed localization of 111In-octreotide, 111In-exendin, 111In- 
minigastrin and megalin 21-24.
In our experiments in rats, co-administration of FRALB effectively reduced renal 
uptake of 111In-octreotide, presumably due to interaction of the albumin 
fragments with the megalin receptor in the kidneys. Barone et al. demonstrated 
that uptake of 111In-octreotide by oppossum kidney (OK) cells was, at least partly, 
mediated by endocytosis via the megalin/cubilin receptor complex 25. The most 
convincing evidence was reported by de Jong et al., who showed that renal 
uptake of 111In-octreotide was very low in kidney-specific megalin-deficient mice
21, and that 111In-octreotide colocalized with megalin staining on murine kidney 
sections 212.
FRALB significantly reduced renal radioactivity concentrations of 111In-octreotide 
in a concentration dependent manner. Fragments with a molecular weight 
between 3 and 50 kDa appeared to be most potent. Injection of as little as 1 mg 
FRALB-3-50 per rat resulted in the same reduction in renal 111In-octreotide 
concentration as administration of 20 mg Gelofusine or 80 mg lysine.
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Interestingly, Gelofusine and FRALB efficiently reduced renal uptake of all studied 
peptides, whereas a high dose of 80 mg lysine did not decrease uptake of 111In- 
minigastrin significantly. This confirms our previous hypothesis that inhibition of 
tubular reabsorption of radiolabeled somatostatin analogs by basic amino acids 
may be an exception, rather than the rule for radiopeptides 23.
The megalin receptor has been described to possess four distinct negatively 
charged binding domains 26. This may explain why renal reuptake of some 
substances is blocked by lysine, while reuptake of other substances is not. Lysine 
and octreotide may interact with the same binding domain, whereas exendin 
and minigastrin may bind to one or more other domains. One or more 
components of FRALB and Gelofusine, consisting of various different smaller and 
larger molecules of different structure and charge, may interact with two or more 
of megalin's binding domains, thus efficiently blocking renal reabsorption of 
various substances.
An alternative explanation could be that renal uptake of 111In-exendin and 111In- 
minigastrin is not inhibited by lysine, because uptake of these radiolabeled 
peptides may be mediated by other mechanisms than the megalin receptor. 
Whereas renal uptake of 111In-octreotide has been shown to be, at least partially, 
mediated by megalin 2122, the role of megalin in uptake of exendin and 
minigastrin is not yet established. Our group and Melis et al. have previously 
suggested the possible involvement of various different uptake mechanisms in 
the tubular reabsorption of radiolabeled peptides, like organic anion 
transporters, cubilin and fluid-phase endocytosis 2324. We are currently 
conducting further studies into the mechanisms of renal reuptake of these 
radiolabeled peptides.
The effect of FRALB on the reduction of renal reabsorption of 111In-octreotide, 
111In-exendin and 111In-minigastrin in this study was equal to or more pronounced 
than the effects of either Gelofusine or lysine. On a mass basis, the administered 
dose of FRALB that induced this effect was 5 to 20 times lower than the 
Gelofusine dose, and 16 to 80 times lower than the lysine dose. Using FRALB, more 
potent inhibition of uptake may be achievable with less chance of side effects. 
However, although intact albumin is not toxic under physiological conditions, 
albumin-derived peptides could be toxic as they have different physical and 
chemical characteristics than albumin. Unlike albumin, these peptides can reach 
relatively high concentrations in the glomerular filtrate upon intravenous
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injection. Obviously, toxicity studies of FRALB must be performed before it can 
safely be used in patients.
The FRALB used in these studies, obtained by trypsinization of albumin, contains a 
poorly defined mixture of many different albumin fragments. In order to identify 
the most potent inhibitor of renal reuptake of radiolabeled peptides and to 
minimize the chance of unwanted side effects, further studies are warranted to 
purify FRALB and to further elucidate its mechanism of action.
C o n c l u s io n
Renal uptake of 111In-octreotide, 111In-minigastrin and 111In-exendin is effectively 
reduced by administration of relatively low amounts of albumin fragments. 
Administration of 1 mg of albumin fragments with a molecular weight between 3 
and 50 kDa was equally effective in reducing renal uptake of 111In-octreotide as 
administration of 80 mg lysine. Further studies will be performed to identify which 
specific albumin fragments are responsible for this effect.
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A bstract
Purpose: In peptide-receptor radionuclide therapy (PRRT), the maximum activity 
dose that can safely be administered is limited by high renal uptake and 
retention of radiolabeled peptides. The kidney radiation dose can be reduced 
by coinfusion of agents that competitively inhibit the reabsorption of 
radiolabeled peptides, such as positively charged amino acids, Gelofusine or 
trypsinized albumin. The aim of this study was to identify more specific and potent 
inhibitors of the kidney reabsorption of radiolabeled peptides, based on albumin. 
Methods: Albumin was fragmented using cyanogen bromide. In addition, six 
albumin-derived peptides with different numbers of electric charges were 
selected and synthesized. The effect of albumin fragments (FRALB-C) and 
selected albumin-derived peptides on the internalization of ’’ ’In-albumin, ’ ’’ In­
minigastrin, ” ’In-exendin and ’’’In-octreotide by megalin-expressing cells was 
assessed. In rats, the effect of Gelofusine and albumin-derived peptides on the 
renal uptake and biodistribution of ’’’In-minigastrin, ’’’In-exendin and ’ ’’ In­
octreotide was determined.
Results: FRALB-C significantly reduced the uptake of all radiolabeled peptides in 
vitro. The albumin-derived peptides showed different potencies in reducing the 
uptake of ’ ’’In-albumin, ’’’In-exendin and ’’’In-minigastrin in vitro. The most 
efficient albumin-derived peptide (peptide #6), was selected for in vivo testing. 
In rats, 5 mg of peptide #6 very efficiently inhibited the renal uptake of ’’’ In­
minigastrin, by 88%. Uptake of ’’ ’In-exendin and ’’’In-octreotide was reduced by 
26% and 33%, respectively.
Conclusions: The albumin-derived peptide #6 efficiently inhibited the renal 
reabsorption of ’’’In-minigastrin, ’’ ’In-exendin and ’’’ In-octreotide and is a 
promising candidate for kidney protection in PRRT.
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In tro d u c t io n
Excretion of radiolabeled hydrophilic peptides and small proteins occurs largely 
via the kidneys. In peptide-receptor radionuclide therapy (PRRT), rapid 
clearance of the radiolabeled peptides from the blood and low retention in the 
kidneys are important to minimize the radiation dose to normal tissues. However, 
as outlined in more detail previously ], a part of the filtered load of these small 
proteins and peptides is reabsorbed from the ultrafiltrate in the proximal tubules 
and retained there, exposing the kidneys to a relatively high radiation dose. 
Indeed, acute and chronic kidney dam age have been described in patients 
receiving PRRT and in animal models 2-5 and kidney toxicity is currently dose- 
limiting in PRRT 346. Reduction of the renal radiation dose by reducing the renal 
retention of radiolabeled peptides facilitates the administration of higher activity 
doses in PRRT, which is expected to increase its therapeutic effect.
A possible approach to reducing the renal reabsorption of radiolabeled peptides 
is to interfere with endocytic receptors on the proximal tubular cells. The 
receptors involved in the tubular reabsorption of peptides have not yet been 
characterized completely, but for various peptides involvement of megalin and 
cubilin has been shown 7-]0. Cubilin is a large extracellular receptor that depends 
on other receptors such as megalin for its internalization. Megalin is a multiligand 
receptor belonging to the LDL receptor family. The receptor contains four large 
cysteine-rich ligand binding domains and is a high-capacity transport system with 
varying affinity for the reabsorption of a large series of structurally non-related 
compounds, such as albumin, vitamin D binding protein, ^2-microglobulin, 
aprotinin, C a2+, etcetera 7]] ]2. Charges may play an important role in the 
binding of ligands to megalin ]2']3 or to other renal receptors. Gotthardt et al. 
found a positive correlation between the renal retention and the total number of 
charged amino acid residues of radiolabeled peptides, and suggested a causal 
relationship ]4. It has been shown that some ligands bind to megalin via their 
cationic sites and that co-administration of cationic compounds can inhibit the 
renal reabsorption of these ligands 8-]5. Indeed, in patients undergoing PRRT with 
radiolabeled somatostatin analogs as well as in various animal models, the renal 
uptake of different radiolabeled peptides and antibody fragments can 
effectively be reduced by co-administration of basic amino acids ]6-]9. However, 
these compounds can cause side effects at high doses, such as nausea,
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hyperkalemia, arrhythmias and even nephrotoxicity ]5>]s,2°. Succinylated gelatin 
(Gelofusine®, Gelo), a plasma expander which consists of a mixture of collagen- 
derived peptides, has also been shown to efficiently reduce the renal 
reabsorption of various radiolabeled peptides in animals, and of ’’’ In-octreotide 
in humans ]2]-23. Nevertheless, more efficient inhibitors are needed as none of 
these substances completely inhibits the reabsorption of radiolabeled peptides. 
Albumin, the most abundant plasma protein, is a natural ligand of megalin and 
cubilin. Due to albumin's size and charge (67 kDa, predominantly anionic at 
physiological pH), only a small fraction of circulating albumin is filtered in the 
glomeruli ]3-24-25. This small fraction is subsequently reabsorbed by megalin/cubilin- 
mediated endocytosis. Previously, we showed that peptide fragments obtained 
by trypsinization of bovine serum albumin (BSA) reach higher concentrations in 
the proximal tubules than intact albumin and are efficient inhibitors of the renal 
reabsorption of ’’’In-octreotide, ’’’In-exendin and ’’’In-minigastrin in rats ]. 
However, trypsin cleaves peptides at the carboxyl terminus of arginine and lysine 
residues 26. Since BSA contains 78 arginine and lysine residues, its trypsinization 
yields a complex mixture of many different albumin fragments. We hypothesized 
that some of these may not actually contribute to the blocking of the renal 
reuptake of radiolabeled peptides, but might cause side effects. Better defined 
albumin fragments may be obtained by digestion of albumin by cyanogen 
bromide (CNBr) in formic acid. CNBr cleaves peptides at the carboxyl terminus of 
methionine residues and formic acid cleaves peptides at aspartic acid - proline 
bonds 27. BSA has 4 methionine residues and two aspartic acid - proline bonds. 
Thus, digestion of BSA by CNBr in formic acid yields a maximum of 28 possible 
fragments.
Since megalin binds various structurally different peptides and proteins, we 
hypothesized that different fragments of albumin may bind to megalin and be 
potential candidates for inhibiting the renal reuptake of radiolabeled peptides. 
In addition to the mixture of CNBr-digested albumin fragments (FRALB-C), a set of 
albumin-derived peptides was selected. The selection of these peptides was 
based on the distribution of charged amino acid residues in BSA. We aimed to 
identify albumin fragments that potently inhibit the renal reabsorption of 
radiolabeled peptides, in order to maximize the inhibitory effect and to minimize 
potential side effects.
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In this study, the effect of FRALB-C and a series of synthesized albumin-derived 
peptides on the renal uptake of ’’’In-labeled peptides was analyzed, both in 
vitro and in rats. Studied peptides were [’ ’’ In-DTPA-d-Phe’]-octreotide (’’’In­
octreotide), [Lys40(aminohexanoic acid-DTPA-’’’ In)NH2]-exendin-3 (’’’ In-exendin) 
and [’’’In-DOTA-Glu’]-minigastrin (’’ ’In-minigastrin).
M ater ials  a n d  m eth o d s  
Fragmentation of albumin
Intact BSA (2.26 pmol (’ 50 mg), Sigma) was added to 4.5 ml of 70 % v/v formic 
acid with dithiothreitol (6.7 mM) and heated for 2 min at ’ 00 °C . Subsequently 
’ .’ 3 mmol of CNBr (Sigma) was added and the mixture was incubated for 24 h at 
room temperature in the dark, followed by 5 min incubation at 50 °C. The acid 
was neutralized by adding 9 mL of 4-ethylmorpholine (Sigma), after which the 
mixture was dialyzed against phosphate buffered saline (PBS). The fragmented 
albumin was analyzed by fast protein liquid chromatography (FPLC) and sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The protein 
concentration in the FRALB-C mixture was determined with the Bio-Rad Protein 
Assay® using intact BSA as a reference.
Selection and synthesis of albumin fragments
Six parts of the BSA amino acid sequence were selected for peptide synthesis. 
The selection was based on the distribution of charged amino acid residues in 
these sequences and their net charge at physiological pH. Five peptides 
containing different combinations of positive and negative charges were 
selected and synthesized, each composed of ’ 6 amino acid residues. An 
uncharged peptide was synthesized as well, but this was not studied as it could 
not be dissolved in water. A sixth peptide was synthesized, which was the smallest 
possible fragment formed after CNBr digestion of BSA, consisting of the 36 C- 
terminal amino acid residues. The characteristics of the synthesized peptides are 
summarized in Table 8.’ . Peptides were synthesized by standard solid phase F- 
moc chemistry and purified by high performance liquid chromatography (HPLC) 
at Peptide Specialty Laboratories GmbH (Heidelberg, Germany) and at Peptide
2.0 (Chantilly, VA, USA).
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Table 8.1. Characteristics of albumin-derived peptides*
# Amino ac id  sequence N um ber of 
charged  AA  
residues at 
pH 7
N et 
charge  
at pH 7
Iso­
electric
point
M olecular
mass
(Da)
Location  
in BSA 
(AA 
numbers)
+ tota l
1 IiI 3 k k f i a i g k y l y [| i a r r 5 3 8 +2 10.4 2103 129-144
2 S S A R Q R L R C A S I Q K F G 4 0 4 +4 12.3 1809 191-206
3 0 K P  L L 0 K S H C I A 0 V 0 K 4 4 8 0 4.7 1840 279-294
4 0 a i p [|n l p p l t a |3f a [| 0 4 4 -4 2.7 1714 295-310
5 A l  T P i i l 3 T Y V P K A F i i l 3 K 2 4 6 -2 4.2 1825 489-504
6 [|N F V A F V0KC  C A A|33k I|A 
C F A V 0 G P K L V V S T Q T A L A
3 6 9 -3 4.5 3792 548-583
*  C harac te ris tics  o f the  a lb u m in -d e rive d  p e p tid e s  th a t w e re  synthesized a n d  s tu d ie d  in ou r  
in v itro  assay. A A  = a m ino  a c id . C h a rg e d  a m ino  a c id  residues a re  p rin te d  b o ld  a n d  
un d e rlin e d  (+] o r in ve rte d  (-).
Other compounds used to reduce renal reabsorption
Gelofusine (Braun) is a solution of succinylated gelatin fragments (40 g/L). The 
molecular mass of these fragments in Gelofusine averages 30 kDa. Intact BSA 
was dissolved in PBS at a concentration of 100 g/L. Lysine solution was prepared 
as a 160 g/L solution in PBS.
Radiolabeling
[DTPA-d-Phe']-octreotide (Octreoscan®, Covidien) was labeled with 1,1 In by 
adding 37 MBq of "'InCb (Covidien) to 1 |jg of Octreoscan® and incubating for 
30 minutes at room temperature. [Lys40(Ahx-DTPA)NH2]-exendin-3 (exendin. 
Peptide Specialty Laboratories GmbH, Heidelberg, Germany) was synthesized 
using standard F-moc chemistry. The peptide was labeled with 1 "InCb in a 0.1 M 
2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 5.5. A mixture of 19 MBq of
1,1 In and 1 |jg of exendin was incubated for 30 minutes at room temperature. 
[DOTA-Glu'J-minigastrin (minigastrin. Peptide Specialty Laboratories) was 
synthesized using standard F-moc chemistry. Minigastrin was labeled with "'InCb 
in a 0.25 M ammonium acetate buffer, pH 5.5. 1 "InCb (22.2 MBq) was added to 1 
|jg of minigastrin and the mixture was incubated at 95 °C  for 25 minutes.
120
Reduction of renal peptide uptake by albumin-derived peptides
BSA was conjugated with DTPA as described by Hnatowich et al. 28 and labeled 
with ’ ’’In by adding ’ ’ MBq of ’’ ’ InCb to ’ |jg of DTPA-BSA in a 0.25 M ammonium 
acetate buffer, pH 5.5 (’ 00 jl) and incubating for 20 minutes at room 
temperature.
Radiochemical purity and labeling efficiency of the labeled peptides and 
proteins were determined by silica gel instant thin layer chromatography and 
reverse phase HPLC.
In vitro studies
Rat yolk sac epithelial (BN’ 6) cells, expressing megalin and cubilin 29'30 were 
kindly provided by prof. P.J. Verroust. Cells were cultured at 37 °C  in BN’ 6 
medium, consisting of Dulbecco's modified Eagle's medium plus 4.5 g/l glucose 
(Invitrogen) with 10% fetal calf serum, 100 U/mL penicillin and 100 pg/ml 
streptomycin (Invitrogen).
The potency of FRALB-C to inhibit the interaction of the radiolabeled peptides 
with BN’ 6 cells was determined in vitro in triplicate. The cells were seeded into 6- 
well plates at 3 •’ 05 cells/well and cultured until confluent. The cells were washed 
with PBS and incubated for ’ h with serum free BN’ 6 medium. The cells were 
washed again with PBS, and 2 mL of Ringer's solution (Braun) with ’ 0 mM 4-(2- 
hydroxyethyl)-’ -piperazineethanesulfonic acid (HEPES) buffer, pH 7.4 was added. 
Subsequently ’ 00 jL of the inhibitor was added: either PBS, Gelofusine, or ’ 00 jg  
of FRALB-C. Directly after addition of the inhibitor, 80 kBq (50 jL) of ’’’In-albumin, 
’ ’’In-octreotide, ’’’In-exendin or ’’ ’In-minigastrin was added. After ’ h of 
incubation at 37 °C, cells were rinsed with Ringer's solution and harvested using 
cotton swabs. Radioactivity was measured in a shielded well-type gamma 
counter (Wizard, Wallac).
To study the inhibitory potency of the albumin-derived peptides, the same 
procedure was used. Increasing doses of the six peptides (’ 0, 30 and ’ 00 jg  per 
incubation) were compared with the potency of intact albumin (’ 0 mg) and 
Gelofusine (5 mg) to reduce the binding of ’’’ In-albumin, ’ ’’ In-exendin and ’ ’’ In­
minigastrin.
Internalization of these radiolabeled compounds by BN’ 6 cells was studied using 
essentially the same assay. Cells were incubated with ’’ ’In-albumin, ’ ’’ In-exendin 
or ’’’In-minigastrin for ’ h at 37 °C  or 0 °C . Internalized activity and cell-surface
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bound activity were determined by incubating the cells for 10 min in 1 mL 0.1 M 
acetic acid, 154 mM NaCI, pH 2.8 at 0 °C. The activity in the supernatant (cell- 
surface bound) and the activity in the cells (internalized) was determined.
Animal studies
Groups of 5 male Wistar rats (200-220 g) were used in all experiments. The 
potency of FRALB-C to inhibit the renal reabsorption of 111In-octreotide was 
compared with the reference agents PBS, lysine and Gelofusine. The animals 
were injected i.v. with 0.5 mL of the inhibitor (either PBS, lysine (80 mg), Gelofusine 
(20 mg) or FRALB-C (1 mg, 5 mg or 20 mg)) via the tail vein. One minute later, 
111In-octreotide was injected i.v. (2 MBq/rat).
Animals were killed 20 h after injection, a blood sample was drawn and organs 
were dissected. The kidneys, adrenals, spleen and stomach, as well as samples of 
muscle, lung, pancreas, liver and duodenum were harvested. Tissues were 
weighed and counted in a shielded well-type gamma counter together with the 
injection standards. Radioactivity concentration was expressed as percentage of 
the injected dose per gram tissue (% ID/g).
The albumin-derived peptide which most potently reduced the binding of 111In- 
minigastrin and 111In-exendin in the cell binding assay, peptide #6, was studied in 
rats according to the same procedure. The effect of peptide #6 (0.2 mg, 1 mg or 
5 mg) on the uptake of 111In-minigastrin, 111In-exendin and 111In-octreotide was 
studied, with PBS and Gelofusine (20 mg) as negative and positive control, 
respectively.
Statistical analysis
Data are presented as mean % reduction ± standard deviation. The analysis of 
differences in cell binding and kidney uptake was performed using Student's t- 
test. Biodistribution data in other organs were analyzed by one-way ANOVA. The 
significance level was set at 0.05.
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Results 
Radiolabeling
Radiochemical purity and labeling efficiency of all compounds were higher than 
95%.
In vitro studies
The internalization assay showed that at 37 °C , > 90% of cell-associated 111 In­
albumin and 111In-minigastrin and > 75% of 111In-exendin was internalized (data 
not shown). This indicates that these radiolabeled compounds were rapidly 
internalized by the BN16 cells.
As summarized in Figure 8.1, FRALB-C significantly reduced the uptake of all 
radiolabeled peptides in BN16 cells. A dose of 100 |jg of FRALB-C per incubation 
reduced the uptake of 111In-albumin by 75% ± 5.7% (p < 0.001, Fig. 1A). The 
uptake of 111In-minigastrin, -exendin and -octreotide was reduced by 95% ± 6.3% 
(p < 0.001), 67% ± 6.9% (p < 0.001) and 39% ± 7.4% (p < 0.01), respectively (Fig. 
8.1B-D). The lower doses of 30 jg  and 10 jg  FRALB-C were less effective (data not 
shown). Gelofusine (4 mg) significantly reduced the uptake of all radiolabeled 
peptides as well.
Figure 8.1. Inhibition of the uptake of "'In-albumin (A), ’’’In-minigastrin (B), ’’’In-exendin (C) 
and ’’’In-octreotide (D) in BN ’6 cells by Gelofusine (4 mg) or FRALB-C ( ’00 ¡jg). Results are 
presented as mean %  bound activity, error bars indicate standard error of the mean (SEM). 
*P < 0.05; **P < 0.005.
The effects of 100 jg  of the six albumin-derived peptides on the uptake of 111In- 
albumin, -minigastrin and -exendin in BN16 cells are summarized in Figure 8.2.
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Figure 8.2. Inhibition of the 
uptake of ’’’In-albumin (A), ’’’In­
minigastrin (B) or ’’’In-exendin 
(C) in BN ’6 cells by intact BSA 
( ’0 mg), Gelofusine (5 mg) or ’00 
jg  of albumin-derived peptides. 
Results are presented as mean %  
bound activity, error bars 
indicate SEM. *P < 0.05; **P <
0.005.
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The uptake of "'In-albumin (Fig. 8.2A) was inhibited significantly (all p < 0.003) by 
peptide #1 (54% ± 9.3%), peptide #3 (50% ± 9.1%), peptide #5 (37% ± 11%) and 
most potently by peptide #6 (75% ± 9.1%), as well as by intact albumin (91% ± 
9.1%) and Gelofusine (65% ± 9.0%).
As depicted in Figure 8.2B, the uptake of 111In-minigastrin was reduced 
significantly by peptide #3 (60% ± 6.0%, p = 0.002), peptide #4 (76% ± 4.5%, p =
0.0002), peptide #5 (37% ± 5.7%, p = 0.005) and peptide #6 (96% ± 4.3%, p <
0.0001). Albumin and Gelofusine also significantly reduced the uptake, by 90% ± 
4.5% and by 98% ± 4.3% respectively (both p < 0.0002).
The uptake of 1nIn-exendin by BN16 cells (Fig. 8.2C) was reduced significantly by 
peptide #3 (42% ± 6.2%, p = 0.001), peptide #5 (18% ± 6.4%, p = 0.03) and most 
potently by peptide #6 (94% ± 6.1%, p < 0.0001), as well as by albumin and 
Gelofusine (94% ± 6.2% and 91% ± 6.1% respectively, both p < 0.0001).
The lower doses of 30 pg and 10 pg of the albumin-derived peptides were less 
effective in inhibiting the uptake of these 1nIn-labeled peptides (data not 
shown).
Animal studies
The effect of FRALB-C on the renal retention of 1nIn-octreotide in rats is 
summarized in Figure 8.3. FRALB-C (1 mg) reduced the renal uptake of 1nIn- 
octreotide by 24% ± 12% (p = 0.02).
Figure 8.3. K idney  a c tiv ity  
1111n-octreotide co n c e n tra tio n s  20 hours a fte r
i.v. injection of I I I In- 
octreotide in rats. One to 
three minutes prior to the 
injection of iiiIn-octreotide, 
groups of 5 rats received 0.5 
mL of either PBS, lysine (80 
mg), Gelofusine (20 mg) or 
FRALB-C (I mg). Results are 
presented as mean % ID/g, 
error bars indicate SEM. *P <
0.05; **P < 0.005.
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Higher doses of FRALB-C (up to 20 mg) did not increase this effect. Lysine (80 mg) 
and Gelofusine (20 mg) reduced the uptake by 36% ± 11% and 27% ± 9.7%, 
respectively (both p < 0.003). FRALB-C had no significant effect on the uptake of 
111 In-octreotide in the pancreas, adrenals or other organs.
Figure 8.4 summarizes the effect of peptide #6 on the renal retention of 111In- 
minigastrin, 111In-exendin and 111In-octreotide in rats. Peptide #6 had a 
pronounced effect on the renal uptake of 111In-minigastrin: 5 mg of peptide #6 
reduced the uptake by 88% ± 9.0% (p < 0.0001). Gelofusine reduced the uptake 
by 77% ± 8.9% (p < 0.0001). The renal uptake of 111 In-exendin was reduced by 26% 
± 3.4% by peptide #6, whereas Gelofusine reduced the uptake by 16% ± 3.1% 
(both p < 0.0001). The highest dose of peptide #6 reduced the uptake of 111In- 
octreotide by 33% ± 13% (p = 0.004), comparable to the effect of 20 mg of 
Gelofusine (28% ± 9.9%, p = 0.002). The lower doses of 1 mg and 0.2 mg of 
peptide #6 were less effective in inhibiting the renal uptake of the 111In-labeled 
peptides.
Figure 8.4. Kidney activity concentrations 20 hours after i.v. injection o f 1 "In-minigastrin (A), 
' ' ' In-exendin (B) or "'In-octreotide (C) in rats. One to three minutes prior to the injection of 
the '''In-labeled peptide, groups of 5 rats received 0.5 mL of either PBS, Gelofusine (20 mg) 
or albumin-derived peptide #6. Results are presented as mean 7o ID/g, error bars indicate 
SEM. * P < 0.05; ** P < 0.005.
Surprisingly, peptide #6 also reduced the uptake of n1In-octreotide in the 
adrenals significantly, by 42% ± 13% (p = 0.0008), whereas the uptake in the 
pancreas and other organs was unaffected (Fig. 8.5). The uptake of 111In- 
minigastrin and 111In-exendin in organs other than the kidneys was not affected 
by peptide #6 and no adverse effects of its injection were noted.
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Figure 8.5. Biodistribution o f '' 'In-octreotide in rats, 20 h post injection. One to three minutes 
prior to the injection o f '' 'In-octreotide, groups of 5 rats received 0.5 mL of PBS or peptide 
#6 (5 mg). Results are presented as mean %  ID/g, error bars indicate SEM. ** P < 0.005.
D isc u ss io n
Radiation-induced chronic renal damage due to proximal tubular reabsorption 
and retention of radiolabeled peptides limits the activity dose that can safely be 
administered in PRRT, thereby limiting the efficacy of this anti-tumor therapy. The 
renal reabsorption of ’’’In-octreotide is, at least in part, mediated by megalin 31. 
Megalin is a multiligand scavenger receptor that is involved in the renal reuptake 
of various peptides and proteins, among which albumin ,z'3. We previously 
reported that both the protein-based plasma expander Gelofusine and 
trypsinized albumin are effective inhibitors of the renal reabsorption of various 
radiolabeled peptides '■2Z32. In the current study we aimed to identify specific 
albumin-derived peptides for effective inhibition of the renal uptake of ’’’In­
labeled minigastrin, exendin and octreotide.
FRALB-C, bovine serum albumin fragmented by cyanogen bromide, proved to 
be an effective inhibitor of the uptake of ’ ’’ In-labeled albumin, minigastrin, 
exendin and octreotide in megalin-expressing cells. In rats, FRALB-C inhibited the 
renal reabsorption of ’’’In-octreotide as efficiently as Gelofusine. The inhibitory 
effect of FRALB-C was comparable to the effects we previously obtained with 
trypsinized albumin '.
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FRALB-C is a mixture of at most 28 different albumin fragments. We expected 
these different fragments to have different affinities for megalin. Therefore, we 
aimed to further identify specific albumin fragments that inhibited the renal 
reuptake of radiolabeled peptides efficiently. However, attempts to further purify 
the FRALB-C mixture by filtration, dialysis and HPLC did not yield sufficiently 
purified peptides.
Six albumin-derived peptides were screened for their ability to reduce the uptake 
of 111In-albumin, 111In-exendin and 111In-minigastrin in cells expressing megalin and 
cubilin. The uptake of 111In-albumin was inhibited by peptides #1, #3, #5 and 
most potently by #6, whereas peptides #  2 and #4 did not have a significant 
effect. This suggests that the amino acid sequences of peptides #1, #3, #5 and 
#6 may be involved in the physiological binding of albumin to its renal receptors. 
However, since megalin's binding domains facilitate the binding of various 
endogenous and exogenous peptides, it is also possible that some or all of these 
sequences are not actually involved in the binding of intact albumin to megalin; 
for example because they may not be exposed at the surface of the albumin 
molecule. Each of the peptides #1, #3, #5 and #6 contained both positively and 
negatively charged amino acid residues, whereas peptides #2 and #4 
contained only positive or only negative charges, respectively. It was suggested 
previously that the distribution of charges rather than the overall charge may be 
important for ligand binding to megalin '3. Our results suggest that both positive 
and negative charges might contribute to the binding of albumin to megalin 
and / or cubilin.
Exendin contains 4 positively charged and 6 negatively charged amino acid 
residues, minigastrin contains 7 negatively charged amino acid residues and 
octreotide contains 1 positively charged amino acid residue. Similarly to 111In- 
albumin, the uptake of 111In-exendin by BN16 cells was reduced significantly by 
peptides #3, #5 and most potently by #6, suggesting that the binding 
mechanism of 111In-exendin might be similar to that of 111In-albumin. In addition 
to peptides #3, #5 and #6, peptide #4 significantly reduced the uptake of the 
exclusively negatively charged 111In-minigastrin as well. Each of these peptides 
contained at least 4 negatively charged amino acid residues. Peptides #1 and 
#2, that did not reduce the binding of 111In-minigastrin, contained 3 and 0 
negative charges, respectively. This again suggests involvement of minigastrin's 
multiple negative charges in its renal reuptake. It has been shown previously that
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the effect of polyglutamic acid chains on the renal reuptake of minigastrin 
depends on the number of negatively charged residues in these chains 33. 
Peptide #6, the larger peptide, inhibited the uptake of ’’’In-albumin, ’’’In- 
exendin and ’’ ’In-minigastrin most effectively in vitro, although it was tested at a 
lower molar concentration than the other peptides. Whether its size, its charge 
distribution or other properties determine its effectiveness remains to be 
investigated. This peptide was subsequently studied in vivo.
In rats, peptide #6 reduced the renal uptake of ’’’In-minigastrin very effectively. 
The effect of 5 mg of peptide #6 was larger than the effect of 20 mg Gelofusine. 
The inhibition of the renal uptake of ’’’ In-exendin by peptide #6 was less 
pronounced, although its effects on the cell binding of ’’’ In-minigastrin and ’’’In- 
exendin were comparable in vitro. A possible explanation for the observed 
difference is a relatively short plasma half life of peptide #6. Literature suggests 
longer plasma half lives for exendin than for minigastrin 343s. Peptide #6 might be 
largely excreted, while exendin is still present in relatively high concentrations in 
the plasma and the ultrafiltrate. In our previous study ¡, trypsinized albumin had 
more effect on the renal uptake of ’’ ’In-exendin than peptide #6 had in this 
study, which might be explained by a longer half life of this mixture of peptides. 
Alternative possible explanations for the observed differences between ’’’In- 
exendin and ’’’In-minigastrin in vitro and in vivo include different mechanisms of 
renal reabsorption (e.g. involvement of different transporters or receptors), a 
higher affinity of exendin for renal receptors, or general differences in transport 
mechanisms and kinetics between the kidneys in vivo and the in vitro model.
The inhibition of the renal reabsorption of ’’’In-exendin and ’’’In-octreotide by 5 
mg of peptide #6 in rats was comparable to the effect of 20 mg Gelofusine. The 
effect of FRALB-C on ’’ ’In-octreotide uptake was in the same range as well. Most 
other studies using competitive blockers to reduce the renal retention of ’’’ In­
octreotide report maximum reductions of around 50% ¡,¡5,20,22,36. The residual 
uptake may indicate a contribution of other mechanisms of renal reuptake, such 
as fluid phase endocytosis 37.
Remarkably, peptide #6 significantly reduced the uptake of ’’’ In-octreotide in 
the adrenals. Since rat adrenals predominantly express somatostatin receptor 
subtype 2 (sstr2) 38 and ’’ ’In-octreotide has the highest affinity for sstr2 and lower 
affinities for sstr3 and sstr5 39, this possibly indicates interference of peptide #6 
with the binding of octreotide to sstr2. However, uptake in other organs known to
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express relatively high levels of sstr2, such as the pancreas and the stomach 40-42, 
was unaffected. Other mechanisms for the reduced uptake of 111In-octreotide in 
the adrenals have to be considered and future experiments will have to 
investigate if specific tumor uptake is affected by peptide #6.
Although the peptide is derived from albumin and we did not observe any side 
effects in the animal experiments, it is a new substance which may cause toxicity 
at higher doses. Therefore, the dose of this peptide that can be administered 
safely has to be determined before clinical use becomes possible.
In summary, peptide #6 is a promising candidate for inhibition of the renal 
reabsorption of 111In-minigastrin and perhaps of 111In-exendin. To reduce the renal 
reabsorption of radiolabeled peptides more efficiently, a combination of two or 
more competitive inhibitors of endocytosis and other approaches may prove to 
be useful.
C o n c l u s io n
Albumin digested by CNBr (FRALB-C) efficiently reduced the uptake of 111In- 
labeled albumin, octreotide, minigastrin and exendin in megalin expressing cells, 
and reduced the renal retention of 111In-octreotide in rats. In vitro, the effect of 
albumin-derived peptide #6 on the uptake of 111In-exendin and 111In-minigastrin 
was comparable to the effect of FRALB-C and Gelofusine. In rats, peptide #6 
efficiently reduced the renal retention of 111In-labeled octreotide, exendin and 
especially minigastrin, opening up new possibilities for the reduction of kidney 
dam age in peptide receptor radionuclide therapy with less chance of side 
effects.
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Chapter 9
In tro d u c t io n
This thesis describes studies on the mechanisms of retention of radiolabeled 
peptides in the kidneys, and on methods to reduce this retention. The most 
important examples of radiolabeled peptides are somatostatin analogues, which 
are used for scintigraphic imaging and radionuclide therapy of neuroendocrine 
tumors ]'2. The potential use of various other peptides and antibody fragments for 
the imaging and therapy of neuroendocrine and other tumors is under 
investigation 3-6. The retention of radiolabeled peptides in the kidneys during 
peptide-receptor radionuclide therapy (PRRT) causes a relatively high radiation 
dose to the kidneys, which can induce lethal kidney failure. This nephrotoxicity 
limits the maximum radiation dose that can safely be administered to treat 
tumors 78. Minimizing the uptake and retention of radiolabeled peptides in the 
kidneys would enable an increase of the activity dose that can be administered 
safely, thereby making make more effective therapy possible. In chapter 2 the 
current evidence regarding the mechanisms of renal uptake of radiolabeled 
peptides, radiation-induced renal dam age and strategies to reduce this 
dam age is reviewed.
M e c h a n is m s  o f  r en a l  r ea bso r pt io n  o f  r a d io la beled  peptides
Over the last decades, our knowledge about the mechanisms of renal 
reabsorption and processing of peptides and low molecular weight proteins has 
increased dramatically. Most larger peptides that are filtered through the 
glomeruli are reabsorbed in the proximal tubules by receptor-mediated 
endocytosis and are subsequently degraded in lysosomes 9■,0. Radiolabeled 
catabolites are trapped in the lysosomes, causing high kidney radiation doses 
"■'2. Which proximal tubular receptors are actually involved in the endocytosis of 
radiolabeled peptides has not been fully elucidated. Likely candidates are 
megalin and cubilin, endocytic receptors expressed at the apical membrane of 
proximal tubular cells. These receptors play an important role in the reabsorption 
of various proteins and related substances l3. The recent findings by De Jong et 
al. that the kidney uptake of ’’’In-octreotide in megalin-deficient mice was 
significantly lower than in wild-type mice, confirmed that megalin is indeed 
involved in the renal reuptake of this radiolabeled peptide l4. We studied the
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biodistribution of other ’’’In-labeled peptides in megalin-deficient and wild-type 
mice, as described in chapter 3. The kidney uptake of ’’’ In-octreotide, ’’’In- 
octreotate, ’’’In-neurotensin, ’’’In-exendin and ’ ’’In-minigastrin was measured in 
vivo using single photon emission computed tomography (SPECT), as well as ex 
vivo in organ samples. We observed that the uptake of all five radiolabeled 
peptides was reduced in the megalin-deficient mice, indicating that the megalin 
receptor is involved in the renal reabsorption of these peptides. However, the 
reduced uptake of the ’’’In-labeled peptides in the kidneys of these megalin- 
deficient mice does not necessarily mean that megalin is the only receptor 
responsible for the renal accretion of these peptides. Endocytosis of the cubilin 
receptor is also dependent on megalin expression 's-'7, so the uptake of cubilin 
ligands may also be reduced in megalin-deficient mice. Furthermore, kidney 
uptake of the ’’’In-labeled peptides we studied was not completely absent in 
the megalin-deficient mice. This could be due to the residual megalin that is 
expressed in the kidneys of these mice ,8-'9, but involvement of other receptors or 
transport systems cannot be excluded. Several specific peptide receptors such 
as somatostatin (SST), cholecystokinin2 (CCK2) and glucagon-like peptide-’ (GLP- 
’ ) receptors are expressed on proximal tubular cells 20-22 and the non-specific 
process of fluid-phase endocytosis may also be responsible for some residual 
uptake 23. Nevertheless, based on our observations we conclude that megalin, 
possibly in cooperation with cubilin, plays an important role in the uptake of ’ ’’ In­
octreotide, ’’’ In-octreotate, ’’’In-neurotensin, ’’’In-exendin and ’ ’’ In-minigastrin. 
The expanding number of structurally different peptides and proteins that have 
been reported to bind to megalin's four large binding domains implies that 
megalin may also be involved in the renal uptake of other radiolabeled peptides 
and antibody fragments.
It has been suggested that charges play an important role in the binding of 
(radiolabeled) peptides to megalin or other proximal tubular receptors: several 
studies have shown that substitution or deletion of charged amino acid residues 
reduces the renal uptake of peptides 2425, whereas addition of charged residues 
often increases their renal uptake 2627. Furthermore, the renal uptake of positively 
charged somatostatin analogues can be reduced by coinfusion of positively 
charged amino acids such as lysine 28, whereas uptake of the negatively 
charged ’ ’’In-minigastrin can be reduced by negatively charged polyglutamic 
acid chains, but not by lysine 29.
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During the SPECT studies of megalin-deficient and wild type mice we observed 
that the health of some mice deteriorated several weeks after administration of 
’’’In-exendin. ’ ’’In emits Auger electrons and conversion electrons in addition to 
Y-photons, and has been used for somatostatin analogue PRRT. In humans, no 
kidney damage occurred after kidney doses up to 45 Gy. However, as described 
in chapter 4, kidney histology and urine and serum chemistry showed that our 
mice did develop kidney damage. Dosimetry calculations showed that wild type 
mice received a mean kidney dose of over 70 Gy after administration of an 
imaging dose of 40-50 MBq ’’ ’In-exendin. Since radioactivity is mainly retained in 
the kidney cortex, the dose absorbed by radiosensitive structures such as 
glomeruli and proximal tubules will be even higher, especially when considering 
the relatively low-energy Auger electrons of ’’ ’In. Compared to the human 
situation, the radiation dose to the glomeruli in mice will be higher since their 
kidneys are much smaller. Therefore, when using small animal SPECT for repeated 
imaging in the same animals, one has to consider the absorbed dose to the 
kidneys or other critical organs. Depending on scanner sensitivity and target 
organ uptake, an imaging dose as low as possible should be used.
A better insight in the mechanisms involved in the renal uptake and retention of 
radiolabeled peptides and the resulting damage could guide us to more 
efficient ways to reduce PRRT-induced nephrotoxicity. Several strategies to 
reduce kidney dam age in PRRT have been and are being studied, as described 
below. First, in the development of radiolabeled peptides for imaging and 
treatment of tumors, several analogues of the same peptide are tested and the 
analogue with the best pharmacokinetic properties and optimal tumor-to- 
background ratio is selected. However, some uptake in healthy tissues, like the 
kidneys, is inevitable.
Red u c t io n  o f  k id n ey  uptake o f  ra d io la beled  peptides by  c o m pet it iv e
INHIBITION
To further reduce the kidney uptake of radiolabeled peptides, coinfusion of 
competitive inhibitors of renal reabsorption is currently the most widely used 
approach. This approach is also routinely used in patients treated with 
somatostatin analogue PRRT. Patients are infused with solutions of positively 
charged amino acids such as lysine and/or arginine, or other amino acid
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mixtures 230. Competitive inhibitors interfere with the interaction between 
radiolabeled peptides and proximal tubular receptors such as megalin, reducing 
their endocytosis. The protective effects of lysine / arginine and other amino acid 
solutions on kidney dosimetry and kidney dam age in PRRT have been thoroughly 
studied in preclinical and clinical situations, and significant reductions in kidney 
absorbed radiation dose and resulting kidney dam age have been proven 31-34. 
However, the use of these amino acid solutions has limitations. Infusion of high 
amounts of amino acids is limited by side effects such as hyperkalemia and 
vomiting 33. The maximum reduction in kidney uptake of somatostatin analogues 
that has been achieved by coinfusion of positively charged amino acids lies 
around 50-60% 33,3£,36. The residual uptake may reflect uptake of the peptides 
through other mechanisms, such as fluid-phase endocytosis, or through 
interaction with other transporters / receptors or other domains of the same 
receptor that cannot be inhibited by basic amino acids. Another limitation of the 
use of positively charged amino acids is their inability to reduce the renal uptake 
of certain radiolabeled peptides, such as ’ ’’ In-minigastrin 29. This probably also 
reflects binding of ’’’In-minigastrin to other binding sites on megalin or cubilin. 
Alternative competitive inhibitors are polygeline (protein-based) plasma 
expanders such as succinylated gelatin (Gelofusine®). Succinylation of this 
gelatin solution adds a net negative charge to its peptides. Protein-based 
plasma expanders are known to cause low molecular weight proteinuria, 
probably through competitive inhibition of the proximal tubular reabsorption of 
low molecular weight proteins 3738. In chapter 5 we describe that succinylated 
gelatin efficiently reduced the renal uptake of ’ ’’ In-octreotide in rats and mice 
without affecting the uptake in somatostatin receptor positive organs, whereas 
carbohydrate-based plasma expanders such as hydroxyethyl starch (HES) did 
not have any effect on renal uptake. This indicates that the effect of 
succinylated gelatin was not mediated by the hemodynamic effects of the 
infusion of the plasma expander, but by the protein components of the solution. 
These protein components probably interfere with the binding of ’’’ In-octreotide 
to proximal tubular endocytic receptors. The inhibitory potential of succinylated 
gelatin was confirmed in human subjects, as described in chapter 6. 
Succinylated gelatin, but not HES, inhibited the renal uptake of ’’’In-octreotide in 
these subjects by approximately 45%.
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Albumin is the most abundant plasma protein and is a natural ligand of megalin 
and cubilin 3940, making it a promising candidate for competitive inhibition of the 
renal uptake of radiolabeled peptides. Intact albumin is too large to be 
efficiently filtered through the glomerular basement membrane, limiting its 
concentration in the proximal tubules. To overcome this problem, we 
fragmented albumin by enzymatic digestion. In chapter 7 we show that albumin 
fragments (FRALB) as well as succinylated gelatin reduced the renal uptake of 
’’’In-octreotide and ” ’In-exendin in rats at least as efficiently as lysine. 
Furthermore, the renal uptake of ’’’ In-minigastrin was reduced very efficiently by 
succinylated gelatin and FRALB, but not by lysine. Both succinylated gelatin and 
FRALB contain several smaller and larger polypeptide molecules; the molecular 
weight of succinylated gelatin averages 30 kDa, whereas FRALB contained 
proteins and peptides of up to 67 kDa. This multitude of small and large peptides 
may very well bind to and/or block large parts of the binding domains of 
endocytic receptors such as megalin and cubilin, thereby reducing the renal 
reuptake of various structurally different peptides.
FRALB is a mixture of different fragments that, although derived from the 
generally non-toxic albumin, cannot be administered to humans without further 
testing. Toxicity studies will have to be performed before application in clinical 
PRRT becomes possible. Succinylated gelatin, however, is a registered plasma 
expander that is routinely administered to patients undergoing surgery and in 
acute care. The main side effects are allergic reactions, which are generally mild 
(severe anaphylactoid reactions occur in approximately 0.04% of patients) 4,~43. 
Volume overload due to the infusion of large amounts of succinylated gelatin 
may limit its use in patients suffering from heart or kidney failure. Kidney 
protection with a combination of succinylated gelatin and a lysine / arginine 
mixture has already been used in over 900 cycles of somatostatin analogue PRRT. 
No anaphylactic reactions occurred. Mild to moderate allergic reactions were 
observed in ’ .4% of courses and moderate to severe reactions (such as 
symptomatic bronchospasm) in 0.6% (Richard P. Baum, personal communication, 
2009). Succinylated gelatin indeed seems a promising agent for protection of the 
kidneys in various forms of PRRT.
The heterogeneous nature of FRALB and succinylated gelatin may prove to be 
advantageous, since different components of these mixtures may interfere with 
the interactions between different radiolabeled peptides and their receptors. This
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would make them applicable for reduction of the renal uptake of several 
radiolabeled peptides, whereas lysine, a chemically pure compound, has only 
been shown to reduce the uptake of a limited group of radiolabeled peptides. 
On the other hand, chemically defined compounds may also have advantages 
over mixtures such as FRALB and succinylated gelatin, which are likely to contain 
both active and inactive components. The components that do not contribute 
to a reduction of the renal retention of radiolabeled peptides, may contribute to 
or cause side effects such as allergic reactions or volume overload. Chemically 
pure and defined compounds do not contain other, possibly inactive, 
components.
To combine the potentials of FRALB and defined compounds, we selected and 
synthesized six different albumin-derived peptides and studied their effects on 
the uptake of ’’ ’In-labeled albumin, minigastrin and exendin in cells expressing 
megalin and cubilin. The peptides were selected on the basis of charge 
distribution, since, as explained above, charged amino acid residues are thought 
to play an important role in the interaction of radiolabeled peptides with renal 
receptors. In these studies, described in chapter 8, three out of six albumin- 
derived peptides reduced the uptake of all studied radiolabeled compounds. 
Each of these three peptides contained both positive and negative charges. 
Another albumin-derived peptide, containing four negatively charged and no 
positively charged amino acid residues, efficiently reduced the uptake of 
negatively charged ’’’ In-minigastrin, but not of ’’’In-labeled exendin and 
albumin. This is in line with previous findings that negatively charged polyglutamic 
acid chains of five or more residues can reduce the renal uptake of ’’’ In­
minigastrin in mice 44 and that polyglutamic acid inhibited the renal uptake of 
’ ’’In-minigastrin more efficiently than the uptake of ’ ’’ In-exendin and ’’’In­
octreotide 29. Furthermore, these findings support the hypothesis that electric 
charges play an important role in the binding of ligands to megalin or other 
receptors. The peptide which was most efficient in reducing the uptake of all 
studied radiolabeled peptides in our in vitro experiments, was subsequently 
studied in vivo. In rats, this albumin-derived peptide efficiently reduced the renal 
retention of ’ ’’In-minigastrin and to a lesser extent of ’’’In-octreotide and ’’’In- 
exendin. This albumin-derived peptide, consisting of the 36 C-terminal amino 
acid residues of the bovine serum albumin molecule, contained six negatively 
and three positively charged amino acid residues, again suggesting an
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important role of charges in the interaction of peptides with renal receptors. 
However, like FRALB, this peptide would obviously need to undergo toxicological 
studies before it can be used in patients.
O ther methods and  com bination  strategies to  reduce kidney uptake and  
DAMAGE IN PRRT
As described in chapter 2, several other approaches to reduce the kidney 
uptake of radiolabeled peptides and antibody fragments have been studied. 
Several drugs disturb proximal tubular transport by other mechanisms than 
competitive inhibition, but only a few have been tested in vivo. Colchicine, 
which disrupts the formation of microtubules, reduced the renal uptake of ’’’In­
octreotide in rats. However, a relatively high dose, likely to cause side effects 
when used in patients, was needed 45. Probenecid, an approved drug that 
inhibits the organic anion transport system, reduced the renal uptake of ’’’ In­
octreotide at a relatively low dose 46. Altering radiolabeled peptides or antibody 
fragments by inserting a cleavable linker between the peptide and the 
radiolabel can also reduce the renal uptake or retention of residualizing 
radiolabels 47-50. To reduce the nephrotoxicity of a given radiation dose, dose 
fractionation 832, or free radical scavengers such as amifostine may be used 51. 
Agents that reduce or mitigate counterproductive tissue responses to radiation 
have also shown promising results in reducing kidney dam age after radionuclide 
therapy 52.
Since most of the described approaches interfere with processes of kidney 
uptake and dam age at different levels, combining two or more techniques is 
likely to result in a progressive reduction of kidney damage. Even a combination 
of two inhibitors of the same mechanism - lysine and succinylated gelatin - 
reduced the renal uptake of ’’’In-octreotide more than either agent alone, 
although the additive effects were not very large 29-53. Similar results were 
obtained with a combination of lysine and colchicine, an inhibitor of endocytosis
45. More promising results were reported by combining lysine with an angiotensin- 
II antagonist in rats treated with ’77Lu-octreotate: this resulted in significantly less 
kidney damage than treatment with the angiotensin-II antagonist alone 54. 
However, recent studies have failed to corroborate these results (M. Melis, 
personal communication, 2010).
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Future per spec t iv es
New agents and combination strategies for the reduction of PRRT-induced 
nephrotoxicity open up possibilities for high-dose radionuclide therapy with 
peptides and antibody fragments, maximizing tumor radiation dose while 
minimizing kidney damage. However, more research is needed before most of 
the described strategies can be applied successfully and safely in patients. The 
combination of succinylated gelatin and lysine appears to be a promising 
approach that can be applied safely, but its effects on kidney and tumor 
dosimetry in patients will have to be characterized.
When the application of higher-dose PRRT becomes possible, toxicity to other 
organs needs to be addressed as well, most importantly radiation-induced bone 
marrow damage. The bone marrow is much more sensitive to radiation than the 
kidneys, but due to the high renal uptake and retention of radioactivity in 
somatostatin analogue PRRT, the kidneys are considered the dose-limiting 
organs. Nevertheless, PRRT-induced acute and chronic bone marrow toxicity 
have been described in patients treated with ’77Lu-octreotate 2. If the 
administration of higher radiation doses in PRRT becomes possible with successful 
kidney protection, bone marrow toxicity will undoubtedly increase and become 
dose-limiting. This problem may be solved by autologous bone marrow support, 
which has been used successfully in radioimmunotherapy 55, or possibly by 
protection of bone marrow by amifostine or other radioprotective agents. 
Another interesting development in the treatment of neuroendocrine tumors is 
the use of new targeted therapies, such as inhibitors of the mammalian target of 
rapamycin (mTOR) or tyrosine kinase inhibors such as sunitinib, which have shown 
promising results in recent phase-I trials. Combination of these agents with high­
dose PRRT may prove to be a very effective treatment of neuroendocrine 
tumors.
C o n c l u s io n
Several radiolabeled peptides are promising candidates for the imaging and 
treatment of various tumors. Somatostatin analogue PRRT has already gained an 
important place in the treatment of neuroendocrine tumors, but the relatively
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high kidney uptake leads to dose-limiting nephrotoxicity. More insight in the 
mechanisms of kidney uptake and several new strategies and combinations of 
strategies to reduce PRRT-induced nephrotoxicity increases the radiation dose 
that can safely be administered and makes highly effective PRRT possible.
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Chapter 10
In le id in g
In dit proefschrift worden onderzoeken naar de mechanismen van nieropname 
en -retentie van radioactief gelabelde peptiden beschreven, en manieren om 
deze retentie te verminderen. De belangrijkste voorbeelden van radioactief 
gelabelde peptiden zijn somatostatineanaloga, die gebruikt worden voor 
scintigrafie en radionuclidetherapie van neuro-endocriene tumoren ]2. Van 
allerlei andere peptiden en antilichaamfragmenten wordt onderzocht of ze 
gebruikt kunnen worden voor het afbeelden en behandelen van neuro- 
endocriene en andere tumoren 3-6. De retentie van radioactief gelabelde 
peptiden in de nieren na peptide-receptorradionuclidetherapie (PRRT) 
veroorzaakt een relatief hoge stralingsdosis op de nieren, waardoor ernstige 
nierschade kan ontstaan. Deze niertoxiciteit beperkt de maximale stralingsdosis 
die veilig aan een patiënt kan worden toegediend voor de behandeling van 
diens tumor 78. Vermindering van de opname en retentie van radioactief 
gelabelde peptiden in de nieren maakt het mogelijk om veilig een hogere 
stralingsdosis aan patiënten toe te dienen, waardoor de therapie effectiever kan 
worden. In hoofdstuk 2 wordt de actuele stand van de wetenschap samengevat 
wat betreft de mechanismen van nieropname van radioactief gelabelde 
peptiden, de resulterende nierschade, en verschillende strategieën om deze 
schade te verminderen.
M e c h a n is m e n  v a n  n ie r o p n a m e  v a n  r a d io a c t ief  g ela b eld e  pept iden
De afgelopen tientallen jaren is onze kennis over de mechanismen van opname 
en verwerking van peptiden en kleine eiwitten in de nieren enorm toegenomen. 
De meeste grotere peptiden worden, nadat ze door de glomerulus zijn 
gefiltreerd, heropgenomen uit de voorurine in de proximale tubuli. Dit gebeurt 
via receptorgemedieerde endocytose. Na endocytose komen de peptiden in 
lysosomen terecht, waar ze worden afgebroken tot aminozuren 9-w. Radioactief 
gelabelde afbraakproducten blijven vastzitten in de lysosomen, hetgeen een 
hoge stralingsdosis op de nieren veroorzaakt n-'2. Welke receptoren op de 
proximale tubuluscellen precies betrokken zijn bij de endocytose van radioactief 
gelabelde peptiden, is deels nog onbekend. Belangrijke kandidaten zijn 
megaline en cubiline, endocytotische receptoren op de apicale membraan van
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proximale tubuluscellen. Deze receptoren spelen een belangrijke rol bij de 
tubulaire reabsorptie van allerlei verschillende eiwitten en verwante stoffen l3. De 
Jong et al. ontdekten dat de nieropname van ’’’ In-octreotide in 
megalinedeficiënte muizen significant lager was dan in normale muizen. Dit 
bevestigt dat megaline inderdaad betrokken is bij de nieropname van dit 
radioactieve peptide l4. Wij onderzochten de biodistributie van andere ’ ’’ In­
gelabelde peptiden in normale en megalinedeficiënte muizen (hoofdstuk 3). De 
nieropname van ’’ ’In-octreotide, -octreotaat, -neurotensine, -exendin en - 
minigastrine werd gemeten met behulp van SPECT-scans bij levende muizen en 
in afzonderlijke organen na dissectie van de muizen. We zagen dat de 
nieropname van al deze vijf radioactief gelabelde peptiden was verminderd bij 
de megalinedeficiënte muizen, hetgeen bewijst dat megaline is betrokken bij de 
nieropname van deze peptiden. Echter, de verminderde nieropname bij deze 
megalinedeficiënte dieren betekent niet noodzakelijkerwijs dat megaline de 
enige receptor is die verantwoordelijk is voor de accumulatie van deze peptiden 
in de nieren. Cubiline is bijvoorbeeld een andere receptor die betrokken is bij de 
endocytose van allerlei stoffen in de nieren. Cubiline is voor endocytose 
afhankelijk van megaline '5-'7, dus de opname van liganden van cubiline is 
waarschijnlijk ook verminderd bij megalinedeficiënte muizen. Bovendien was de 
nieropname van de onderzochte ’’’In-gelabelde peptiden niet geheel tot nul 
gereduceerd bij de megalinedeficiënte muizen. Dit zou een gevolg kunnen zijn 
van de residuele megaline-expressie in de nieren van deze muizen ,8'19, maar 
betrokkenheid van andere receptoren of transportsystemen kan niet uitgesloten 
worden. Allerlei specifieke receptoren zoals somatostatine-, cholecystokinine2- en 
glucagonachtig-peptide-’-receptoren zijn aanwezig op de proximale 
tubuluscellen 20-22 en aspecifieke vloeistofendocytose is waarschijnlijk ook 
verantwoordelijk voor enige restopname 23. Toch kunnen we op basis van onze 
metingen concluderen dat megaline, misschien in samenwerking met cubiline, 
een belangrijke rol speelt bij de opname van ’’’ In-octreotide, -octreotaat, - 
neurotensine, -exendin en -minigastrine. Het toenemende aantal peptiden en 
eiwitten waarvan bekend wordt dat ze binden aan de vier grote 
bindingsdomeinen van megaline, suggereert dat megaline mogelijk ook 
betrokken is bij de nieropname van andere radioactief gelabelde peptiden en 
antilichaamfragmenten.
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Mogelijk spelen elektrische ladingen een belangrijke rol bij het binden van 
(radioactief gelabelde) peptiden aan megaline of andere receptoren op de 
proximale tubuluscellen: uit verschillende studies is gebleken dat vervanging of 
verwijdering van elektrisch geladen aminozuurresiduen de nieropname van 
peptiden vermindert 2425, terwijl het toevoegen van geladen residuen vaak tot 
een stijging van de nieropname leidt 2627. Bovendien kan de nieropname van 
positief geladen somatostatineanaloga verminderd worden door positief 
geladen aminozuren zoals lysine toe te dienen 28, terwijl opname van het 
negatief geladen ’’’In-minigastrine verminderd kan worden door negatief 
geladen polyglutaminezuurketens, maar niet door lysine 29.
Tijdens de SPECT-onderzoeken van de megalinedeficiënte en normale muizen 
zagen we de gezondheid van de muizen verslechteren, enkele weken nadat ze 
’’’In-exendin toegediend hadden gekregen. ’’’In zendt naast Y-fotonen ook 
Auger- en conversie-elektronen uit, en is ook gebruikt voor PRRT met 
somatostatineanaloga. Patiënten die hiermee behandeld werden ontvingen 
nierdoses tot circa 45 Gy, waarbij geen nierschade werd gezien. Echter, 
nierhistologie en metingen in urine en bloed van onze muizen toonden aan dat 
deze wel degelijk nierschade hadden opgelopen (hoofdstuk 4). Uit dosimetrische 
berekeningen bleek dat de normale wildtype muizen een gemiddelde nierdosis 
van meer dan 70 Gy hadden opgelopen na toediening van een activiteitsdosis 
van 40-50 MBq ’’’In-exendin. Aangezien radioactief gelabelde peptiden zich 
vooral ophopen in de nierschors, zal de geabsorbeerde dosis in hier gelegen 
gevoelige structuren zoals glomeruli en proximale tubuli nog hoger zijn. Daarbij is 
het effect van de laagenergetische Augerelektronen van ’ ’’ In-exendin in muizen 
relatief groot, omdat deze elektronen ten opzichte van de kleine muizennieren 
nog een relatief lange dracht hebben. Gezien deze nierschade is het belangrijk 
om bij herhaalde SPECT-metingen van kleine dieren de geabsorbeerde dosis in 
de nieren of andere kritieke organen goed in de gaten te houden. Afhankelijk 
van de sensitiviteit van de scanner en de verwachte opname van de te meten 
stof in doelorganen dient een zo laag mogelijke radioactiviteitsdosis gebruikt 
worden.
Beter inzicht in de mechanismen die betrokken zijn bij de nieropname en - 
retentie van radioactief gelabelde peptiden en de resulterende schade kan ons 
helpen bij het vinden van betere en efficiëntere manieren om de niertoxiciteit 
van PRRT te verminderen. Verschillende strategieën om de nierschade van PRRT
150
Samenvatting & algemene discussie
te verminderen zijn en worden al bestudeerd, zoals beschreven in de volgende 
paragraaf. Maar ook al bij de ontwikkeling van radioactief gelabelde peptiden 
voor PRRT wordt de kans op schade aan gezonde weefsels geminimaliseerd: 
verschillende analoga van hetzelfde peptide worden onderzocht, en het 
analogon met de optimale verhouding tussen opname in tumor en in overige 
weefsels wordt geselecteerd. Echter, enige opname in gezonde weefsels zoals 
de nieren blijft onvermijdelijk.
V e r m in d e r in g  v a n  de n ie r o p n a m e  v a n  r a d io a c t ief  g ela b eld e  peptiden
DOOR COMPETITIEVE REMMING
De meestgebruikte aanpak voor het verder verminderen van de nieropname 
van radioactief gelabelde peptiden is momenteel het toedienen van 
competitieve remmers tijdens het toedienen van het radiofarmacon. Deze 
aanpak wordt ook gebruikt bij patiënten die PRRT met somatostatineanaloga 
ondergaan. Deze krijgen een infuus met een oplossing van basische (positief 
geladen) aminozuren zoals lysine en/of arginine, of andere aminozuurmengsels 
2'30. Competitieve remmers blokkeren de interactie van radioactief gelabelde 
peptiden met receptoren zoals megaline, en verminderen daardoor hun 
endocytose. Het beschermende effect van lysine/arginine en andere 
aminozuuroplossingen op nierdosis en nierschade tijdens PRRT is grondig 
onderzocht in preklinische en klinische studies, en significante vermindering van 
de nierdosis en nierschade zijn bewezen 3,~34. Echter, het gebruik van deze 
aminozuuroplossingen heeft beperkingen: infusie van hoge doses aminozuren 
wordt beperkt door bijwerkingen zoals hyperkaliëmie en braken 33, en de 
maximaal bereikte reductie in nieropname van somatostatineanaloga bedraagt 
circa 50-60% 33.35.3ó. De resterende opname wordt mogelijk veroorzaakt door 
andere mechanismen, zoals aspecifieke vloeistofendocytose, of door interactie 
van de peptiden met andere transporters of receptoren, of met andere 
domeinen van dezelfde receptor die niet geremd kunnen worden door basische 
aminozuren. Een andere beperking van deze positief geladen aminozuren is hun 
onvermogen om de nieropname van bepaalde peptiden, zoals 111 In­
minigastrine, te verminderen 29. Dit wordt waarschijnlijk veroorzaakt doordat het 
negatief geladen minigastrine bindt aan andere bindingsplaatsen op megaline 
of cubiline dan de positief geladen aminozuren.
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Alternatieve competitieve remmers zijn polygelineplasmavervangers, zoals 
gesuccinyleerd gelatine (Gelofusine®). Het is bekend dat deze op eiwit 
gebaseerde plasmavervangers een toegenomen uitscheiding van 
laagmoleculaire eiwitten in de urine kunnen veroorzaken, waarschijnlijk door 
competitieve remming van de heropname van laagmoleculaire eiwitten in de 
proximale niertubuli 3738. Succinylatie geeft een netto negatieve lading aan de 
peptiden in deze gelatineoplossing. In hoofdstuk 5 beschrijven we dat 
gesuccinyleerd gelatine de nieropname van ’’’In-octreotide bij ratten en muizen 
kan remmen, zonder de opname in somatostatinereceptorpositieve organen te 
verminderen. Plasmavervangers op basis van koolhydraten, zoals 
hydroxyethylzetmeel, remden de nieropname niet. Dit geeft aan dat het effect 
van gesuccinyleerd gelatine op de nieropname niet veroorzaakt werd door de 
hemodynamische effecten van de plasmavervanger, maar door de 
eiwitcomponenten van de oplossing. Deze componenten verstoren waarschijnlijk 
de binding van ’’’In-octreotide aan receptoren op de proximale tubuluscellen. 
Het remmende effect van gesuccinyleerd gelatine op de nieropname van 
radioactief gelabeld octreotide werd bevestigd bij menselijke proefpersonen, 
zoals beschreven in hoofdstuk 6. Gesuccinyleerd gelatine remde de nieropname 
van ’ ’’In-octreotide bij deze mensen met circa 45%, terwijl hydroxyethylzetmeel 
dit niet deed.
Albumine is het meest voorkomende plasma-eiwit en is een natuurlijk ligand van 
megaline en cubiline 3940, waardoor het een veelbelovende kandidaat is voor 
het competitief remmen van de nieropname van radioactief gelabelde 
peptiden. Intact albumine wordt vrijwel niet doorgelaten door de glomerulaire 
basaalmembraan omdat het te groot is. Hierdoor is de concentratie van 
albumine in de voorurine relatief laag. Om dit probleem te verhelpen hebben 
we albumine enzymatisch gefragmenteerd. In hoofdstuk 7 tonen we aan dat 
albuminefragmenten (FRALB) en gesuccinyleerd gelatine de nieropname van 
’’’In-octreotide en ’’’In-exendin bij ratten effectief verminderen, minstens zo 
efficiënt als lysine. Bovendien werd de nieropname van ’’’ In-minigastrine ook 
zeer effectief geremd door zowel gesuccinyleerd gelatine als FRALB, maar niet 
door lysine. Zowel gesuccinyleerd gelatine als FRALB bevatten allerlei kleinere en 
grotere polypeptidemoleculen; het gemiddelde molecuulgewicht van 
gesuccinyleerd gelatine bedraagt 30 kDa en FRALB bevat eiwitten en peptiden 
van maximaal 67 kDa. Deze veelheid aan kleinere en grotere peptiden bindt
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waarschijnlijk aan verschillende delen of bindingsdomeinen van endocytotische 
receptoren zoals megaline en cubiline en blokkeert deze. Hierdoor kan de 
heropname van allerlei structureel verschillende radioactief gelabelde peptiden 
geremd worden.
FRALB is een mengsel van verschillende fragmenten dat, hoewel het is afgeleid 
van het niet-toxische albumine, niet zomaar aan mensen kan worden 
toegediend. Voordat toepassing in klinische PRRT mogelijk wordt zullen eerst 
toxiciteitsstudies moeten worden uitgevoerd. Gesuccinyleerd gelatine is 
daarentegen een geregistreerde plasmavervanger, die regelmatig wordt 
toegediend aan patiënten die geopereerd worden en/of veel bloed hebben 
verloren. De belangrijkste bijwerkingen zijn allergische reacties, die over het 
algemeen mild zijn (ernstige anafylactische reacties treden op in ongeveer 0,04% 
van de patiënten) 4,~43. Overvulling ten gevolge van de infusie van grote 
hoeveelheden gesuccinyleerd gelatine kan het gebruik bij patiënten met hart- 
of nierfalen mogelijk beperken. Nierbescherming met een combinatie van 
gesuccinyleerd gelatine en een lysine/argininemengsel is reeds gebruikt in meer 
dan 900 cycli van PRRT met somatostatineanaloga, waarbij geen anafylactische 
reacties optraden. Milde tot matige allergische reacties werden gezien bij 1,4% 
van de toedieningen, en gemiddelde tot ernstige reacties (zoals 
symptomatische bronchospasmen) bij 0,6% (R.P. Baum, persoonlijke 
correspondentie, 2009). Gesuccinyleerd gelatine lijkt inderdaad een 
veelbelovend middel voor bescherming van de nieren bij verscheidene vormen 
van PRRT.
Het heterogene karakter van FRALB en gesuccinyleerd gelatine heeft mogelijk 
voordelen, aangezien verschillende bestanddelen van deze mengsels kunnen 
interfereren met de interacties tussen verschillende radioactief gelabelde 
peptiden en hun receptoren. Dit maakt ze geschikt voor remming van de 
nieropname van verschillende radiopeptiden, terwijl lysine, een chemisch zuivere 
stof, alleen de opname van een beperkte groep radiopeptiden remt. Aan de 
andere kant hebben chemisch zuivere stoffen ook voordelen boven mengsels 
zoals FRALB en gesuccinyleerd gelatine. Mengsels zullen namelijk naast actieve 
ook inactieve bestanddelen bevatten. Bestanddelen die niet bijdragen aan 
reductie van de nieropname van radioactief gelabelde stoffen, dragen mogelijk 
wel bij aan bijwerkingen zoals allergische reacties of overvulling. Werkzame 
chemisch zuivere stoffen bevatten in principe geen inactieve bestanddelen.
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Om de mogelijkheden van FRALB en zuivere, gedefinieerde middelen te 
combineren selecteerden en maakten we zes verschillende peptiden die van 
albumine afgeleid waren (albuminepeptiden). We bestudeerden het effect van 
deze peptiden op de opname van ’’’In-gelabeld albumine, minigastrine en 
exendin in cellen die megaline en cubiline tot expressie brachten. De peptiden 
werden geselecteerd op basis van de verdeling van elektrisch geladen 
aminozuurresiduen, omdat, zoals hierboven beschreven, geladen 
aminozuurresiduen waarschijnlijk een belangrijke rol spelen bij de interactie van 
radiopeptiden met receptoren in de nieren. In deze onderzoeken, beschreven in 
hoofdstuk 8, verminderden drie van de zes albuminepeptiden de opname van 
alle bestudeerde radiopeptiden. Deze drie albuminepeptiden bevatten alle 
zowel positieve als negatieve ladingen. Een ander albuminepeptide dat alleen 
vier negatieve en geen positieve ladingen bevatte, remde de opname van het 
negatief geladen ’’’In-minigastrine effectief, terwijl het de opname van ’’’ In- 
exendin en -albumine niet remde. Dit komt overeen met eerdere bevindingen 
dat negatief geladen polyglutaminezuurketens de nieropname van ’’’ In- 
minigastrine bij muizen kunnen remmen 44 en dat polyglutaminezuur de 
nieropname van ’’’In-minigastrine efficiënter remde dan de opname van ’’’ In- 
exendin en ’ ’’ In-octreotide 29. Het peptide dat de opname van alle bestudeerde 
radiopeptiden het meest efficiënt remde in onze in vitro experimenten, werd 
vervolgens in vivo getest. Bij ratten remde dit albuminepeptide zeer effectief de 
nieropname van ’’ ’In-minigastrine en in mindere mate van ’’’ In-octreotide en - 
exendin. Dit albuminepeptide bestond uit de 36 aminozuurresiduen aan de C- 
terminus van het runderserumalbuminemolecuul en bevatte zes negatief en drie 
positief geladen aminozuurresiduen. Dit wijst opnieuw op een belangrijke rol van 
ladingen in de interactie van peptiden met nierreceptoren. Echter, net als FRALB 
zal ook dit peptide eerst toxicologische studies moeten ondergaan voordat het 
aan patiënten toegediend kan worden.
Andere methoden en com binatiestrategieën om nieropname en 
NIERSCHADE BIJ PRRT TE VERMINDEREN
Zoals beschreven in hoofdstuk 2, zijn tal van andere strategieën ter vermindering 
van de nieropname van radioactief gelabelde peptiden onderzocht. 
Verschillende middelen verstoren het transport van stoffen in de proximale tubuli
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door andere mechanismen dan competitieve remming, maar slechts enkele 
hiervan zijn in vivo onderzocht. Colchicine remt de endocytose door het 
verstoren van de vorming van microtubuli, en remde de nieropname van 111 In­
octreotide bij ratten. Hiervoor was echter een relatief hoge dosering nodig, die 
waarschijnlijk bijwerkingen zou veroorzaken bij patiënten 45. Een relatief lage dosis 
probenecide, een goedgekeurd medicijn dat het transportsysteem voor 
organische anionen blokkeert, verminderde eveneens de nieropname van ^In- 
octreotide 46. Het invoegen van een enzymatisch afbreekbare structuur tussen 
peptide en radiolabel in het radioactief gelabelde molecuul kan ook de 
nieropname of -retentie van radioactiviteit verminderen 47-50. Om de niertoxiciteit 
bij een gegeven stralingsdosis te verminderen, zou dosisfractionering nuttig 
kunnen zijn 8-32, of het gebruik van zogenaamde ‘scavengers', die vrije radicalen 
wegvangen 51. Stoffen die contraproductieve reacties van weefsel op straling 
tegengaan, zogenaamde ‘mitigaters', hebben ook veelbelovende resultaten 
getoond bij het verminderen van nierschade na in vivo radionuclidetherapie 52. 
Omdat de verschillende strategieën ter voorkoming van nierschade op 
verschillende niveaus interfereren met de nieropname en -schade, zou een 
combinatie van twee of meer technieken waarschijnlijk kunnen bijdragen aan 
een verdere reductie van nierschade. Zelfs een combinatie van twee 
competitieve remmers van de nieropname - lysine en gesuccinyleerd gelatine -, 
verminderde de nieropname van 111In-octreotide meer dan de individuele 
stoffen, hoewel het toegevoegde effect niet zeer groot was 29'53. Gelijkaardige 
resultaten zijn gerapporteerd met de combinatie van lysine en colchicine, ook 
een remmer van endocytose 45. Een combinatie van lysine met een 
angiotensine-II-antagonist bij ratten die behandeld werden met 177Lu-octreotaat 
leverde veelbelovende resultaten op: men zag significant minder nierschade 
dan na behandeling met alleen de angiotensine-II-antagonist 54. Echter, recente 
studies konden deze resultaten niet bevestigen (M. Melis, persoonlijke 
correspondentie, 2010).
To ek o m st per spec t iev en
Nieuwe middelen en combinatiestrategieën voor het verminderen van 
nierschade bij PRRT zullen radionuclidetherapie met hogere stralingsdoses 
mogelijk maken, waardoor bestraling van de tumor gemaximaliseerd kan
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worden terwijl de kans op nierschade verminderd wordt. De meeste beschreven 
methodes moeten echter verder onderzocht worden voordat ze succesvol en 
veilig bij patiënten kunnen worden toegepast. De combinatie van 
gesuccinyleerd gelatine en lysine lijkt een veelbelovende aanpak die veilig 
toegepast kan worden, maar ook hierbij zullen eerst de effecten op nier- en 
tumordosimetrie bij patiënten bestudeerd moeten worden.
Wanneer de toepassing van PRRT met hogere stralingsdoses mogelijk wordt, 
moet ook aandacht besteed worden aan schadelijke effecten van de straling 
op andere organen, met name op het beenmerg. Dit orgaan is veel gevoeliger 
voor straling dan de nieren, maar ten gevolge van de hoge nieropname en - 
retentie van radioactief gelabelde somatostatineanaloga zijn de nieren de 
belangrijkste dosisbeperkende organen bij PRRT. Toch is ook acute en chronische 
beenmergtoxiciteit beschreven bij patiënten die behandeld werden met 177Lu- 
octreotaat 2. Als het toedienen van hogere stralingsdoses mogelijk wordt door 
succesvolle bescherming van de nieren, zal beenmergtoxiciteit ongetwijfeld 
vaker voorkomen en de dosisbeperkende factor worden. Dit probleem kan 
mogelijk deels opgelost worden door behandeling van beenmergschade met 
autologe beenmergondersteuning, wat al met succes is gebruikt bij 
radioimmunotherapie 55, of door bescherming van het beenmerg met middelen 
zoals amifostine.
Een andere interessante ontwikkeling bij de behandeling van neuro-endocriene 
tumoren is het gebruik van nieuwe doelgerichte medicijnen, zoals remmers van 
het ‘mammalian target of rapamycin' (mTOR) of tyrosinekinaseremmers zoals 
sunitinib, die al goede resultaten hebben opgeleverd in recente fase-I-studies. 
Combinatie van deze middelen met PRRT in hoge doses zou een zeer effectieve 
behandeling van neuro-endocriene tumoren kunnen opleveren.
C o n c lu s ie
Verscheidene radioactief gelabelde peptiden zijn veelbelovende kandidaten 
voor scintigrafie en behandeling van allerlei tumoren, en peptide- 
receptorradionuclidetherapie (PRRT) met somatostatineanaloga heeft al een 
belangrijke plaats bij de behandeling van neuro-endocriene tumoren. De 
effectiviteit van deze behandelingen wordt echter beperkt door relatief hoge 
nieropname van de radiopeptiden, die kan leiden tot dosisbeperkende
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niertoxiciteit. Meer inzicht in de mechanismen van nieropname en verschillende 
nieuwe strategieën om deze nierschade te beperken kunnen het veilig 
toedienen van hogere stralingsdoses mogelijk maken, en zo leiden to zeer 
effectieve PRRT.
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Da n k w o o r d
De titel van dit hoofdstuk geeft al aan dat hier mensen bedankt gaan worden, 
en dat klopt. Het woord ‘dank' komt dan ook regelmatig in verschillende vormen 
voorbij - om precies te zijn 48 keer. Mijn excuses dat ik op dat gebied wat vaak in 
herhaling val, maar een promotieonderzoek doe je nu eenmaal niet alleen. Een 
groot aantal collega's heeft bijgedragen aan dit onderzoek, en ook buiten het 
werk om hebben veel mensen me gestimuleerd, gesteund en soms de 
onvermijdelijke dipjes geaccepteerd. Ik wil iedereen die aan de totstandkoming 
van dit proefschrift heeft bijgedragen hierbij bedanken, en enkelen in het 
bijzonder.
Allereerst mijn promotoren, de professoren Otto Boerman, Wim Oyen en Marion 
de Jong.
Otto, jij verzorgde de dagelijkse begeleiding van het grootste deel van mijn 
onderzoek. Tijdens ons wekelijkse overleg bedachten we nieuwe experimenten 
en zo hielden we de vaart erin. Je  enthousiasme werkte zeer aanstekelijk en je 
gaf me de vrijheid om mijn ideeën ten uitvoer te brengen. Op momenten dat 
mijn aandacht meer lag bij mijn specialisatie dan bij het onderzoek stimuleerde 
je me, en je bleef vertrouwen in een goede afloop. Bedankt!
Wim, je had een mooi onderzoeksproject voor me klaarliggen toen ik net 
begonnen was met de opleiding tot nucleair geneeskundige en je maakte het 
mogelijk het onderzoek goed te combineren met de opleiding. Bedankt 
daarvoor en voor je vlotte en nuttige commentaar op de manuscripten.
Marion, ook jou wil ik bedanken voor de fijne begeleiding die je me hebt 
gegeven, vooral tijdens mijn tijd in Rotterdam, maar ook bij de analyse van de 
resultaten en het schrijven van de artikelen. Zelfs in een voor jou moeilijke tijd 
bleef je nauw betrokken bij ons onderzoek.
Dan mijn paranimf en steun en toeverlaat in het lab, Annemarie Eek. Annemarie, 
zonder jou was dit proefschrift er waarschijnlijk nooit gekomen. Jij hebt de kweek 
en karakterisering van de megalinedeficiënte muizen opgezet en voor een groot 
deel uitgevoerd, en het grootste deel van het laboratoriumwerk voor je rekening 
genomen. Op momenten dat ik (te) weinig betrokken was bij het onderzoek liet 
je dat duidelijk blijken, waarmee je me bij de les hield. Daarnaast zorgde je voor 
een boel gezelligheid op de afdeling. Bedankt voor alles!
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Dr. Melis, Marleen, bedankt voor de prettige samenwerking. Jij was een 
belangrijke copromovenda voor mij; we hebben samen nagedacht over de 
optimale uitvoering van de experimenten met de megalinedeficiënte muizen in 
Rotterdam, en die ook samen uitgevoerd. Ook bedankt voor de proeven die je 
in mijn afwezigheid hebt uitgevoerd. Onze discussies over de interpretatie van de 
uitkomsten waren boeiend, en het was altijd een plezier om naar Rotterdam te 
komen.
Ook dr. Van Eerd wil ik bedanken. Juliëtte, jij hebt met je promotieonderzoek de 
weg geplaveid voor een groot deel van mijn onderzoek. De studie over 
getrypsiniseerd albumine heb je nog voor een groot deel uitgevoerd, en bij 
onduidelijkheden was je, ook op je nieuwe werkplek, altijd bereid tot overleg.
Dr. Masereeuw, Roos, bedankt voor het stimulerende overleg tijdens mijn 
promotieonderzoek. Je  uitleg was onmisbaar bij het doorgronden van de 
fysiologie van de proximale niertubuli; al zal dat doorgronden waarschijnlijk nooit 
helemaal lukken.
Prof. dr. Jack  Wetzels en prof. dr. Frans Russel, jullie wil ik ook bedanken voor de 
stimulerende inbreng. Jack, jouw encyclopedische kennis van de nieren was 
essentieel bij het vervolmaken van het reviewartikel.
Collega Gotthardt, Martin, je was al langere tijd bezig met de nieropname van 
radiopeptiden, maar in het begin waren we nog niet betrokken bij elkaars 
onderzoek. Gelukkig veranderde dit in de loop van de tijd; het was leuk en nuttig 
om met je te brainstormen. Gotti bedankt.
Ook veel dank aan drs. (nog even) Maarten Brom. Ondanks dat je veel werk had 
aan je eigen promotie, vond je ook nog de tijd om voor mij labelingen uit te 
voeren, te helpen met biodistributie-experimenten en zelfs voor het doen van 
een SPECT-experiment in Rotterdam. Bedankt!
Dan zijn er nog vele onderzoekers uit het Nijmeegse aquarium die me hebben 
geholpen. Cathelijne Frielink, heel erg bedankt voor het doen van de 
(immuno)histochemische kleuringen en het scoren van de megaline-expressie. 
Lieke Joosten, Gabie de Jong, Gerben Franssen, Janneke Molkenboer-Kuenen, 
Rafke Schoffelen en Peter Laverman, bedankt voor al jullie hulp bij de dissecties, 
uitleg over autoradiografie en andere praktische zaken.
Monique de Visser, jij schreef in Rotterdam de DEC-aanvraag voor de 
megalinedeficiënte muizen. Bedankt daarvoor en voor de SPECT's die je hebt 
uitgevoerd. Later kwam Saskia Berndsen de analistenploeg versterken. Saskia,
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zonder jouw vaardigheid in injecties via de staartvene verliep het onderzoek een 
stuk lastiger. Bedankt voor al het werk dat je hebt verricht aan de SPECT- 
experimenten en voor de fijne samenwerking! Jan de Swart, veel dank voor je 
hulp bij de praktische uitvoering en instelling van de nanoSPECT camera. Erik de 
Blois en Wout Breeman, bedankt voor het Rotterdamse labelwerk!
Bianca Lemmers - van de Weem en Kitty Lemmens - Hermans, jullie hebben de 
dieren in Nijmegen geweldig verzorgd! Bedankt daarvoor en voor jullie hulp bij 
de uitvoering van de proeven. Emile Koenders, bedankt voor het meet- en 
invoerwerk dat je hebt gedaan.
Nijmeegse laboranten (alias MNW'ers), in het bijzonder Antoi Meewis, bedankt 
voor jullie hulp bij de planning en uitvoering van de gammacamera­
experimenten met vrijwilligers.
Bedankt Mark Konijnenberg voor de dosimetrieberekeningen die je hebt 
uitgevoerd voor het artikel over de nierschade veroorzaakt door 111 In.
Prof. dr. Frans Corstens, bedankt voor het in mij gestelde vertrouwen door me 
aan te nemen voor de opleiding tot nucleair geneeskundige en me te stimuleren 
onderzoek te doen.
En ik vergeet de overige coauteurs niet: Magda Bijster, Marcel Vermeij en prof. 
dr. Eric Krenning, bedankt voor jullie bijdragen en correcties.
De manuscriptcommissie, bestaande uit prof. dr. Paul Smits, prof. dr. René Bindels 
en prof. dr. François Jamar, wil ik bedanken voor het grondig lezen van dit 
proefschrift en hun vlotte goedkeuring ervan.
Ook mijn collegae AIOS nucleaire geneeskunde wil ik bedanken. Wouter Vogel, 
Baudewijn, Marc, Maarten, Wouter v.d. Bruggen, Jan-Willem, Rozemarie, Marcel, 
Elske, Michelle en Cüneyt, jullie hielden de kliniek draaiende als ik aan het 
onderzoeken was. Maar bovenal waren en zijn jullie geweldig fijne collega's (en 
soms ook vrienden). Wouter V. ook bedankt dat je mij (via Margreet) enthousiast 
hebt gemaakt voor de nucleaire geneeskunde. Ook de onderzoekskamer- 
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